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Abstract
Several diseases including cancer and pathogen infection are mediated by protease activity.
In HIV infection, the viral protease plays a central role in the virus lifecycle, which has made
it a clear therapeutic target. The dominant approach for the treatment of HIV is heavily
dependent on inhibitors of this enzyme, but no new drugs have reached the market since
2006. There is thus a need for new design principles for the development of anti-retroviral
therapies. Traditional methods of HIV detection are also limited in their use at point-of-
care in resource-limited settings due to their reliance on highly trained laboratory personnel,
cold-chain transport and expensive reagents.
This thesis examines the role of peptide-protein interactions for the inhibition and detection
of HIV-1 protease. Phage display is used to isolate heptameric peptide sequences which
interact specifically with the enzyme. These peptides are then utilised as sensors for the de-
tection of the enzyme through Fo¨rster Resonance Energy Transfer (FRET). The inhibitory
properties of the peptides, both in isolation and through multivalent conjugates are also
investigated.
Finally, insights into the nature of these peptide-protein interactions are explored through
molecular docking and all-atom classical molecular dynamics simulations. The expression of
recombinant HIV-1 protease in E. coli is also discussed. The peptide based systems described
here are expected to be more stable to environmental effects than protein based therapies
and it is hoped that this work will provide new pathways for the design of peptide-based
therapeutics and diagnostics for protease related diseases which do not rely on traditional
methods.
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Scope of the Thesis
The role of peptide-protein interactions is critical in biology and underlies the principle of
protein-protein interactions. Such interactions are highly important in cell signalling and
regulation and are thus of increasing importance in the search for new therapeutic strategies
for a range of diseases. Biotechnology now offers us new tools to search for non-natural
peptides which show interactions with proteins of choice. This offers exciting new potential
to target proteins where appropriate native binders have not yet been identified. This
thesis examines the role of non-native peptides within peptide-protein interactions for the
inhibition and detection of HIV-1 protease, a key viral enzyme in the lifecycle of HIV/AIDS.
Chapter 1 introduces Human Immunodeficiency Virus/Acquired Immune Deficiency Syn-
drome. It begins by discussing the fundamental molecular basis of all disease before consid-
ering the unique role that enzymes play in the mediation of disease states. The chapter then
considers the clinical impact of HIV/AIDS on the global population and studies in partic-
ular the numerous detection strategies which exist on the market. The chapter concludes
with an in-depth examination of HIV-1 protease and its role in the lifecycle of HIV/AIDS.
The use of the protease as a drug target is discussed as well as the effects that observed
mutations have on the efficacy of antiretroviral therapy. Due to the broad range of topics
covered within this thesis, each subsequent section begins with a review of relevant literature
specific to the theme of that chapter. In this way it is hoped that this chapter will act as a
more general introduction to the field of HIV/AIDS diagnostics and therapeutics.
In Chapter 2 peptides which bind to HIV-1 protease are isolated through phage display.
This study used a commercial heptameric peptide library and identified five sequences which
showed preferential binding to the protease over a globular control protein (Bovine Serum
Albumin). While no consensus was found through the sequence analysis, the peptides which
showed binding all shared characteristics of being relatively hydrophobic and being rich in
aromatic residues. Having identified strong candidates, the peptides were then synthesised
through solid-state peptide synthesis and submitted to further studies. These peptides
were characterised through biochemical and biophysical techniques including ELISA and
SPR. One peptide sequence was shown to exhibit inhibition of the enzyme. The principle
of multivalency in drug design is then studied through the construction of peptide-PEG
5
conjugates. It is hypothesised that strong enzyme inhibitors can be constructed from weakly
binding ligands through the enhanced avidity offered by multiple presentations.
Chapter 3 builds on the work presented in Chapter 2, using one of the peptides isolated
through phage display alongside a peptide sequence from the literature, to act as a detection
strategy for HIV-1 protease. Most published studies on the detection of proteases rely on
the cleavage of a substrate peptide-based probe. In this work, the use of two independent
binding events is used to detect the presence of the enzyme. The two peptides acting as
sensors are fluorescently labelled with organic dye molecules, acting as a FRET pair. The
protease molecule is successfully detected both on surface and in solution. The assay was
further shown to be highly specific by using pepsin, a member of the same enyzmatic family
as a control enzyme. This demonstrates the potential of the approach to minimise false
positive signals.
Chapter 4 uses all-atom classical molecular dynamics to further study the findings from
Chapters 2 and 3. The interactions between the peptide ligands isolated in Chapter 2
and HIV-1 protease are studied in simulation to elucidate possible binding mechanisms and
locations. The work of Chapter 3 is then continued in silicio and comparisons drawn between
the experimental and computational results. Conclusions gained from these simulations can
be used to explain findings in these previous chapters. These studies can also guide future
inhibitor design.
Chapter 5 describes the expression and purification of HIV-1 protease, recombinantly pro-
duced in E.coli. Although the production of HIV-1 protease was first described in 1990
it remains a challenging synthesis due to the insolubility of the expressed protein and the
enzyme’s instability and susceptibility to autoproteolysis. Since all studies within this thesis
will focus on HIV-1 protease, having an in-house production of the enzyme would prove
beneficial.
Finally Chapter 6 summarises the major findings of this work and discusses the possibility
of future extensions. It aims to show the research within this thesis as a part of the wider
context of the field, thus highlighting the contribution offered.
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1.1 Introduction
Evolution has given Nature a building set consisting of a few nucleotides, some 20 amino
acids, a collection of lipid molecules and approximately two dozen sugars. From these simple
molecules, a hugely diverse range of complex structures and materials has emerged, which
exhibit self-assembly, are fabricated with incredibly high precision, display an exacting speci-
ficity of function and are also self-replicating and adapting.
Bionanotechnology aims to go someway towards replicating this naturally occurring di-
versity with two main purposes; to offer biology new tools from the field of nanotechnology
and to give nanotechnology access to new types of biologically functional nanoscale sys-
tems and materials [1]. This interdisciplinary approach gives us new techniques for the
development of new materials and systems which have potential for the diagnosis, imaging
and treatment of disease, catalysis and the creation of ’smart’ materials with integrated
optical and electronic responses. It also allows us to address fundamental questions about
biological processes by utilising physical characterisation techniques and advanced materials.
Biology and nanotechnology merge at the same length scale, with biomolecules being of
order 5-200 nm, and even the most complex biological machines (for instance the bacterial
flagellar motor or the ribosome) being less than 100 nm in size. As Richard Feynman so
aptly described it, “there’s plenty of room at the bottom” [2].
1.2 The Molecular Basis of Disease
The understanding of human disease has changed drastically since the first studies of medicine
in the ancient world. The Ancient Greek surgeon Galen believed that disease states were
modulated by an imbalance in the four humours (black bile, yellow bile, phlegm, and blood)
and this theory persisted through the Middle Ages. The development of the scientific method
through the 18th and 19th centuries led to a revolution in the medical fields; giving the study
of pathological conditions a foundation in the underlying science. This advance changed the
focus of medicine from being centred on observations and whole organ systems to the study
of biology at a cellular and molecular level.
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In 1949 Linus Pauling published a study of sickle cell anaemia based on the observed dif-
ferences between the haemoglobin of sufferers and healthy patients [3]. This was the first
description of a pathological condition from a molecular basis and alongside seminal work
in molecular biology led to a new paradigm in the treatment and diagnosis of disease.
The central dogma of molecular biology states that the flow of information in biological
systems flows from DNA to RNA to proteins [4]. From this principle, the majority of non-
communicable diseases can be traced back to changes to the genome - either as changes to
the genetic code or to changes in the transcriptional regulation of individual genes. These
changes, whether somatic (arising over the course of a patient’s life) or congenital, can con-
sist of only a single base pair mutation (leading to diseases such as thalassemia) or a larger
genetic structure replacement (for instance in Turner Syndrome) [5,6]. These genetic muta-
tions within an individual’s genome are responsible for a range of protein malfunctions that
define inherited conditions. The resulting proteins may either be folded incorrectly (causing
loss of activity or unwanted interactions), over-produced or simply not produced, causing
both up- and down-stream effects to physiological molecular pathways.
Gene regulation controlling the over- or under-expression of various proteins can be con-
trolled at the transcriptional or post-transcriptional level. In both instances this is medi-
ated by protein-protein and protein-DNA molecular interactions. As a result a single protein
mis-folding can affect the regulation of many other proteins downstream. While the effect
of regular exposure to some toxins such as alcohol or tobacco can be clearly defined from
a molecular basis, the role other lifestyle factors will have on genetic regulation of proteins
and other biological molecules is still poorly understood. This relationship is made harder
to define by the reliance of epidemiological data on patient self-reporting as well as the vast
complexity in the human genome [7].
Infectious disease can also be described in terms of its molecular basis. Viruses and bacteria
have evolved complex mechanisms to avoid host defences. These strategies can involve the
release of toxins which can inhibit native proteins (including enzymes) or alternatively the
hijacking of a cell’s machinery by the pathogen to allow it to reproduce, eventually causing
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cell apoptosis. In contrast to pathogens which rely on DNA and/or RNA to control their
molecular mechanisms, prions are proteins which can have multiple conformations and can
cause the conformational change of other isoforms of the protein. These simple molecules
are the causative agent of a number of transmissible, infectious neurodegenerative diseases
such as Creutzfeldt-Jakob disease [8]. Prion diseases provide interesting insights into the
molecular function of protein plasticity and structure-function relationships in protein be-
haviour.
In response to pathogen invasion, the body’s highly complex immune system is activated.
This response is mediated by molecular interactions which occur on the cell surface and
within the blood plasma. Humoral immunity is caused by the release of antibodies from
B-cells which uniquely and specifically recognise an antigen. This molecular recognition is
the product of several weak affinity non-covalent chemical bonds, which, when antibody and
antigen have complementary structures, results in a high-avidity interaction. These proteins
are key for the diagnosis of many disease states and the induction of such a response is the
basis for many vaccination strategies.
Our understanding of the molecular nature of disease has also revolutionised disease di-
agnosis. The development of molecular biology techniques such as the polymerase chain
reaction (PCR), western blots, enzyme-linked immunosorbent assays (ELISA) and genetic
sequencing offer unprecedented accuracy in delivering a diagnosis. The molecular signal of
many diseases can be detected within the blood, urine or saliva of patients. These biomark-
ers can include increased enzyme concentrations [9], pathogenic DNA (including genetic
analysis for common drug resistant mutations) [10] or human RNA as evidence of genetic
dysregulation in pathogenic conditions such as cancer and liver disease [11,12].
1.3 The Role of Proteases in Disease
Since the description of pepsin activity by Schwann in 1836, approximately 1000 unique
proteases have been identified within the human genome [13]. Broadly, their underlying
function is to cleave polypeptide chains through hydrolysis of peptide bonds. This cleavage
can be non-specific, causing protein catabolism and releasing amino acids, or highly specific,
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responsible for the catalysis of specific reactions. Protease activity can affect the activation
of other proteins, cause the creation of bioactive molecules, affect protein-protein interac-
tions and generate and amplify molecular signals involved in cell signalling pathways [14].
As a result of this specific proteolytic processing, members of the protease family directly
regulate a wide range of functions within the body. By controlling the cellular (and extra-
cellular) level of various proteins, proteases are known to influence cell proliferation, tissue
remodelling, wound repair, blood coagulation, inflammation, immunity and cell apoptosis,
among many others [14].
Proteases can be classified into one of six different classes based on the catalytic mecha-
nism used to cleave a substrate. Aspartic, glutamic and metalloproteases use active site
residues to activate (deprotonate) a water molecule which acts as a nucleophile to attack a
peptide bond. In contrast, cysteine, serine and threonine proteases use an activated amino
acid residue (Cys, Ser or Thr depending on type) as the nucleophile for hydrolysis. Glutamic
proteases have yet to be discovered in mammals, leaving five major classes within human
physiological pathways [13].
Proteolytic processing can have three major functions within these cellular pathways: pro-
teins can gain function, for example processing of a zymogen (pro-enzyme) into the active
form; they can lose function, for instance the inactivation of Bcl-2 through capsase cleavage
within apoptotic pathways [15,16]; or their function can be switched, for example in cytokine
processing in extracellular remodelling [17]. These functions act to control the majority of
signalling pathways and hence changes in activity of only one protease can have further
consequences downstream.
Given their ubiquity within the body, dysregulation of protease activity underlies several dis-
ease states including cancer, osteoporosis and cardiovascular and inflammatory diseases [18].
Currently around 30 protease inhibitors are licensed for use in the UK for the treatment of
hypertension, AIDS, thrombosis, hepatitis C and diabetes [19]. The majority of these drugs
target the active site of the enzyme by mimicking the natural substrate. The design of these
inhibitors thus requires an in-depth knowledge of the structure and mechanism of the en-
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zyme. The use of high-throughout methods in drug discovery, alongside positional scanning,
combinatorial libraries, proteomic studies and computational design have revolutionised the
targeting of proteases as a therapeutic target [20].
A full study of all disease states mediated by proteases would constitute several indepen-
dent textbooks, but we give here a few key examples to demonstrate the breadth of influence
up- or down-regulation of proteolytic enzymes can have. These examples also allow us to
examine in more detail the role proteases may have in therapeutic and diagnostic design.
1.3.1 Matrix Metalloproteases
Matrix Metalloproteases (MMPs) are a family of proteases whose activity is dependent on
the presence of zinc. To date, 24 structurally related MMPs have been discovered in hu-
mans [21]. Their primary function is the degradation of extracellular matrix (ECM) proteins
for the regulation of tissue remodelling. This degradation creates room for cells to migrate
and can generate or deactivate signalling molecules [22].
Because of their ability to degrade the ECM and their role in angiogenesis, MMPs are
found to be greatly upregulated within tumour cells. They were thus one of the first pro-
teases to be targeted by the pharmaceutical industry as a cancer drug target [23]. Preclinical
studies of MMP inhibitors showed great promise but all failed in clinical trials due to major
side-effects [24]. This failure was largely due to the broad-spectrum inhibition displayed by
the lead compounds and the unintended downstream affects of blocking MMP activity [25].
These studies highlighted the dangers of inhibiting enzyme function without a full under-
standing of the enzymatic family, their structure and role in biology. As further fundamental
studies revealed the many critical functions MMPs are involved in within the body, their
inhibition as a cancer therapeutic has largely been dropped. Their use as therapeutic targets
for inflammatory diseases including sepsis is, however, still under study [26,27].
1.3.2 Cathepsin Cysteine Proteases
Cathepsin cysteine proteases are part of the larger papain enzymatic family and all contain
a cysteine within their active site. This family of proteases is widely expressed in a number
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of organs and are responsible for protein hydrolysis within cellular lysosomes [28]. Various
members of the Cathepsin proteases are involved in cellular apoptosis [29], skeletal remod-
elling [30] and antigen presentation [31] among other processes.
However, despite their role in many physiological pathways, recent interest in these enzymes
has arisen due to their importance in certain disease states. Cathepsin upregulation has been
observed in many different human cancers including breast, lung, brain and melanoma [28].
In this context the enzymes are involved in the breakdown of the extracellular matrix, al-
lowing cancer to grow and metastasise [32]. This upregulation is also being investigated as
a way of detecting cancer within the body. Cathepsin B levels in serum have been shown
to be a good predictor of cancer [33] and its overexpression can also be directly detected in
cells [34]. Upregulation has also been observed in atherosclerosis, osteoarthritis, Alzheimer’s
disease and some inflammatory muscle disease [28]. Managing this enzyme family’s activity
could thus be an exciting avenue for the treatment of many diseases.
1.3.3 Retroviral Proteases
Retroviruses are a family of viruses which replicate within an infected cell through reverse
transcription - single stranded RNA is transcribed into a DNA heteroduplex and then a
homoduplex before being integrated into the host cell’s DNA by viral enzymes [35]. This is
in contrast to most viruses, where DNA is transcribed into RNA and subsequently trans-
lated to protein. Members of the retrovirus family include leukaemia viruses (Human T-
Cell Leukaemia Virus, HTLV), mammary tumour viruses (Mouse Mammary Tumour Virus,
MMTV - postulated to play a role in human breast cancer [36]), Rous Sarcoma Virus (an
avian oncovirus) and immunodeficiency viruses (including human, simian and feline viruses).
The efficacy of these viruses depends on their viral enzymes; to transcribe and integrate
the RNA/DNA and cleave the precursor proteins. Of these enzymes, the retroviral protease
is a key enzyme for viral reproduction and around 93 individual proteases from correspond-
ing viruses have been sequenced to date [37]. All retroviral proteases are aspartyl proteases,
sharing a consevered structure and a conserved Asp-Thr-Gly sequence in their active site
but are considerably smaller than other aspartyl enzymes such as pepsin [38].
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1.4 Human Immunodeficiency Virus/Acquired Immune
Deficiency Syndrome
Acquired Immune Deficiency Syndrome (AIDS) is the terminal disease state of infection by
the Human Immunodeficiency Virus (HIV). The virus is a lentivirus which is predominantly
transmitted by sexual contact but also through injection of infected blood (or blood prod-
ucts) and from mother to child. The disease is characterised by the gradual depletion of
CD4+ helper T-cells. This reduction causes an immunodeficiency leaving the patient vul-
nerable to opportunistic infections (primarily tuberculosis, other pathogenic infections and
some types of cancer).
In the nearly 35 years since the first reports of HIV/AIDS some 25,000 papers have been
published related to various aspects of the disease. This introduction thus aims to cover
those aspects of the virus and its impact, most pertinent to the rest of the thesis.
1.4.1 Historical Context
The beginning of the global Acquired Immune Deficiency Syndrome (AIDS) pandemic was
first reported in 1981 with a short paper detailing the diagnosis of five young homosexual
male patients in Los Angeles who presented with a rare form of pneumonia, Pneumocys-
tis carinii [39, 40]. These patients showed abnormal levels of lymphocyte subgroups (T-
lymphocyte depletion) and two of the five quickly died. Within a month another 26 cases
were reported in New York and California and over the course of the next two years cases
were reported in haemophilia patients (suggesting a blood borne disease), Haitians (the first
reported non-US patients), heterosexual patients (including women) and injection drug users
(supporting an infectious disease model) [41].
In these first few years the causative agent behind the disease remained a source of contro-
versy. Possible theories included an unexpectedly virulent cytomegalovirus (which can cause
immunosuppression), amyl nitrite (a prescription drug) and the related chemical isobutyl
nitrite (both are known immunosuppressants), genetic immune system overload or a vector-
borne disease [41,42]. It was not until 1983 that the viral cause of AIDS was reported [43,44]
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Figure 1.1: Annual US deaths from AIDS between 1983-2012. A significant drop in death
rate can be observed after the introduction of the first combined antiretroviral therapies in
1995. Number of deaths from AIDS include actual and suspected deaths. Data extracted
from the US Centre for Disease Control’s HIV Surveillance Reports 1988-2013 [48].
as a retrovirus related to the Human T-cell Leukaemia virus family.
After the discovery of a viral cause, the search for treatment options could begin. Many
compounds were trialled, some fraudulent and others which showed short-lived promise. The
median survival after an AIDS diagnosis was typically weeks to months, with palliative care
to treat opportunistic infections and AIDS-related cancers the only available treatment [45].
Figure 1.1 shows the number of deaths from AIDS in the United States between 1983 and
present. The first approved drug for the treatment of AIDS, azidothymidine (AZT), was
introduced in 1987 [46]. As can be seen from the graph, despite most expectations it did
little to slow the death rates of patients. AZT is a nucleoside reverse transcriptase in-
hibitor, preventing transcription of the viral RNA to DNA. Between 1995 and 1997, highly
active anti-retroviral therapy (HAART) was introduced. This combined the earlier reverse
transcriptase inhibitors with the first generation of viral protease inhibitors [47]. This ther-
apeutic innovation had a dramatic effect on the death rates of infected patients, with the
number of deaths more than halving over two years.
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Today, the life expectancy of an otherwise healthy young adult diagnosed with HIV is around
fifty years, approaching an almost normal length [45]. There are now fifteen different drugs
in five different classes approved for the treatment of HIV/AIDS. These advances in treat-
ment and prevention have caused new problems for public health systems as HIV can now
be considered a long-term chronic disease. Since treatment does not restore full immune
health, cardiovascular disease and cancer are more likely among HAART recipients and over
an extended lifetime, regular exposure to antiretroviral drugs may cause toxicity issues and
organ damage [49]. Annual health care costs (both direct and indirect) to the UK for the
treatment of HIV/AIDS is approximately £1.3 billion, with a patient’s lifetime treatment
cost between £200,000 and £350,000 [50,51].
In light of the growing burden to both the patient and the health-care system, interest
has turned to the development of a functional cure. A few reports of such cures exist where
stem cell transplants have been given to treat co-existing leukaemia. These cells carried a
genetic defect that prevented the replication of the circulating HIV [52]. This is, of course,
not a viable option for the millions of infected patients but does demonstrate that a func-
tional cure is possible and this will certainly be the goal of HIV/AIDS research in the coming
decades.
1.4.2 The Genetic Diversity of HIV
HIV has been isolated in two distinct strains: HIV-1 and HIV-2. The former is the predom-
inant strain responsible for the HIV pandemic whilst HIV-2 is less virulent and generally
constrained to West Africa. HIV-1 can be further subdivided into four major groups M,
O, N and P of which M is the most widespread and genetically diverse (being further sub-
dividable into ten clades) [53].
Phylogenetic analysis has shown that HIV arose as zoonotic transmissions of the closely
related Simian Immunodeficiency Virus (SIV). Groups M and N can be traced back to two
independent crossings of SIVcpz, the chimpanzee form of the virus, while groups O and P
are both related to independent crossings of SIVgor, the commensal gorilla virus [54,55]. In
contrast, HIV-2 has arisen from multiple crossings of SIVsmm, from the sooty mangabey
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monkeys [56]. Assuming a constant mutation rate, the date of these transmissions can be
traced back to around 1884-1924 for group M, the 1920s for group O and group N in the
1960s [57]. HIV-1 group P was only confirmed in 2011 and so far only in two individuals in
Cameroon [58].
HIV also displays a vast genetic diversity within a single host. This variability is a result
of the rapid replication of the virus (plasma virions have a turnover half-life of approxi-
mately 2 days) and the high rates of error in reverse transcription [59, 60]. This can result
in the viral genetic code varying by up to 10% within a single host [61]. This large, rapid
genetic variation gives the virus the advantage in avoiding host immune defences through
the formation of escape variants as a quasi-species. Interestingly, despite this diversity,
most new sexually-transmitted infections are found to be the result of infection by a single
(founder) clone which then goes on to create a multitude of related molecular clones [62]. It
is thought that this bottleneck occurs because of the mucosal barrier but this is not yet fully
known [63]. If this resistance to entry by multiple species could be understood it would offer
a new mechanism that could be exploited in the development of vaccines and pre-exposure
prophylaxis.
1.4.3 The Structure of HIV
The Human Immunodeficiency Virus is a complex lentivirus from the Retroviridae family.
Viruses from this family are membrane enveloped particles which utilise RNA to encode
their genome. After host cell infection, this RNA is then transcribed into DNA and inte-
grated into the cell’s own genomic code by viral enzymes. They are known as slow viruses
given the length of time between initial infection and the onset of severe clinical symptoms.
The virus encapsulates two identical copies of positive sense, single-stranded RNA. It is
hypothesised that the requirement for two copies protects against restriction nucleases and
the error-prone transcriptases and enables a faster rate of genetic replication [64]. The un-
spliced RNA molecule is around 9.5 kb in length and through complex splicing methods
encodes 15 different proteins within three different reading frames [65]. Like all retroviruses,
the single strand encodes the major viral proteins: Gag, Pol and Env as well as six acces-
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sory and regulatory proteins (Vif, Vpr, Vpu, Tat, Rev, Nef). Figure 1.2 shows the genomic
organisation of the virus. The Gag and Pol proteins are produced without RNA splicing
while a single splice gives a group of 4.5 kb mRNA strands encoding Env, Vif, Vpr and Vpu.
Finally, multiple splicings lead to 2 kb mRNA for Tat, Rev and Nef [66].
After production, Gag is further cleaved into matrix, capsid and nucleocapsid proteins,
Pol is cleaved into the viral enzymes – protease, reverse transcriptase and integrase, whilst
Env is cleaved into two glycoproteins (gp120 and gp41) forming the viral surface and trans-
membrane units. The proteins that make up the virus have been well characterised as part
of ongoing efforts to develop therapeutics for the disease. We outline here the key features
and mechanisms of these proteins to aid in future discussion of the therapeutic, diagnostic
and preventative strategies involved in HIV/AIDS research. Figure 1.3 gives an overview of
the viral structure.
The Structural Proteins
MA – The matrix proteins are formed from the N-terminus of the Gag precursor protein
and are highly conserved throughout retroviruses. The matrix proteins form the inside coat
of the viral envelope and are closely associated with the viral membrane [67]. The protein is
crucial for viral assembly and for the targeting of the Gag-Pol precursor to the viral mem-
brane. In native trimeric form, the myristoylation of the protein allows the insertion of these
lipids into the acquired host lipid bilayer of the virus [68].
CA – The capsid proteins (p24) assemble to form an unusual cone-shaped shell around
the viral RNA. The protein consists of two independently folded domains which are joined
through a flexible linker [69]. These proteins form hexameric structures (and occasionally
pentamers) which assemble to form the shell. The capsid is important for delivering the
viral RNA into the host cell through association with a host cell protein, cyclophilin A [70].
In non-human primates, the protein TRIM5 binds to capsid proteins, preventing viral un-
coating and is thought to be part of the high levels of viral control infected primates display
(see Section 1.4.7). Human TRIM5 is not active against HIV but is being explored for the
design of potent inhibitors [71]. The presence of p24 can also be used as a diagnostic assay
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Figure 1.2: Genomic structure of HIV. The provirus is coded for by a 9.5 kb strand of
RNA, bordered by long terminal repeats (LTR). This RNA strand encodes the genes for
the structural proteins (GAG), enzyme cassette (POL) and envelope proteins (ENV) as
well as regulatory and assistant proteins. Through differential RNA splicing and reading
frameshifts nine gene products can be coded for. Figure adapted from [72] and [73].
for HIV through detection of the p24 antigen (Section 1.4.6).
SU/TM – The envelope proteins SU (gp120) and TM (gp41) are formed from the cellular
cleavage of the 160 kDa precursor Env protein. These two proteins assemble into a trimer
of heterodimers which form the surface of the virion. One viral particle contains around 17
of these structures [74]. These proteins are heavily glycosylated with high-mannose sugar
chains. These carbohydrate chains are used by the virus to ’hide’ the well-conserved regions
of the virus which could generate an antibody response and by being added by the host cell,
aid the virus in avoiding immune detection by appearing as ‘self’ [75].
SU initiates viral entry through binding to CD4, a protein expressed on the surface of
a family of T-cells and macrophages. This binding occurs cooperatively with binding to
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Figure 1.3: The viral proteins of HIV. The fifteen proteins encoded for by the viral RNA,
can be classed as viral enzymes (which carry out the main functions of the virus), structural
proteins (encompassing the viral membranes) and accessory proteins (which assist the virus
in replication and infection). Figure adapted from [78].
chemokine receptors such as CCR5. The binding induces large conformational changes in
both SU and TM. The core of TM rearranges into a bundle of six α-helices. This fusion
peptide is inserted into the cell membrane and a subsequent rearrangement of gp41 draws
the virus and cell together [76]. gp41 has been targeted with a fusion inhibition drug, En-
furtivide [77].
NC – The nucleocapsid proteins bind with the viral RNA forming a stable complex. This
interaction is crucial for both the reverse transcription of the RNA (by destabilising RNA
secondary structures aiding the reverse transcriptase enzyme) and for packaging the RNA
into the new virion [79,80].
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The Viral Enzymes
RT – The reverse transcriptase is responsible for transcribing the viral RNA into double-
stranded DNA which can be integrated into the host genome. In this role it both acts as a
DNA polymerase and an RNAse (if the RNA is complexed with DNA) [81]. RT is highly
error prone; mis-transcribing one in every 2000-5000 nucleotides [82]. The first antiretroviral
drugs to be approved were transcriptase inhibitors and now over half of approved HIV drugs
aim to inhibit this transcription. This inhibition is either through nucleoside analogues -
where nucleoside analogues which lack the 3’ hydroxyl group cause a termination in the
sequence, or non-nucleosides which act as non-competitive inhibitors by binding to a hy-
drophobic pocket in the enzyme [81].
IN – The integrase enzyme takes the transcribed viral DNA and ligates it to the host genome.
The protein monomer consists of three distinct domains: a sequence specific DNA binding
region, a catalytic core and a zinc binding region which allows the protein to oligomerise into
a tetramer [83]. The enzyme first removes two nucleotides from the 3’ end of both strands
of the viral DNA and then ligates these ‘sticky’ ends into the 5’ end of the host DNA [68].
Integrase inhibitors are the most recent addition to the antiretroviral therapy arsenal and
are included within combined therapies to minimise viral resistance.
PR – The viral protease is responsible for the cleavage of the Gag and Gag-Pol precursor
polyproteins. It is responsible for the formation of MA, CA, NC, p6 and all viral enzymes.
Its structure and function are reviewed in depth in Section 1.5.
Viral Accessory Proteins
HIV is distinct from the other members of the retroviral family due to the six additional
accessory proteins it synthesises. Of these Tat and Rev are both crucial to viral replication
by controlling gene regulation. Tat increases the rate of RNA replication by binding to the
5’ end of the viral RNA and acting as a promoter [84]. Rev meanwhile binds to incompletely
spliced RNA and carries it across the nuclear membrane into the cytoplasm [85]. In this
way Rev regulations the production of the structural proteins but also downregulates the
expression of Rev and Tat by removing mRNA before it can be spliced.
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The remaining four proteins, Vpu, Vif, Vpr and Nef are not required for viral replication
but are important for the infectivity of the virus. Nef down-regulates the display of CD4
and CCR5 receptors on the cell’s surface, thereby preventing super-infection which would
ultimately destroy the cell [86]. Vpu is only expressed by HIV-1 and also acts to down
regulate CD4. In addition, this protein aids in the release of the new virion from the cell
although the exact mechanisms are still unclear [87]. Vif protects the provirus from RNA
degradation by cellular enzymes by binding to an enzyme which edits RNA and ultimately
causing its proteolysis [88]. Finally, Vpr inhibits normal cell growth, delaying the cell in the
G2 phase where viral transcription is at its highest. It is also hypothesised that Vpr can
induce apoptosis in non-infected cells since it circulates in the blood plasma [89].
1.4.4 The Pathogenesis of HIV
HIV is most often transmitted through sexual contact (accounting for over 80% of cases)
where the virus targets the mucosal surfaces [90]. Given the range of routes for infection
and the associated variety of anatomy and histology, several cell types are hypothesised to
be the primary target for viral infection. Evidence suggests that ‘resting’ CD4 T-cells (those
which show no signs of activation) are responsible for the majority of initial infections, but
dendritic cells associated with the mucosal barriers are also thought to play a role [91].
Regardless of the site of primary infection, over the first few days of viral replication, the
virus collects in the gut-associated lymphoid tissue where initial viral amplification occurs.
Infected T-cells and virus particles then move into the blood stream resulting in a rapid
burst of replication in the spleen, bone marrow and blood. This corresponds to a spike in
the circulating viral load (Figure 1.4, green line). This rise in viremia levels (to 106–107 viri-
ons per millilitre of plasma) is associated with the onset of clinical symptoms which mimic
mononucleosis and are often attributed to influenza [92].
The sharp rise in viral numbers also corresponds to a dramatic drop in CD4+ cells, the hall-
mark of HIV infection. This depletion takes place primarily among gastrointestinal mucosa
CD4+ cells, rather than in the blood, though an understanding of this observation remains
to be found [94]. The levels of CD4+ cells may recover slightly but never return to normal.
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Figure 1.4: The acute phase of HIV infection is characterised by a steep drop in CD4+ cells
(orange line), a spike in the circulating viral load (green line) and a sudden rise in CD8+
cells (blue line). Progression to AIDS is classified by a drop in CD4+ level and a rise in viral
load. Figure adapted from [92,93]
The viral load also significantly decreases after its peak. This reduction and the recovery of
CD4+ count is due to the onset of immune system control of the virus.
As further discussed in Section 1.4.6, an initial antibody response is not detected until
about 3 months post-infection. However, within days of the viral load reaching its peak,
CD8+ T-cells, which recognise epitopes of HIV proteins, appear (Figure 1.4, blue line).
These cytotoxic T-cells cause the lysis of cells presenting HIV antigens and are thus thought
to control viral replication. The efficacy of viral control by CD8+ cells is responsible for es-
tablishing the ‘set-point’ of the viral load. The level of this plateau is crucial in determining
how fast progression to AIDS will occur [92].
The onset of immune system control establishes a clinical latent state which, without an-
tiretroviral therapy, may last for around a decade [95]. During this phase, patients are
typically asymptomatic and viral loads remain stable. However, despite the immune re-
sponse, viral levels are never totally eradicated since reservoirs of the virus are established
within certain cell lines. Predominantly these are long-lived macrophages which are also
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responsible for delivery of the virus to brain tissue [96]. Macrophages are ideally suited to
act as reservoirs since they can hold large quantities of circular viral DNA for almost two
months and are resistant to the viral cytopathic effects [97]. The clearance of these reser-
voirs remains a major challenge for antiretroviral therapy; it is predicted that with currently
available drugs it would take 60 years of constant therapy to totally eradicate the virus
from these cell lines [98]. Very recent work has shown that delivering extracellular ATP to
macrophages induces release of HIV-1 from these cells and may prove a new pathway to
clearing the virus from its latent resting sites [99].
The WHO defines progression to AIDS as the point at which the CD4+ cell count reaches
200 cells/µL [100]. This stage of the disease also corresponds to an increase in opportunistic
infections and the development of certain types of cancer which are more prevalent in the
case of a compromised immune system. Virologically, the levels in the blood plasma rise dra-
matically again. By this point, the majority of lymphoid tissue has been destroyed, causing
the release of harboured virions [95]. The destruction of the lymphoid tissue is also responsi-
ble for the majority of the late-stage immunosuppression, with CD8+ cells and macrophages
being the sole remaining circulating T-cells. Death, usually from an opportunistic disease,
follows within a year and a half without treatment [101].
1.4.5 Clinical Prevalence
Since the beginning of the HIV/AIDS pandemic an estimated 78 million people have been
infected with the HIV virus. Globally at the end of 2014, around 36 million people currently
live with HIV of which 2.6 million are children under the age of 15. In 2014 (the most
recently available data) there were 2.0 million newly reported infections and 1.2 million
deaths [102]. HIV is also the world’s leading infectious killer.
Although HIV/AIDS is a global pandemic, its incidence is not uniform across the globe
(Figure 1.5). The majority of cases (24.7 million, 70.6% of total patients living with HIV)
are in Sub-Saharan Africa where the prevalence is 4.7% compared to a global prevalence of
0.8%. The Sub-Saharan population also accounted for 73% of adult and child deaths due to
AIDS in 2013 [103]. This global imbalance has worsened in recent decades, despite interna-
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Figure 1.5: Map showing the global prevalence of HIV/AIDS. Figure adapted from WHO
Global Health Observatory data 2013 (2014 country breakdown not yet available). Data
is given as the number of reported cases per WHO region. Values shown are mid-range
estimates to account for variation in public health reporting.
tional efforts to increase access to antiretroviral therapies. Until 1994, AIDS was the leading
cause of death amongst 25-44 year old adults within the US population, but successful treat-
ment programmes have significantly lowered the death rate in developed countries [104].
Within most countries, the HIV/AIDS epidemic is usually concentrated within specific
groups of the population who are considered at higher risk of contracting the disease. For in-
stance higher prevalence is found in men who have sex with men (MSM), injecting drug users,
sex workers and those who are regular partners of these groups. Sub-Saharan Africa mean-
while has a generalised epidemic which is self-sustaining within the population at large [73].
1.4.6 Diagnosing HIV
The early and accurate diagnosis of HIV is critical to a good clinical prognosis and minimising
the risk of developing AIDS. Acute HIV infection also corresponds to the highest levels of
infectivity and thus prompt commencement of antiretroviral therapy can also significantly
reduce the risk of further transmission [105]. Very early detection, however, still remains
challenging due to the lack of detectable circulating biomarkers for the first ten days after
infection (Figure 1.6). HIV can be detected serologically or genomically. Testing guidelines
recommend all positive results are confirmed by a secondary test. The EU specifies that
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all new assays reaching the market must demonstrate a sensitivity (correctly identifying
positive cases) of 99.5% (based on at least 400 HIV-1 cases and 100 HIV-2 cases) and a
specificity (correctly identifying negative results) of 99.5% (based on at least 5000 samples
including 100 from patients who have a diagnosed condition which could affect results) [106].
Enzyme Immunoassays
The majority of HIV diagnosis relies on the detection of antibodies and antigens within the
blood plasma. The first generation of these tests detected IgG antibodies but were only
specific to a single clade of HIV-1. In addition, they were only able to detect infection
around two months after infection [107]. Second generation tests replaced antigens from
viral lysates with recombinant proteins. These also detected HIV-1 IgG but around a week
earlier than the original assays [105]. First and second generation tests were replaced by
third generation tests in 2007. These tests proved a considerable improvement as they were
able to recognise IgG and IgM from both HIV-1 and HIV-2 [108]. The use of two antibodies
lowered the detection limit of the assay, resulting in positive signals being detected only three
weeks after infection. The most recent fourth-generation tests build on the third generation
by adding the multiplexed detection of the viral capsid (p24) protein [109]. These tests can
now detect HIV within two weeks of infection. To date, the WHO has evaluated around 40
commercially available assays for use as diagnostic devices [110]. The majority of these tests
show a 100% sensitivity and a specificity above 99%.
Nucleic Acid Testing
Nucleic acid tests (NAT) detect HIV specific RNA sequences through amplification by the
polymerase chain reaction (PCR). The RNA is first transcribed into DNA by the recom-
binant, viral reverse transcriptase before being amplified by PCR and detected through
hybridisation. NAT gives the earliest positive signal, appearing several days before the first
antigens (Figure 1.6). The tests are widely used in the United States for screening blood
banks where samples are pooled and batch tested [111]. Despite their accuracy and early
detection, they are being phased out for fourth generation antibody tests which are less
expensive and can recognise at least 80% of individuals who tested positive through NAT
but were negative to earlier assays [108].
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Figure 1.6: Graph showing time until reliable positive detection of HIV given the varying
circulating load of biomarker. (1-4) indicate 1st-4th generation immunoassay tests and N is
nucleic acid amplification. Figure adapted from [108].
Confirmatory Testing
Testing guidelines require that any positive result is subsequently retested to confirm the
diagnosis [112]. Traditionally these confirmatory tests used Western blots to identify HIV
antibodies within the sample. However, with the advances in enzyme based immunoassays
described above, it has become simpler and more cost-effective to use a fourth generation
assay. These Western blot confirmatory tests also only detect IgG antibodies (like the first
and second generation tests) and thus an early reactive sample detected via NAT or fourth
generation assay may give a false negative on confirmation.
Rapid Testing
Rapid antibody tests have been developed which can detect HIV specific IgG or IgM in whole
blood and saliva as well as in plasma. These most commonly utilise lateral flow devices and
can give a result within 30 minutes. These tests do not require a laboratory, allowing HIV
testing to be performed in any setting within the community at the point-of-care. Due to
the biomarkers used, these tests do not perform as well as the enzyme techniques but are
convenient for targeting people who may be unwilling to have a blood test.
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In 2014 the UK government revoked the 1992 HIV Testing Kits and Services Regulations
allowing the legal sale of home-testing kits [113]. In April 2015, the first such test reached
the market offering an antibody based assay with a clinical sensitivity of 99.7% and a speci-
ficity of 99.9%. It is hoped the option of testing at home will encourage people to ascertain
their HIV status, especially those who may be reluctant to approach traditional healthcare
providers. However, the availability of a self-diagnosis for a chronic disease such as HIV
raises ethical questions about the effect of user error on test results or user misunderstand-
ing over the eclipse period (where the test may generate false negatives). There is also the
chance that users who have a positive result may not follow up with healthcare professionals
to seek confirmation or treatment, while undue psychological damage could follow from a
false positive result [114]. The advantages to minimising the transmission of HIV within the
population are, however, considered to be greater than the potential concerns raised by the
availability of these tests.
Diagnostic Challenges
In the developed world HIV testing is generally available to all those request it. However,
as discussed in Section 1.4.5 the majority of the disease burden rests in resource-limited
settings. Despite accounting for over 70% of the world’s cases, Sub-Saharan Africa only has
access to 1.3% of the world’s healthcare workers [115]. Diagnostic devices for these countries
must be cost-effective (the WHO’s analysis describes tests ranging from USD 0.35 to USD
21.5 per test [110]), rapid, accurate and robust. In many community settings the test must
also be able to function without access to electricity, cold-chain transport and storage of
biological reagents and complex equipment.
While the development of lateral-flow rapid assays has gone some way to alleviating these
problems, challenges still remain in identifying early acute infection (as discussed above),
the unreliability of tests posed by the vast genetic diversity of HIV (making resistant strains
or newly emerging strains difficult to detect) and the presence of coinfection (usually tuber-
culosis, malaria or hepatitis) reducing the accuracy of diagnosis. The use of rapid tests also
generally requires confirmatory testing which may be unfeasible in resource-limited settings.
Infant (less than 18 months) diagnosis also remains challenging due to the presence of ma-
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ternal antibodies which can disguise their true HIV status. Standard tests in these cases
require laboratory based immunoassay or NAT which may not be available. Alternatively
p24 assays are available but these remain highly susceptible to problems associated with
cold-chain transport and ensuring the reagents are still viable on use [116].
The development of HIV into AIDS is typically monitored through measurements of the
viral load and CD4 count (Section 1.4.4). In developed countries these measurements rely
on expensive, laboratory-based instruments and highly trained personnel. CD4 counts are
usually made using flow cytometry and several simple, low-cost cytometers have been de-
veloped for use in centralised resource-limited settings. There has also been progress on
the development of point-of-care assays for CD4 count which are now reaching the mar-
ket [117]. In contrast, no point-of-care devices exist for viral load measurements due to the
difficulty of DNA amplification in the field. Currently these tests must be sent to centralised
laboratories, causing a loss to patient follow-up, given the time required for results to be
received [115,117].
The detection methods described here all rely on the identification of serological mark-
ers or HIV RNA. However, as discussed in Section 1.3, many conditions can be diagnosed by
detection of the disease related enzyme. Assays detecting HIV-1 protease have been devel-
oped and their limit of detection (compared to traditional biomarkers) is reviewed in [118].
Although there have only been a few assays described to date, these show detection limits of
the same order of magnitude as traditional methods such as immunoassays. Application of
protease biosensing to HIV could offer improvements to the cost and robustness of detection
assays by removing the dependence on antibodies and their associated cost and complexity.
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1.4.7 Towards a Vaccine for HIV
Despite many years of research, a vaccine for HIV still remains elusive. Vaccination would of-
fer the safest and most effective way of controlling the spread of the HIV pandemic. However,
vaccine development to date has only highlighted how much still remains to be understood
about the interactions of HIV with the host immune system. Many of the difficulties in
developing an effective vaccine can be attributed to the wide genetic diversity of the virus,
not only within one patient but within the global population (Section 1.4.2) as well as to
the innate ability of the virus to avoid the host immune defences [61]. These factors are
also responsible for the lack of knowledge of the immune correlates of protection – despite
almost 80 million infections there have been no reports of a natural immunity to HIV infec-
tion based on a cellular or humoral immune response [119]. Without an understanding of
natural immunity, vaccine development becomes more challenging.
Much of what we have learnt from HIV vaccinology has come from studies of the SIV
in non-human primates. Infection of Asian macaque monkeys with SIV most closely resem-
bles the progression of HIV in humans and as such these primates are the most commonly
used animal model in the development of HIV vaccines. Interestingly, SIV infection in most
natural African host primates remains a background infection and the characteristic destruc-
tion of CD4+ helper T-cells is never observed. This non-pathogenic infection thus never (or
extremely rarely) progresses to AIDS [120]. It is hoped studies of this natural viral control
can help to elucidate immunological mechanisms which can be exploited for human vaccine
development.
To date, almost 150 early phase clinical trials have studied HIV vaccines [121]. Of these, only
six have reached phase IIb/III trials (summarised in Table 1.1), and of those six, only one
has shown promising results. Detailed reviews of HIV vaccinology can be found in [122–124]
but we describe here a few of the key strategies currently under study.
Broadly Neutralising Antibodies
Neutralising antibodies recognise a pathogenic antigen and prevent it from infecting a host
cell. In the context of HIV, broadly neutralising antibodies (BNAbs) elicit a response to
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Study Vaccine Type Population Efficacy Other Results Ref.
VAX003
+
VAX004
recombinant
Gp120
2546 injection drug
users (VAX003)
5403 high risk
MSM (VAX004)
None
observed
N/A [125,126]
Step +
Phambili
recombinant
adenovirus
(rAD5)
expressing
Gag, Pol, Nef
3000 high risk
MSM (Step)
801 heterosexuals
(Phambili)
None
observed
Trial halted
early due to
increasing in-
fection risk in
uncircumcised
men who were
Ad5 seroposi-
tive. Phambili
recruitment
was halted
due to Step
results.
[127]
RV144 canarypox
viral vector
expressing
Env, Gag, Pol
with VAX003
boost
16,402 primarily
low-risk
heterosexuals
31.2% over-
all efficacy
for preven-
tion
68% efficacy
for low or
medium risk
participants,
no efficacy
for high risk
group
[128]
HVTN505 DNA encod-
ing Gag, Pol,
Nef and Env
with aden-
oviral vector
boost
2505 high risk
MSM
None
observed
Trial halted
due to in-
creased risk
of infection
among vac-
cine recipients
compared to
placebo
[129]
Table 1.1: Summary of phase IIb/III HIV vaccine trials to date. Table adapted from [123,
124].
multiple genetically diverse HIV strains. Natively, a broad response only arises in a few HIV
infected patients and then only after several years. The production of neutralising antibod-
ies on exposure to a vaccine is a strategy that has been well utilised in other diseases and
the search for HIV BNAbs has been studied for some years.
As discussed in Section 1.4.3 the viral envelope glycoprotein (Env) consists of a heavily gly-
cosylated trimeric group of heterodimeric gp120 surface proteins and gp41 transmembrane
proteins. This glycosylation helps to shield the highly conserved regions of the proteins from
antibody recognition. Many of the BNAbs isolated to date target the V2 and V3 loops of
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gp120 as well as the glycans bound to those proteins [130]. Others target the CD4 binding
site although a recent study found the protective effects of CD4-targeting BNAbs were less
effective at protecting macaque monkeys than antibodies targeting the Env proteins [131].
On account of this, the first vaccines to enter later stage clinical trials (VAX003 and VAX004)
were recombinant gp120 protein subunit vaccines derived from two different primary isolates
of HIV. Both trials elicited a minimal neutralising antibody response and showed no activ-
ity in protecting high risk individuals from HIV infection. Subsequent analysis of the trial
results showed that while the recombinant protein monomers were simple to construct, they
lacked the native conformational structure of viral Env. The lack of glycosylation of these
proteins also led to an in vivo lack of recognition of the immune system between the vaccine
and virus [132].
More recently, broadly neutralising responses have been stimulated by exposure to trimeric
structures that more closely resemble the native protein conformation [133, 134]. These
reports show that adding disulphide bridges between the gp41 and gp120 subunits or ex-
pressing the Env construct on a cell surface can stabilise the structure into its native shape.
While neither method produced antibodies against heterologous strains, these advancements
show that the generation of native-like immunogens is now possible which will help in the
design of the next-generation vaccine.
Eliciting Cellular Immunity
With the apparent failure of the VAX trials, focus shifted to the development of vaccines
which stimulate a cytotoxic T-lymphocyte response. These cells produce an immune re-
sponse by recognising pathogenic antigens displayed on the surface of MHC-1 molecules and
then destroying infected cells. Priming a T-cell response (specifically CD8+) is hypothesised
to react to a viral challenge far earlier than a humoral response. By inducing an immediate
response, the virus should be able to be destroyed within infected cells before the infection
can be established throughout the host [135].
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T-cell targeting vaccines take advantage of the ability of antigen presenting cells to take up
plasmid DNA and can express the encoded proteins via MHC-1. There are several different
ways in which a T-cell response can be induced but the most utilised in HIV vaccinology are
the delivery of genes using a viral vector or the delivery of genes encoded in DNA plasmids
as a DNA vaccine [136]. These can be combined with a protein boost such as those described
earlier.
The next set of vaccines to enter phase III clinical trials after the failed VAX trials all
used a recombinant viral vector to induce a T-cell response. Step and Phambili both used a
recombinant adenovirus expressing the Gag, Pol and Nef genes. The trials were halted early
when efficacy boundaries were reached and an increased risk of HIV infection was found
among men who were adenovirus seropositive before the trial and who were uncircumcised.
The reason for this increased rate of infection remains unclear [137]. These trials showed
an induced but weak CD8+ response. The successful RV144 also used a viral vector, in this
case a recombinant canarypox virus with a follow up boost of the protein subunit used in the
VAX003 trial. Together, this generated a moderate T-cell response as well as a weak neu-
tralising antibody response – suggesting both cellular and humoral responses are required
for immune protection [138].
The most recent HIV vaccine trial to conclude was the HVTN505 trial. This used a DNA
vaccine which can deliver the same genes as the vector methods described above but without
generating an immune response to the vector itself as was observed in the Step trials. Un-
fortunately, this trial was also halted early due to efficacy boundaries being reached. Each
trial, whether successful or not, presents a greater understanding of the immunological inter-
action between host and HIV and demonstrate that a safe and effective vaccine is possible.
It is predicted that given the current development timelines, the next phase III trial of an
improved vaccine is unlikely to start until 2019 [139].
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Figure 1.7: The structure of HIV-1 protease with the catalytic triad Asp-Thr-Gly shown in
bond form. Structure coordinates taken from PDB 1HHP and visualised in Visual Molecular
Dynamics (VMD) 1.9.1 [142].
1.5 HIV-1 Protease and its Role in HIV/AIDs
As discussed in Section 1.4.3, the viral enzymes are crucial to the activity and infectivity of
HIV. Of these enzymes, the viral protease is responsible for the maturation of new virions as
they leave the host cell. Specifically, the enzyme cleaves the Gag and Gag-Pro-Pol precursor
polyproteins, separating MA-CA, CA-p2, p2-NC, NC-p1, p1-p6, PR-RT and RT-IN [140].
Due to its ubiquity in forming mature viral proteins, inhibition of HIV-1 protease has been
a key aspect of antiretroviral approaches (discussed in more detail in Section 1.6). Indeed
it has been shown that a 50-fold reduction in enzyme activity (kcat) is sufficient to prevent
the formation of new infectious virions [141].
HIV-1 protease is an aspartyl protease, comprised of a symmetrically arranged homodimer
of a monomer of 99 amino acids, making it the smallest of the aspartic enzymes. Its crys-
tal structure was first reported in 1989 by Navia et al. and later refined by Wlodawer et
al. [143,144]. These crystal structures revealed that each monomer of the enzyme contains a
glycine rich loop (formed as an extended β-sheet) which forms a flap over the binding cavity
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and that the N- and C-terminii of the monomers form the dimer interface as four β-strands
(Figure 1.7). The enzyme’s active site is formed at this interface, with each monomer pro-
viding one Asp-Thr-Gly sequence, the catalytic triad characteristic of the aspartyl proteases.
Since these first studies, more than 140 enzyme structures have been reported of both wild-
type and mutant forms, complexed with various inhibitors [145]. The structure of HIV-1
protease differs from other aspartyl proteases by having two flaps rather than the single
flap observed in pepsin-like (non-viral) aspartic enzymes [146]. These flaps are crucial to
substrate binding and to exclude water from the active site.
The protease is also responsible for its own formation (autoprocessing) from the precursor
proteins. This is initiated by the correct folding and dimerisation of the Gag-Pol polypeptide
chain, forming an active site which can then cleave the protease free of the precursor. The
catalysis rate of this formation is controlled by the pH of the environment, helping to regu-
late viral replication, although the exact method of regulation remains unknown [147, 148].
The cleavage sites for autoprocessing are found to be L5/W6, L33/E34 and L63/I64 [149].
However, this autoproteolysis can make working with the enzyme difficult as at room tem-
perature it thus degrades rapidly.
The HIV-1 protease also differs from most other aspartyl enzymes by being most active
between pH 4-6 compared to an optimal pH range of 2-4 in other members of the family.
This is thought to be due to the hydrogen bond network within the active site, where the
HIV-1 protease lacks a hydrogen bond from Asp32 [150]. The enzyme is also most stable
between these pH values due to the stabilisation of the salt bridges linking the two protease
subunits (Asp29/Arg87 - Arg8’). This is also unusual since most proteins are most stable
near their isoelectric point (in this case pI=8.66) which is not observed in this case [151].
1.5.1 Substrate Recognition
Since HIV-1 protease is responsible for the cleavage of around ten, non-homologous, se-
quences within the Gag-Pol precursor polypeptide, its substrate specificity is not easy to
define. The cleavage sites can, however, be grouped into two types; the first have an aro-
matic residue adjacent to a proline, the second have hydrophobic residues (excluding Pro)
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at the scissile point [140, 152]. Analysis of protease crystal structures bound to substrates
reveals that enzyme recognition relies on the asymmetric shape of the peptide sequence,
rather than on a specific amino acid sequence [153].
In its symmetric, homodimeric form, the protease forms a binding ’tunnel’ along the dimeric
interface. The binding of an asymmetric substrate causes a conformational change that
adapts to the shape of the substrate. The enzyme’s active site has seven sub-sites which can
bind individual amino acid residues, meaning that the shortest sequence the protease can
cleave is six amino acids in length, though efficient cleavage usually requires at least seven
residues [154]. The substrates bind to the active site in an extended β-sheet conformation
and are stabilised through several hydrogen bonds, predominantly between the protease
backbone (particularly Asn25’, Gly27/27’ and Asp29/29’ in the binding cleft and Gly49/49’
in the flap tips) and the substrate backbone [153,155].
1.5.2 The Catalytic Mechanism of HIV-1 Protease
After the discovery of the viral protease it took ten years for a consensus on the catalytic
mechanism of the aspartic enzyme family to emerge. These studies eventually led to a
description of an acid-base catalysis where cleavage of the peptide bond occurs through a
water molecule mediated nucleophilic attack on the carbonyl amide [156, 157]. The most
commonly accepted mechanism of HIV-1 protease catalysis was described in 1996 by Silva
et al. who used a combination of X-ray crystallography studies and quantum chemistry
molecular modelling [158].
These studies show that a peptide substrate first binds in an ’asymmetric’ fashion. This
asymmetry arises since the trans conformation of a peptide bond is almost 1 A˚ longer than
the cis conformation. Thus, due to the structure of the enzymatic binding cleft, only one
side of the cleavage site will be favourably interacting. In the presence of an active site water
molecule, the peptide carbonyl is hydrated and as a result a proton is transferred from the
initially protonated aspartic residue (Asp25) to the non-protonated aspartic acid (Asp25’)
of the other monomer (Figure 1.8i). The rotation of the peptide around the C-N bond into
a cis conformation is energetically favourable and stabilises the
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Figure 1.8: Catalytic mechanism of HIV-1 Protease. i) asymmetric binding of peptide to
active site, ii) conformational rotation around the C-N peptide bond, iii) proton exchange
from one hydroxyl to Asp 25 and the substrate N accepting a proton from Asp25’, iv)
peptide bond breakage and regeneration of initial aspartate protonation states. Figure
adapted from [158].
binding of the hydrated substrate (Figure 1.8ii). This binding conformation brings the
peptide in closer contact with the aspartic residues and causes the donation of a proton
from one hydroxyl to the charged aspartate (Asp 25) and the concurrent acceptance of a
proton by the backbone nitrogen’s lone pair from the other aspartate (Figure 1.8iii). This
results in the cleavage of the peptide bond and a return to the original protonation state of
the aspartic residues (Figure 1.8iv).
More recent conformational dynamics studies have elucidated the role of the protease flap
regions in catalysis [159, 160]. These studies show that the isoleucine found at the tip of
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the flap (Ile50, Ile50’) are critical for the stability of the substrate within the active site
since they provide hydrogen bonding to the carbonyls on either side of the scissile site via
a water molecule. These hydrogen bonds lock the enzyme and substrate complex into the
correct position for the proton transfer described above to occur. These experiments also
reveal that the rate-limiting factor of peptide bond hydrolysis is the organisation of the
active site, mediated by a structural reorganisation of the flap regions in preparation of sub-
strate entrance and not substrate binding/release as had earlier been hypothesised. Other
mechanisms taking into account the distortion of the scissile bond (which is hypothesised to
polarise the carbonyl group, increasing its electrophilicity) have been suggested but are less
favoured and are reviewed in [145].
1.6 HIV-1 Protease as a Drug Target
Given the essential role HIV-1 protease plays in the lifecycle of HIV, it is little surprise
that the development of inhibitors of the enzyme has been a key focus in the path to HIV
therapeutics. As discussed in Section 1.4.1, the development of the first protease inhibitor,
Saquinavir in 1995, caused a significant drop in the death rate of patients with AIDS. To
date, ten protease inhibitors (PIs) (Figure 1.9) have been approved for use. Four of these
drugs were approved within a decade of the identification of the viral protease as a potential
target, under accelerated FDA approval regulations.
The development of these drugs has been the product of a significant shift towards structure-
assisted (‘rational’) drug design. The structural insights detailed in Section 1.5 have relied
on techniques such as X-ray crystallography, Nuclear Magnetic Resonance (particularly for
acquiring information on protein dynamics) and computational studies. These experimen-
tal techniques have shown how the protease interacts with its natural substrates, allowing
for the design of inhibitors which mimic the high binding affinity of the native polypeptide
sequences, while preventing cleavage. To this end, all of the inhibitors with the exception of
one, Tipranavir, are competitive peptidomimetic structures. These drugs contain a hydrox-
yethylene core in place of the scissile peptide bond [161].
Crystal structures of the PIs complexed with the protease have revealed several shared
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Figure 1.9: Structures of clinically approved Protease Inhibitors. Amprenavir was replaced
by its prodrug form in 2003. IC50 data extracted from [161].
features between the different drug structures. In general, these drugs are smaller than the
natural peptide substrates and thus show the strongest affinity to the four subsites closest to
the centre of the active site [162]. They also contain large hydrophobic groups surrounding
the hydroxyethylene core which improves the affinity by interacting with the hydrophobic
sites within the binding cleft [163]. In order to mimic the natural peptide substrate, these
molecules also contain polar groups which mediate the hydrogen bonding networks between
the substrate, protease and active site water molecule.
Saquinavir, the first drug to be approved, showed an IC50 (the concentration required to
inhibit viral replication by 50%) between 20-500 nM dependent on cell type but suffered
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from poor bioavailability. This was soon joined by Ritonavir (the first drug to be approved
in Europe) and Indinavir. These showed IC50 values of 4-158 nM and IC95 values of 25-100
nM respectively. Ritonavir showed a much longer circulating half-life than Saquinavir, per-
mitting twice daily dosing [164]. However both drugs were limited by extensive toxicity
issues, mainly affecting the kidneys and gastrointestinal tracts and their use has thus been
almost totally been replaced by newer drugs [161].
Nelfinavir demonstrated a better IC50 than the previously approved drugs (10-60 nM) and
with far fewer side effects. It too, suffered from poor bioavailability and has also been grad-
ually phased out except for use during pregnancy, where its lack of side-effects results in a
safer drug [165]. It was subsequently discovered that Ritonavir inhibited cytochrome P450
3A4, an enzyme commonly found in the liver and intestines which oxidises small organic
molecules. Combining existing PIs with a low dose of Ritonavir was thus shown to signif-
icantly improve the half-life and bioavailability of these drugs, allowing lower dosages and
thus reducing the associated toxicity [166].
The next drug to be approved, Amprenavir, showed equivalent IC50 values to Nelfinavir
but analysis showed it failed to suppress HIV-RNA in most patients. This was found to be
due to the high pill burden which dissuaded patients from taking the drug [161]. In 2003,
Amprenavir was discontinued and replaced by its prodrug form, Fosamprenavir, which is
metabolised in the body into the drug compound. This form led to a higher plasma concen-
tration (due to the slower drug release time) and hence lower pill burden [167].
Lopinavir has been the only drug to be originally co-formulated with Ritonavir. The drug
shows an excellent IC50 of 6-17 nM and remarkably shows very little resistance with only
isolated mutations being reported [168]. However, failure of the drug was reported in those
patients who were PI-experienced and had thus built up a wide library of protease muta-
tions [169] before beginning Lopinavir treatment. Atazinavir, by contrast to the other PIs,
is an azapeptide (where the Cα of a peptide bond is replaced by a nitrogen [170]). It shows
potent activity (IC50 = 2-5 nM) and as a result only requires once-daily dosing and exhibits
few side-effects.
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Tipranavir was brought to the market in 2005. It is the only non-peptidomimetic PI and as
a result is less effective than the other inhibitors described above. It also induces expression
of cytochrome P450, resulting in the need for a double dose of Ritonavir as a boost. Severe
side-effects have also been reported including intracranial bleeding and hepatitis [171]. De-
spite these problems, this inhibitor shows superior behaviour as a salvage drug in patients
who demonstrate resistance to multiple PIs.
The most recently approved PI was Darunavir in 2006. Although initially designed to target
drug-resistant proteases, the molecule demonstrated exceptional potency (IC50 = 1-5 nM)
and its use has thus been expanded into earlier treatment regimes. It is thought that the
hydrogen bonds Darunavir forms with the protease backbone slow the development of drug
resistance [172]. Structurally, Darunavir is an analogue of Amprenavir where the terminal
tetrahydrofuran (THF) group has been duplicated and fused to form bis-THF, thereby im-
proving its efficacy [173].
It has now been almost ten years since the last new protease inhibitor was approved, however
there is still a considerable need for new therapeutic options since the number of patients
receiving antiretroviral therapy is growing and with their increased life expectancy comes
a greater risk of becoming resistant to multiple drug options. Between 2008 and 2010 four
compounds reached phase 0 or 1 clinical trials, but none have progressed further [174]. Fu-
ture inhibitor development will need to rely on a novel chemical structure and not simply an
improvement on the peptidomimetic backbone. In this pursuit, more detailed understand-
ing of the nature of protease mutations is required along with a holistic approach which
combines both the “rational” structural methods and the high-throughput library scanning
techniques that the pharmaceutical industry have developed.
1.6.1 Drug-Resistance Conferring Mutations
As described in Section 1.4.2, HIV undergoes rapid replication and through the error-prone
Reverse Transcriptase enzyme quickly establishes a quasi-species with a large genetic vari-
ability within one host. The number of distinct HIV variants within one patient can be
orders of magnitude higher than the number of wild-type viruses within the HIV-infected
CHAPTER 1. INTRODUCTION 53
Figure 1.10: Mutations to the structure of HIV-1 protease which affect resistance to PIs. a)
Number of clinical PIs affected by mutations in different residues (Data extracted from the
Stanford HIV Drug Resistance Database [175]), b) Residues outlined in (a) shown within
the structure of HIV-1 protease. Residues are colour coded by the impact a mutation has
on broad-spectrum resistance.
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population [176]. This ability to rapidly mutate allows the evolution of viral proteins which
show resistance to all clinical HIV drugs, not only PIs (reviewed in [177]).
The first generation of PIs (Saquinavir, Indinavir, Ritonavir, Nelfinavir) were all designed
with large hydrophobic side chains to improve the binding efficiency. However, exposure
to these drugs led to significant resistance through active site mutations, specifically D30N,
G48V, I50L/V, V82A/F/T, I84V and L90M [178]. Some of these mutations cause the failure
of only one drug (for instance, the D30N affects only Nelfinavir) while the I84V mutation
causes broad resistance to all PIs [179] (Figure 1.10). These active site mutations cause a
conformational shift to the binding cavity. Changes in binding affinity are a result of a loss
of hydrophobic interactions (from the loss of hydrophobic residues) and a rearrangement of
the backbone due to the flexibility of the enzyme structure [180]. These structural shifts
show changes both in the vicinity of the catalytic triad but also in the position of the loop
in relation to the bound inhibitor.
In contrast, the second generation PIs (Fosamprenavir, Lopinavir, Atazanavir, Tipranavir
and Darunavir) were designed with much smaller hydrophobic moieties [162]. These smaller
groups improve the resistance profile of the drugs by making them less susceptible to changes
to the binding cavities. Their enhanced number of hydrogen bonds, also makes them less
sensitive to mutations, since the hydrophilic residues are more highly conserved (47.5%
of hydrophilic residues within the protease are only observed to mutate in <1% of struc-
tures [153]).
In general, these PIs have a much higher barrier to resistance, and often require multi-
ple mutations before a decrease in efficacy is observed. Strong resistance to Lopinavir or
Darunavir (boosted with Ritonavir), usually requires at least 3 mutations, although pro-
teases with upwards of 20 mutations have been regularly observed in patients displaying
resistance to these drugs [181]. Atazanavir, however, has a distinct resistance profile to the
others, being vulnerable to an I50L mutation. This mutation however, increases the suscep-
tibility of the enzyme to other drugs [182].
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Mutations to the enzyme structure not only affect the binding efficiency of the inhibitors
but will also impact the catalytic ability of the enzyme. While an initial mutation may
lower the binding affinity but also lower the catalytic rate of the enzyme, secondary (com-
pensatory) mutations can often lead to a recovery of activity through additional structural
changes [183]. The mutations K45I and M46L, for instance, increase the enzyme’s activity
by upwards of 100% [184].
1.7 Conclusions
Despite almost 35 years of research, the field of HIV/AIDS still poses many unique problems.
This Chapter has aimed to give a brief overview of the current state of knowledge in this
area, against a background of the historical, medical and societal implications of the AIDS
pandemic. The major focus of research in the coming decades will undoubtedly focus on the
development of an HIV vaccine, novel therapeutics and diagnostic devices that can detect
the virus earlier. Given the large burden of this disease in resource-limited countries, these
new drugs and technologies will have to be cost-effective and easy enough to use at the
point-of-care. This thesis will examine the role peptide-protein interactions will have in
providing new routes to answering some of the challenges raised in this review.
Chapter 2
Multivalent peptide interactions
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protease
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2.1 Introduction
This chapter describes the isolation of peptide ligands of HIV-1 protease through phage
display. These peptides are then combined to explore the effect of multivalency on enzyme
inhibition. The concepts of multivalency and its role in nature is described here before the
discussion of experimental work is carried out. Sections of this chapter have been accepted for
publication in Chemistry of Materials as “Designing peptide nanosensors with dual specificity
for the detection of HIV-1 protease” authored by K. Herpoldt, A. Artzy-Schnirman, A.J.
Christofferson, A.J. Makarucha, R. de la Rica, I. Yarovsky and M.M. Stevens.
2.1.1 Multivalency in Nature and Design
Multivalency can be considered as the “operation of multiple molecular recognition events
of the same kind occurring simultaneously between two entities such as molecules, molecular
aggregates, viruses, cells, surfaces” (Krishnamurthy, Estroff and Whitesides, 2006 [185]).
Multivalency is an ubiquitous concept in biology involved in the binding of virus particles
and bacteria to the surface of cells, the binding and interactions of cells to other cells and
immune system recognition among many others [186]. Of these, antibodies are one of the
most well-studied systems, having multiple recognition sites for their antigens or “non-self”
particles. This can range from two receptor sites (e.g. IgD, IgE, IgG), four (IgA), six (IgA)
or even ten (IgM). Polyvalency here allows high-affinity binding to surfaces with repeated
characteristics (common with particles such as viral capsids).
Multivalency in most instances will improve the effective binding constant by orders of
magnitude. This has been particularly well described for carbohydrate binding proteins
(lectins) where the affinity constant of binding to a monomer unit of the carbohydrate may
only be on the order of mM but binding to a longer polymer (tetravalent compared to mono-
valent) shows an increase of 106 in binding strength [187, 188]. It is believed multivalent
recognition offers several advantages to biological processes – binding characteristics can be
fine tuned by small changes to individual monomeric units meaning that recognition can be
more easily modulated (of particular advantage to immune system recognition), multivalent
recognition will also have different kinetic profiles than single recognition events which can
help with the specifity of binding.
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These principles have also been well studied in the design of novel therapeutics where mul-
tiple protein interactions can be incorporated into non-natural systems. The flexibility and
scope offered by chemical synthesis techniques opens up new avenues that do not necessarily
depend on the manipulation of existing biological systems. One of the first systems designed
along these principles was a polyvalent inhibitor of anthrax toxin [189], where a peptide that
inhibited the binding of antrax toxin to cells was identified through phage display and poly-
valently displayed on a polyacrylamide backbone increasing the IC50 value by ∼7500 times
on a per-peptide basis, showing the potential of this technique. By tuning the valency and
spacing between the ligands, later work on a related system showed an increase in inhibition
of over 4-orders of magnitude [190].
Similar systems have also been developed that mimic natural antibodies where the comple-
mentarity determining region (CDR) of the antibody (the sections of the protein responsible
for recognising and binding to the target protein) are incorporated into synthetic polymer
structures. This has been demonstrated for blocking HIV-1 entry into T-cells and for de-
veloping carbohydrate, synthetic vaccines for HIV [191,192]. In these systems, multivalency
is used to confer the multiple recognition sites that antibodies utilise but also incorporates
the advantages of polymer therapeutics such as their inexpensive synthesis and purification
(which are very low compared to antibody production), stability to environmental shifts in
temperature and chemical storage and protection from enzymatic degradation. The latter
system above also uses this approach to target ’immunologically silent’ sites for binding
through the incorporation of non-natural peptide motifs.
2.1.2 “Molecular Tongs” for the Inhibition of HIV-1 Protease
As discussed in Chapter 1, HIV-1 protease is a dimeric enzyme made of two identical
monomer sub-units. One approach to inhibiting the enzyme is to destabilise the interface
between the two sub-units. This interface is formed by an anti-parallel β-sheet consisting
of the four N- and C- terminii of the two monomers. This β-sheet acts to join the two
monomers and to stabilise it.
In 1991 Zhang et al. and Schramm et al. [193,194] found that peptides derived from the N-
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and C- terminus of the HIV-1 PR monomer could be used to inhibit the enzyme’s activity.
Through sedimentation experiments it was observed that the size of the protein increased,
suggesting that the peptides were interfering with the interface of the enzyme, preventing
the protein from folding correctly. Further studies [195,196] showed that the inhibitory effect
of these peptides could be modulated by changing the length of the peptide sequence and
through which segment of the terminii was chosen. For instance, the addition of a serine to
the N-terminus of the C-terminal fragment (Thr-Leu-Asn-Phe-OH) increased the potency
of the inhibition 10-fold.
These peptides were then used in the first “molecular tongs” for the inhibition of HIV-1
PR. This term describes the use of two separate inhibitory ligands of the enzyme which are
joined together by a linker. This was first done using a Gly-Gly-Gly spacer [197] however
this is only 3.5 A˚ whilst crystallographic studies suggest a more appropriate distance for
the interfacial region is approximately 10 A˚. From this work flexible alkyl linker molecules
of a variety of lengths were designed to investigate the spacial requirements of the peptides
when bound to the protease [198,199].
Whilst these strategies target an area of the protease which is highly conserved due to
its role in stabilising the enzyme (and is thus more resistant to mutational changes), the
major disadvantage of these systems is their high conformational freedom which leads to
an unfavourably high entropy term in the formation of the inhibitor-enzyme complex. To
overcome this Bouras et al. and later Merabet et al. [200, 201] designed aromatic scaffolds
linked through flexible carboxy propyl arms to the peptide strands used previously. Scaffolds
based on naphthalene and quinoline were used to orient the peptide inhibitors. However,
in general, conversely to the expected entropic effects, rigidly linked systems remain less
effective than those joined by flexible linkers.
Concise reviews on this topic, including more detailed comparison about the effect of amino
acid sequence can be found in [202,203].
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2.1.3 Peptide Aptamers of HIV-1 Protease
Peptide aptamers are randomised peptide sequences of amino acids which are selected for
their ability to bind to a target protein of interest. They are the peptide analogue of DNA
aptamers which have been well-studied for this purpose [204]. Whilst both DNA and peptide
systems benefit from combinatorial searches which can reveal novel binding sequences, the
complexity of sequences that can be generated through peptide structures greatly outpaces
that found with standard DNA libraries since amino acids possess many more functional
groups as side residues than nucleic acids. However, the work of Gold et al. recently devel-
oped a DNA aptamer selection method using non-natural bases which incorporate as much
versatility in functional groups as peptide-based libraries [205]. This variety of side chains
can thus act to improve the affinity to the target as interactions are no longer limited to
hydrogen bonding. Peptides also have a more rigid backbone than nucleic acids which can
prove useful in reducing the entropy of interactions. A full comparison can be found in [206].
Peptide aptamers provide new tools for drug design, protein therapy and biosensing. They
are especially useful for monitoring protein-protein interactions where they can act as antag-
onistic binding partners. Their use as such tools is reviewed in [207, 208]. Peptides derived
from phage display also offer alternatives for antibody design [209] where the end product
can display affinities comparable to natural antibodies but, being peptide based, have lower
synthesis costs, higher activity on a per-mass basis and are far more stable to environmental
changes.
This chapter aims to use phage display, an in vitro biopanning technique, to isolate new
peptide motifs that bind to and recognise HIV-1 PR. These aptamers will then be incorpo-
rated into polymer systems where the principles of multivalent design will be used to design
inhibitors of HIV-1 PR with increased avidity. This should enable improvements in efficacy
of exisiting inhibitors and new methodologies to overcome the loss of inhibitor recognition
due to enzyme mutation (as discussed in Section 1.6.1).
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2.2 Materials and Methods
Unless otherwise stated all reagents and materials were purchased from Sigma-Aldrich
(Poole, UK) and used without further purification. HIV-1 protease was purchased from
BioVendor (Brnu, Czech Republic) and used without further purification.
2.2.1 Phage Display
Phage display is an in vitro selection technique which allows peptides with desired properties
to be extracted from large libraries. Other in vitro display technologies include yeast display,
ribosome display and mRNA display. Filamentous bacteriophage are viruses which infect
bacteria. They are useful for displaying a wide library of peptides since they have a small
genome which tolerates the insertion of genes of interest into non-essential regions. These
genes of interest are fused to the phage coat protein, resulting in particles that display the
encoded protein and contain its gene [210,211].
The M13 bacteriophages used in this work are part of the Ff family which specifically infect
E.coli. These phage particles are composed of five coat proteins (pIII), held together by
hydrophobic interactions, resulting in five surface-exposed N-terminal residues. By insert-
ing the gene of interest into this region, five versions of the encoded peptide are displayed
multivalently.
The Ph.D. kits from New England Biolabs are commercially available systems for per-
forming phage display, derived from orignal work by Scott and Smith, 1990 [212]. Three
variants of the kit are available; -7, -12 or -C7C. The -7 and -12 kits display a random
library of seven or twelve amino acids respectively whilst the -C7C kit displays a chain of
seven amino acids which is flanked by a pair of cysteine residues. These residues oxidise
during assembly, forming a disulfide bridge which cyclises the peptide sequence to a loop.
The libraries contain approximately 109 electroporated sequences which are amplified once,
giving approximately 100 copies of each sequence.
The general principle of phage display is shown in Figure 2.1. The phage, displaying the li-
brary of encoded peptides, is exposed to the immobilised target protein. After being allowed
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Figure 2.1: Schematic for the isolation of peptides through phage display. 1) phage display-
ing a library of peptides is exposed to the target protein, 2) non-bound phage are washed
away, 3) bound phage are eluted at low pH, 4) these phage are amplified in E.coli and
reapplied to the target protein and the process is repeated.
to interact, the non-bound phage are then washed away. Bound phage are eluted at low pH
and a population of E.coli is infected with the eluted particles. The E.coli act to amplify
the bound population. The phage are then extracted from the bacteria and applied to the
immobilised protein again. The process is repeated until enrichment is observed (normally
3 rounds). Phage DNA can be extracted from the E.coli and sequenced to give the amino
acid sequences that bind to the protein. Relative binding affinities of isolated clones are
measured by ELISA.
A Ph.D.-7 phage display kit (New England Biolabs, MA, USA) was purchased and the
recommended protocol was followed [213]. In brief, 2.4 µM HIV-1 protease was coated onto
the surface of a well of Nunc-ImmunoTM MicroWellTM 96 well plate in 0.1 M NaHCO3 and
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left at 4oC overnight. The well was then washed and blocked with a blocking buffer of 5
mg/mL bovine serum albumin (BSA) in PBST for an hour. After washing to remove bound
proteins, 5 µL of the phage library was added to each well in 95 µL Tris Buffered Saline with
0.05% (v/v) Tween-20, pH7.4 (TBST). The phage were allowed to interact for an hour before
non-bound phage were removed through vigorous washing. Bound phage were eluted with
0.2 M glycine-HCl (pH 2.2) including 1 mg/mL BSA. The eluted phage were then neutral-
ized with the addition of 1M Tris-HCl (pH 9.1) and then added to 20 mL of E.coli ER2738
and left to grow for 5 hours for amplification. The eluted phage were quantified by plating
these E.coli on LB XGal/IPTG (5-bromo-4-chloro-3-indoyl-b-D-galactoside/ isopropyl-b-D-
thiogalactoside) plates. Since the library phages are derived from the M13mp19 vector,
which carries the lacZa gene, phage-infected plaques acquired a blue colour when plated
on media containing Xgal and IPTG. Coloured plaques were picked and DNA sequenced
from these plates (sequencing was carried out by GATC Biotech, Germany). Subsequent
biopanning rounds were then carried out by applying the eluted and amplified phage to
plated HIV-1 protease. Three rounds of biopanning were carried out in this manner.
2.2.2 ELISA
Nunc-ImmunoTM MicroWellTM 96-well plates were coated with 1.2 µM HIV-1 protease in
0.1 M NaHCO3 and incubated overnight at 4oC. BSA was prepared at 1 mg/ml and coated
in the same buffer as a control. Wells were then blocked with 2% (w/v) skim milk in
PBST (0.05% v/v Tween-20) for 1 hour at room temperature and washed well with PBST.
Biotinylated peptides were purchased at >95% purity from Genscript (Piscataway, USA).
These were dissolved in PBS with 10% (v/v) DMSO (dimethyl sulfoxide) and were then
added at 100 µg/mL to each well and left to incubate for 1 hour at room temperature. The
plate was then washed again in PBST before the addition of streptavidin-linked hydrogen
peroxidase and left to incubate for 45 minutes. The presence of the peptide was quantified
by the addition of a tetramethylbenzidine (TMB) colorimetric substrate and the absorbance
at 450 nm was measured.
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2.2.3 Peptide Synthesis
Peptides can be synthesised through solid-state methods first described by Merrifield in
1963 [214]. Through this method, N-terminus protected amino acid monomers are sequen-
tially added on to a growing peptide chain, whose C-terminus is chemically tethered to a
polymeric solid-state support resin. The deprotected N-terminal amino group of the immo-
bilised peptide reacts with an excess (>4-fold) of an activated ester derivative of the next
amino acid to be incorporated, forming an amide bond between the amine group of the last
amino acid and the carboxylic acid group of the subsequent monomer.
The monomers to be added have their N-terminus protected by a labile group (usually
-Boc or -Fmoc), preventing potential self-polymerisation. After amino acid addition, the
free N-terminus is then deprotected (in the case of -Fmoc groups through exposure to mild
basic conditions, such as 20% piperidine in dimethylformamide (DMF)), exposing the amino
group. The resin is then washed with solvent to remove excess reagents and the cycle is
repeated for the next amino-acid in the sequence. Reactive side-groups of the amino acids
in the chain are also prevented from reacting with incoming amino acids through protecting
groups that are stable to the basic conditions required for synthesis but can be cleaved under
acidic conditions on completion of the target sequence.
When the desired sequence has been synthesised the peptide is then cleaved from the sup-
port resin under acidic conditions (which also acts to remove the protecting groups from
the the side-chains). This methodology is excellent for producing short peptide sequences
(generally <50 residues) at high purity. However, longer peptides or sequences with com-
plicated reside patterns are more challenging and require more technical approaches such
as fragment condensation where small sections of the final sequence are synthesised and
then linked off resin [215]. Alternatively, for long or complex sequences, synthesis through
recombinant bacterial expression can simplify the production process.
The peptides isolated through phage display were synthesised using this method on Fmoc-
Rink Amide aminomethyl-polystyrene resin (AGTC Bioproducts, Hessel, UK). Fmoc pro-
tected amino acid monomers (AGTC Bioproducts) were used in a 4-fold molar excess. Pep-
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tide bond formation was carried out through activation with N,N,N’,N’-Tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) at a 3.95-fold excess in basic con-
ditions (in the presence of N,N-Diisopropylethylamine (DIPEA) at a 6-fold molar excess).
After coupling, protecting groups were removed in 20% piperidine in DMF. All peptides were
synthesised on a 0.2 mmol scale. After synthesis the peptides were then cleaved and depro-
tected with 95:2.5:2.5 trifluoroacetic acid (TFA):triisopropylsilane(TIS):H2O for 3 hours and
precipitated and washed with cold diethyl ether. The crude peptides were purified to >95%
(determined by LC-MS) on a preparative C18 HPLC column using a water/acetronitrile
mobile phase containing 1% TFA and then lyophilised to remove any excess solvent.
2.2.4 Inhibition Assays
An assay to measure the inhibition of HIV-1 protease was performed using a fluorogenic sub-
strate of HIV-1 protease, purchased from Sigma-Aldrich [216]. This is a synthetic peptide
sequence that contains the HIV-1 PR cleavage site (Tyr-Pro) and two covalently modified
amino acids labelled with a FRET pair (EDANS, 5-2(aminoethylamino)-1-napthalene sul-
fonate and DABCYL, 4, 4’-dimethylaminoazobenzene-4-carboxylate). The substrate was
prepared in a 500 µM stock solution in DMSO. Assays were performed at room temperature
in a buffered solution of 0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 mM ethylenedi-
aminetetraacetic acid (EDTA), 1.0 mM dithiothreitol (DTT), 10% (v/v) DMSO, 1 mg/mL
BSA at pH 4.7. Enzyme and substrate concentrations were kept constant at 240 nM and
10 µM respectively. Measurements of the intensity at 490 nm were taken over 3 minutes in
a FluoroLog spectrophotometer (Horiba).
2.2.5 Surface Plasmon Resonance
Surface plasmon resonance (SPR) is an optical, biophysical technique that allows the moni-
toring of ligand-analyte interactions. Incident light at a sharply defined angle interacts with
a thin gold film on a glass surface (Figure 2.2a). Under conditions of total internal reflection,
an electric field passes through the glass in the form of an evanescent wave. The evanescent
field decreases exponentially with distance from the surface (on a Biacore instrument such as
that used here, the evanescent electric field penetrates about 150 nm [217]). At the correct
angle and intensity of incident light the evanescent field interacts with the delocalised elec-
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Figure 2.2: Schematic showing the principle of SPR. a) Incident light reflects from a glass
slide, the evanescent wave passes through and interacts with the gold surface where a surface
plasmon is created. This reduces the intensity of the reflected light. b) The relationship
between incident light angle and reflected light intensity. The absorption of energy by the
plasmon is highly dependent on refractive index and is thus affected by the presence of
ligands bound to the gold surface. When interactions occur on the surface, the angle at
which SPR occurs shifts (red curve).
trons in the gold generating plasmons (electron oscilations). This results in a characteristic
decrease in reflected intensity. The penetration of the evanescent field is highly dependent
on the refractive index of the media it passes into. Thus the angle at which the interaction
with the Au electrons occurs is also dependent on refractive index. This relationship can
then be used to measure the binding of ligands to the gold surface (and analytes binding to
the ligands) since binding events will cause a shift in the refractive index and hence SPR
angle (Figure 2.2b).
Because of its sensitivity to refractive index change, SPR is ideally suited to measuring
biological interactions. It can be used to investigate many biological systems including
antibody-antigen, ligand-receptor, DNA-DNA, DNA-protein and lipid-protein interactions.
Quantitative data for these systems can be easily extracted by measuring the rate of pro-
tein binding and dissociation, giving information about reaction kinetics (ka, kd), affinity
constants and equilibrium constants (KD) which can be used to understand the thermody-
namics of a system (∆G). A full discussion of the applications of SPR is beyond the scope
of this work but can be found in [218–220].
SPR experiments were carried out on a Biacore 3000 (GE Healthcare, Uppsala, Sweden) at
25oC using PBST, pH 7.4 (Tween at 0.005% v/v) as the running buffer. Dextran coated CM5
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chips were purchased from GE Healthcare and 50 µg/mL of BSA and 50 µg/mL of HIV-1
PR were coated to flow cells 1 and 2 respectively. Coating was performed using NHS/EDC
(N-Hydroxysuccinimide/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) coupling at a flow
rate of 10 µL/min and the surface was subsequently deactivated with 1 M ethanolamine.
LLEYSL and WSRVGYW were injected for 90s over the surface of both flow cells at a flow
rate of 40 µL/min in a concentration series. The injection was followed by a 2.5 minute
dissociation period. The surface of the CM5 chips was regenerated through a 30 second
injection of 0.2 M glycine-HCl (pH 2.2) at 30 µL/min. Data were evaluated using Scrubber
2 (BioLogic Software, Australia) and OriginPro 8.5 and equilibrium dissociation constants
were calculated from Kd = koff/kon.
2.2.6 Peptide-PEG Conjugation
Peptides were synthesised as described above (2.2.3). A Gly-Gly-Gly spacer was added to the
N-terminus of the phage derived peptide WSRVGYW. Whilst still on resin an SM-PEG(n)
linker (Thermo Fisher Scientific, Waltham, USA) was added to the peptide sequence (Figure
2.3). SM(PEG) linkers are poly(ethylene glycol) polymers of fixed repeat number with a
maleimide group on one end and an NHS ester group on the other. The heterobifunctional-
ity allows the linkage of primary amines and sulfhydryl groups. Three separate conjugates
were synthesised with different length spacers, these are outlined in Table 2.1.
SM(PEG)2 SM(PEG)12 SM(PEG)24
n 2 12 24
spacer arm 17.6A˚ 53.4A˚ 95.2A˚
net mass addition 310.12 750.38 1279.01
Table 2.1: Characteristics of SM(PEG)n linkers
The PEG linker was prepared to a 250 mM stock solution in DMSO and added to the resin
at a 1:10 molar ratio under basic conditions (in the presence of DIPEA at a 6-fold molar
ratio to the peptide on resin) in DMF. The reaction was left overnight at room temperature.
After conjugation the peptide-PEG conjugate was cleaved from the resin under standard
conditions and purified by reverse phase HPLC. Fractions containing the conjugate were
identified by LC-MS and lyophilised to remove residual solvent. In parallel, an inhibitory
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Figure 2.3: Synthesis scheme of bivalent conjugates.
peptide sequence was also synthesised with a Cys-Gly-Gly-Gly spacer on the N-terminus.
This peptide was synthesised and purified as described in Section 2.2.3. The inhibitory
peptide was then added at a 1:1 molar ratio to the phage peptide-PEG conjugate at 1
mg/mL in PBS (pH 6) and left to react overnight at room temperature. The mixture was
then purified again by HPLC and the fraction containing the peptide-PEG-peptide conjugate
was identified by MALDI.
2.3 Results and Discussion
2.3.1 The Search for a Secondary Binding Site
Having identified a peptide inhibitor of HIV-1 protease in the literature, LLEYSL, originally
isolated from oyster protein isolates by Lee and Maruyama in 1998 [221], we next tested
peptides which were reported to bind outside of the active site.
The mAb1696 antibody recognises the N-terminus of HIV-1 PR. It was first isolated by
Lescar et al. in 1999 [222]. Due to its interaction with the interface region of the protease
this antibody is known to have inhibitory properties of both HIV-1 and HIV-2 protease.
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Figure 2.4: Structure of mAb1696 anti-HIV-1 protease antibody interacting with the N-
terminus of the protease. a) Crystallographic structure of Fab fragment of anti-HIV-1
antibody interacting with HIV-1 PR (blue) with the CDR sections highlighted in purple
(PDB: 1JP5). b) Diagram showing hydrogen bond interactions between Ab and HIV-1 PR
(adapted from [223]). c) Structure of HIV-1 PR with the N- and C-terminii highlighted. The
peptides used for these studies are taken from this part of the protease structure. Figures
created using Visual Molecular Dynamics (VMD) 1.9.1 [142].
The structure of the interaction (taken from crystallographic studies [223], PDB entry 1JP5)
shows hydrogen bonds between the heavy and light chain CDRs of the antibody (Figure
2.4a,b). From this structure, the hypervariable loop segments, with the most bonds to the
protease were synthesised and studied for their ability to inhibit the protease. The sequences
NH3-Thr-Asp-Tyr-Ser-Met-His-CONH2, corresponding to the H1 chain and NH3-Lys-Tyr-
Val-Gly-Trp-Ile-Asn-Thr-Glu-Thr-Asp-CONH2, corresponding to a segment from the H2
chain were both synthesised through solid-state synthesis techniques described above.
In addition, the interface peptides used in the studies described in Section 2.1.2 were syn-
thesised, these sequences are taken from the N- and C-terminii of the protease monomer
(Figure 2.4c) and through single amino acid mutation to find the best inhibitors (SYEL).
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Figure 2.5: Inhibition studies of HIV-1 protease inhibiting peptides taken from the liter-
ature. a) Peptides taken from the hypervariable loop segment of the mAb1696 α-HIVPR
antibody. b) HIV-1 PR C-terminus peptide, SYEL c) TLNF, inhibitory peptide discovered
through sequence mutation, d) HIV-1 PR N-terminus PQI. Region shaded grey represents
the standard deviation of the activity of the uninhibited enzyme.
The sequences Ac-Ser-Tyr-Glu-Leu-COOH, Ac-Thr-Leu-Asp-Phe-COOH and Pro-Gln-Ile-
Thr-Leu-Trp-COOH were synthesised on Wang resin (where the initial amino acid is already
congugated, providing a carboxylic group at the C-terminus) and the N-terminii were then
capped with an acetyl group. The inhibitory properties of these peptides were studied as
described. The literature reports these peptides as having Ki values of 55 µM, 45.1 µM
and >100 µM (100 µM inhibits the enzyme by 40%, so IC50 will be above this) respec-
tively [193,195,196].
As can be seen in Figure 2.5 none of these peptides proved a suitable ligand. The pep-
tide sequences taken from the antibody recognition sites show no inhibition of the enzyme
(Figure 2.5a). Despite a vast body of literature based on the use of peptide fragments of
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Figure 2.6: Enrichment of peptides through phage display as seen by E.coli growth. a) Agar
plate showing titration of E.coli. In “out 3” plaques can be seen at a 107 dilution, whilst
for “out 4” plaques can still be seen at a 109 dilution. b) enrichment in phage/mL observed
over biopanning rounds. Error bars represent a 10% counting error.
antibodies as recognition elements, in general these display a lower binding affinity and have
been shown to have poorer recognition of biological targets [224]. This has been shown to
be due to the enhanced structual rigidity the larger protein molecule gives to the binding
regions.
The peptides taken from the literature also all fail to show the inhibition that had been
previously reported (Figure 2.5b-d). While all show inhibition at 1 mM by 100 µM this
inhibition has disappeared. This inhibition is thus far below the mid-micromolar range
reported. The reason for this is unclear since the experimental conditions used here are
identical to those used within the papers. Since none of these peptides proved successful,
the use of phage display to identify a suitable peptide ligand was investigated.
2.3.2 Phage Display
Enrichment
Phage display against HIV-1 protease was carried out over 3 rounds of biopanning. After
each elution of bound phages (this population was labelled ’out n’, where n is the round of
the biopanning), a titration was carried out to see how many phages were in the enriched
population. This was done by diluting the phage into E.coli and allowing the bacteria to
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grow overnight on plates containing Xgal/IPTG. Bacterial plaques which have been infected
by phage turn blue in the presence of Xgal/IPTG. Figure 2.6a shows a typical ’spot’ dilution
of phage comparing out 3 (after the 2nd panning round) and out 4 (after the 3rd panning
round). Growth can be seen until the 109 dilution for out 4, but only until the 107 for out
3. Whole plate dilutions were also performed to allow clones to picked from the plaques.
Dilutions where individual plaques could not be discerned were discounted since an ac-
curate estimate could not be achieved from these. The number of individual spots on each
dilution was counted (as can be seen clearly from out 4, the number of spots also approx-
imately decreases 10-fold with each dilution). The number of spots counted on the whole
plates was compared to the spot dilution to gain an estimate of the number of phage per
mL. Figure 2.6b shows the calculated number of phage/mL at each round of the biopanning
process. Enrichment of the phage population can be seen with an increase of an order of
magnitude. Error bars represent a standardised 10% counting error.
Phage ELISA and Sequencing
From the blue plaques described above, individual colonies were selected and grown in E.coli.
The phage were then harvested from the E.coli and used in an ELISA experiment to com-
pare the relative binding of each sequence to HIV-1 PR. The ELISA technique is used to
rapidly determine whether a selected phage clone binds the target protein, without having
to use an antibody specific for HIV-1 PR. In short, a 96-well polystyrene plate is coated
with HIV-1 PR and the purified phage is applied. Bound phage are then detected with an
anti-M13 antibody (specific to the coat protein of the phage particle). Figure 2.7 shows the
results of this ELISA.
The control experiment shown is a positive control where naked M13 helper phage is plated
to show recognition of the phage by the antibody. Since neither the amount of protease
coated onto the well surface nor the number of phage present in each sample after growth
in E.coli is quantifiable, this method is insufficient to determine whether a selected peptide
binds with a high or low affinity. The immobilised target protein may also be present at a
high enough density to enable multivalent binding, which will also obscure the real affinity.
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Figure 2.7: ELISA of phage clones showing specificity to HIV-1 PR through biopanning
rounds 1-3 (a-c), d) shows the positive control of binding to M13 helper phage. Data has
been normalised to the negative control (non-specific binding of the anti-M13 antibody to
the blocked well). Sequences marked with a * were selected for futher study, ** represent
that these two sequences were shown to be the same sequence, # could not be sequenced.
Clones chosen for further analysis have also been identified by sequence.
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Figure 2.8: Sequences isolated from phage clones. Sequences have been rearranged to clar-
ify similarities in amino acid type and are colour coded to represent common amino acid
groupings.
However this method is useful to make a qualitative comparison between a large number of
clones in parallel and also helps to screen for sequences that bind to the polystyrene plate it-
self. Based on relative binding of the phage to HIV-1 PR and to BSA, the sequences marked
with a * were used for further study. The majority were taken from out 4 as these peptides
should have been more heavily selected for. Sequence 4 from out 2 was selected due to its
strong binding at an early stage. The clone marked with a # was not able to be sequenced
(the quality of the extracted DNA was too low). These five sequences were identified as:
WSRVGYW, WTLHYSY, TPYMTPK, MSITRVH and KINEVWN. From the same phage
that were isolated for the ELISA study, DNA was extracted and sequenced to obtain the
corresponding peptide sequence. Those sequences are shown in Figure 2.8. The amino acids
have been colour coded by type (negatively charged, positively charged, aromatic, polar,
aliphatic and prolines). Whilst no consensus sequence was reached, increasing similarities
can be seen between sequences in out 4 compared to out 2. The sequences in Figure 2.8
have been arranged to highlight these similarities. For instance aromatic groups are usually
situated next to small aliphatic residues.
Some sequences which showed good binding compared to BSA in Figure 2.7 were nonethe-
less not chosen to continue. For instance, sequence 4 in out 3 shows strong binding but on
examination of the sequence the di-phenylalanine motif is indicative of a peptide sequence
that will self-assemble and be highly insoluble.
The five sequences that were selected for further study all share the characteristics of being
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Amino Acid Codons Expected Freq. Observed Freq.
Arg CGK, AGG 9.4% 4.9%
Leu CTK, TTG 9.4% 8.4%
Ser TCK, AGT 9.4% 10.2%
Ala GCK 6.2% 6.3%
Gly GGK 6.2% 4.7%
Pro CCK 6.2% 6.8%
Thr ACK 6.2% 8.8%
Gln CAG, TAG 6.2% 4.9%
Val GTK 6.2% 5.7%
Asn AAT 3.1% 5.8%
Asp GAT 3.1% 4.33%
Cys TGT 3.1% 0.91%
Glu GAG 3.1% 3.4%
His CAT 3.1% 4.6%
Ile ATT 3.1% 4.1%
Lys AAG 3.1% 3.3%
Met ATG 3.1% 3.7%
Phe TTT 3.1% 2.7%
Trp TGG 3.1% 2.2%
Tyr TAT 3.1% 4.3%
Table 2.2: Expected and observed amino acid frequency in the na¨ıve phage library. Here
K means the codon can exist with any base present in this position. Adapted from NEB
Ph.D-7 datasheet.
slightly positively charged (1+ with the exception of MSITRVH which has a 2+ charge) and
4/5 have aromatic residues.
Sequence Analysis
Table 2.2 shows the amino acid distribution expected and observed in the na¨ıve library
as received. Sequencing was performed using Ion Torrent technology to find the observed
amino acid frequencies. Expected frequencies are calculated from the number of codons that
represent that amino acid ÷ 32 possible codons. As can be seen from the table, Arg and Cys
are under-represented in the observed amino acids. This is because the positively charged
arginine residue interferes with the secretion of the pIII surface protein, reducing infectivity
and unpaired cysteine residues also affect phage infectivity [225].
The observed amino acids in the na¨ıve library were then compared to the observed amino
acids found through rounds of panning. This data is displayed ratiometrically in Figure
2.9. Amino acids are colour-coded here as in Figure 2.8. Whilst it is difficult to extract
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Figure 2.9: Amino acid statistics of isolated phage display derived peptides. Graphs show
observed amino acids over the frequency expected. Values higher than 1 show amino acids
that occur more commonly than would be expected and less than 1 are amino acids which
are undersampled in the population. a-c show the statistics for panning rounds 1-3.
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sweeping trends from this data (due to the relatively low sampling number compared to the
possible clones), it is interesting to observe that Asn and Gln, the two amide-terminated
amino acids, are highly underrepresented here. Prolines are also under-represented which
may suggest that the rigidity of peptide conformation induced by the presence of prolines
in a sequence may not be conducive to identifying the most appropriate peptides in this case.
All three amino acids with aromatic side groups are over represented, which suggests hy-
drophobic binding (potentially with the enzyme’s active site) is likely. New England Biolabs
caution against sequences which display a large number of alternating aromatic groups as
these have been shown to be polystyrene binding sequences and may be binding to the
surface of the 96-well plate. However, none of the sequences identified here show the charac-
teristic features of these polystyrene binding peptides and the specificity to HIV-1 PR over
BSA in the same conditions rules this out.
2.3.3 Peptide Synthesis and Characterisation
The five peptides (Figure 2.10) chosen from the phage display described above were syn-
thesised and purified for further characterisation. The peptide sequence LLEYSL was syn-
thesised using the same methods. This sequence is known to inhibit HIV-1 PR with an
inhibition constant of 15 nM and will be used as a standard against which to compare the
phage display peptides which are of a similar length. Figure 2.11a shows a representative
HPLC UV trace of the purification of WSRVGYW synthesised by the methods described
above. The dominant peaks collected after purification were then analysed by MALDI (Fig-
ure 2.11b) or LC-MS to identify the correct peptide by its molecular weight. For brevity
only the HPLC/MS of one peptide is shown here as a representative image. The other
peptides synthesised throughout this chapter were purified and analysed analogously (mass
spectroscopy for peptides synthesised in this chapter can be found in the appendices).
Binding Studies
The binding ELISA performed to determine which of the phage clones displayed the best
binding to HIV-1 PR was repeated using the free peptide, rather than the phage conjugated
version used previously. This is because the peptide is displayed multivalently on the phage
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Figure 2.10: Structure of peptides chosen from isolated phage clones.
and this may introduce avidity affects into the binding analysis. In the absence of the phage
particle the peptide can also be used at higher concentrations (solubility permitting). The
use of the free peptide also allows exact control over the concentration allowing quantitative
information about the binding to be extracted, rather than just relative, qualitative informa-
tion. The peptides were synthesised using amide-terminated resin to remove the negatively
Figure 2.11: Representative HPLC trace of peptides synthesised by solid-state peptide syn-
thesis by hand and subsequent MALDI analysis of the dominant peak a) HPLC trace at 220
nm (peptide backbone) and 280 nm (aromatic group) of WSRVGYW. b) MALDI analysis
of the dominant fraction collected after HPLC corresponding to the expected mw.
CHAPTER 2. MULTIVALENT INHIBITORS OF HIV-1 PROTEASE 79
0
0.1
0.2
0.3
0.4
0.5
0.6
WSRVGYW WTLHYSY TPYMTPK MSITRVH KINEVWN
Fl
uo
re
sc
en
ce
n(A
U
)
HIV-1nPR
BSA**
*
*
***
**
Figure 2.12: ELISA showing binding of sequences to HIV-1 protease compared to control
protein (BSA). * = p < 0.05, ** = p <0.005, *** = p < 0.0005.
charged -COOH group that would otherwise be found on the C-terminus of the peptide.
This is because when conjugated to the phage, these peptide sequences would be joined
through a peptide bond to Gly-Gly-Gly spacer and the presence of an additional negative
charge can dramatically affect binding. Figure 2.12 shows the results of this binding ELISA.
Binding was measured using biotinylated peptides and streptavidin-conjugated Horseradish
Peroxidase (HRP). All peptides show good binding to HIV-1 PR compared to binding to
BSA. Binding to BSA is approximately the same for all five peptides, showing that this is
likely the non-specific background signal. KINEVWN, which did not display strong binding
when attached to the phage, still shows comparable binding which is likely due to the higher
concentrations used for this ELISA (500 µg/mL). Significance shown is calculated using a
2-tail student T-test with independent samples with different variance, * = p < 0.05, ** =
p <0.005, *** = p < 0.0005.
Inhibition Studies
Inhibition studies were carried out using a competitive assay where the inhibition of the
enzyme was monitored with a cleavable substrate. All peptides were used at a large ex-
cess (10 µM) compared to the enzyme (240 nM). Figure 2.13a shows the results of this
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Figure 2.13: Inhibition of HIV-1 PR by phage display peptides. a) Competitive inhibition
assay of sequences in the presence of a large excess of phage display peptides (10 µM). Region
shaded in grey represents the standard deviation on the activity of the uninhibited enzyme.
b) Inhibition data for WSRVGYW showing a Ki of 40.1 µM through a dose-response fit to
the data.
study. Of the five peptides sequenced, one peptide – WSRVGYW shows inhibition at this
concentration. This peptide’s inhibition was then further studied (Figure 2.13b) and its
inhibition constant, Ki which was found to be 40.1 µM. It is likely that this inhibitory
mechanism results from the Val in position four – HIV-1 protease cannot hydrolyse pep-
tides with a β-branched amino acid in this position [184]. The positively charged Arg is
also not a preferred substrate amino acid in this position, preventing cleavage. Substrates
which demonstrate these characteristics also usually bind with µM affinity which is further
discussed in Section 2.3.3 [72].
Enzymatic Cleavage Studies
Since HIV-1 PR is an aspartyl protease it targets the peptide bond between a wide range
of amino-acids. Specifically identified cleavage points from the native gag-pol-env proteins
include Tyr-Pro, Leu-Ala, Met-Met, Asn-Phe, Phe-Leu, Asn-Phe, Phe-Pro, Phe-Tyr, Leu-
Phe, Trp-Leu [226]. Although none of these points are found in the five peptides chosen
(TPYMTPK has a Pro-Tyr bond but this should be immune to cleavage since the N and C
bonds are reversed), all five peptides were incubated with HIV-1 PR at 37oC overnight at
pH 4.5 (for optimal enzyme activity). Peptides were dissolved at an excess (1 mg/mL,
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Figure 2.14: Enzymatic degradation studies. Peptides were incubated with and without the
presence of active HIV-1 PR overnight at 37oC. The peptides were then analysed by LC-MS
to identify any products of cleavage by the formation of new peaks. Graphs show the UV-vis
trace at 220 nm to identify the peptide backbone.
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except for WTLHYSY which was dissolved at 0.25 mg/mL for solubility reasons). Control
peptides were incubated in the same buffer at the same temperature without the enzyme to
ensure that degradation was not on account of environmental conditions.
Figure 2.14 shows the results of this study. Peptide cleavage was analysed by LC-MS where
the appearence of new peaks in the UV-Vis trace at 272 nm would be indicative of new
fragments. However, none of the traces in the presence of the protease show any differences
to the peptides on their own, establishing that these peptide sequences are not substrates
of the enzyme.
Peptide-Protein Interactions
The strength of the interaction between the peptide and protein is dependent on the valency
of its presentation as demonstrated above in the differences in relative binding observed for
the phage peptides free in solution or connected to the phage particle. Previous studies have
shown that the affinity of a seven amino-acid peptide isolated through phage display has a
binding affinity of 120 µM whilst the same peptide on phage had an affinity of 16 pM (7
orders of magnitude difference) [227]. A synthetic polymer-based pentavalent construct of
the same peptide displayed a 1 µM affinity.
However this same study found that although the affinity of the pentavalent construct when
measured by SPR was 1 µM when the same construct was measured by ELISA the binding
constant was found to be 22 nM, a 100-fold difference. Differences in binding as measured
by these two techniques with regard to phage isolated peptides have also been studied sys-
tematically by Lunder et al. [228]. Whilst the differences they describe are less extreme
than those discussed above, both papers ascribe the observed discrepancies to differences in
ligand surface density. A technical note published by Biacore reports inter-assay variability
as 38% for ELISA but only 3.7% for SPR, with intra-assay variability being measured as
22% and 0.35% respectively [229]. For antibody binding, differences between calculated KD
from SPR and ELISA have been estimated to be around 100-fold [230]. This is attributed
to the inability of ELISAs to accurately measure fast dissociation times. ELISA is also a
time-averaged measurement and is thus less sensitive to kinetic events. SPR measures inter-
CHAPTER 2. MULTIVALENT INHIBITORS OF HIV-1 PROTEASE 83
Figure 2.15: ELISA studies of interactions between MSITRVH (a), WSRVGYW (b),
KINEVWN (c), TPYMTPK (d) and HIV-1 protease. Data shown is in triplicate and error
bars represent a standard deviation. * = p < 0.05, ** = p <0.005.
actions at a constant concentration of ligand and hence has the ability to measure weaker
affinity interactions than ELISA which has been discussed by Lofgren et al. [231]. All phage
peptides were analysed by ELISA with SPR being used to measure the most efficient binder
as well as the inhibitory peptide.
Binding Affinity as Measured by ELISA
Binding studies were carried out over a range of concentrations to estimate a value of the KD
of the phage peptides. The results of this experiment can be seen in Figure 2.15. WTLHYSY
was not studied due to difficulties in solubilising this peptide above a 100 µM concentration.
MSITRVH (Figure 2.15a) shows an increasing binding trend, however the highest concen-
tration measured (1 mM) was unstable in solution and tended to sediment over the course
of the incubation period, resulting in a lower binding here. This same instability at high
concentration was also observed for KINEVWN (Figure 2.15c). In fact, if left at room
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Figure 2.16: SPR studies of interactions between LLEYSL, WSRVGYW and HIV-1 protease
ai) SPR binding curves for LLEYSL, aii) equilibrium analysis for LLEYSL, giving a KD of
3.04 nM. bi) SPR binding curves for WSRVGYW, bii) equilibrium analysis for WSRVGYW,
giving a KD of 44.6 µM.
temperature for 48 hours, solutions of KINEVWN at concentrations of 1 mM and above
formed transparent hydrogels, demonstrating that the peptide is interacting with itself
(likely due to the charged residues). TPYMTPK (Figure 2.15d) also shows the start of
a binding curve. Given the rate of increase in signal it is likely the KD of the peptide is
greater than 2 mM. The peptide was thus not further studied due to inherent difficulties of
working with peptides with a high koff rate. The highest concentrations measured of WS-
RVGYW (Figure 2.15b) have plateaued and also show a high level of non-specific binding
(evidenced by the binding to BSA). This indicates that the KD is below those concentrations
trialled by ELISA. Following this study, the peptides TPYMTPK, MSITRVH, WTLHYSY
and KINEVWN were discarded from future studies, either due to the problems discussed
regarding their solubility or their low binding affinity. These experimental difficulties meant
that extracting an accurate KD for these peptides was not possible.
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Binding Affinity as Measured by Surface Plasmon Resonance
The binding of LLEYSL and WSRVGYW was further studied by SPR. The peptides at a
range of concentrations were injected over immobilised HIV-1 protease for 90 seconds. Figure
2.16ai shows a characteristic SPR binding trace for LLEYSL. A 1:1 (Langmuir) binding
model fit to the data (described in [232] and implemented in the BIAeval software) gives
a calculated KD of 4.3 nM. Figure 2.16bi shows the SPR binding traces for WSRVGYW.
Here the ’top-hat’ like function is a result of the ka and kd rates being faster the instrument
sampling times [233]. Since in this case the on and off curves cannot be measured, equilibrium
analysis is used to establish the KD [234]. In the steady state, KD = kd/ka, taking the
plateaued response value allows the calculation of the dissociation constant. These values
are shown in Figures 2.16aii and 2.16bii. The KD value for WSRVGYW is found to be 44.6
µM. This is in good agreement with the Ki of the peptide found through inhibition studies
of 40.1 µM. In comparison, the equilibrium value for the KD of LLEYSL is found to be 3.04
nM, in good agreement with the value extracted from the Langmuir model.
2.3.4 Peptide-PEG Conjugates
On the basis of the studies above measuring both binding affinity and inhibition of the
enzyme, the sequence WSRVGYW was identified as the most promising of the peptides
found through phage display. The sequence along with the inhibitory sequence LLEYSL
were then combined through a poly(ethylene glycol) linker and the relative inhibitory effects
of the peptides separated and conjugated with varying linker lengths was studied.
The Effect of Sequence Modification
The binding affinity of peptides can be affected by the mutation of only a single residue (as
utilised in alanine scanning experiments). Before conjugating the peptides with the PEG
linker we examined the effect that the addition of a triple-glycine spacer to the N-terminus
would have on the binding properties of the peptides. This glycine spacer was added to
give flexibility to the conjugate. The results of this study can be seen in Figure 2.17. As
is illustrated by the shift in calculated IC50 values for these peptides, even the addition of
a short, non-charged peptide spacer can affect peptide-protein binding, likely due to the
enhanced steric hinderance. In both cases the addition of the glycine spacer lowers the
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Figure 2.17: Dose response curves showing the effect of the addition of a triple-glycine
spacer on inhibition constants, LLE (black-solid), CGGGLLE(black-dashed), WSR (red)
and GGGWSR (red-dashed).
inhibition constant by two orders of magnitude.
Conjugate Inhibition Studies
The synthetic routes used to produce the peptide-PEG conjugates resulted in very low
yields. Typically, such an experiment produced 1-2 mg of final product. The limiting step
was found to be the coupling of the NHS ester group to the terminal amine of the peptide. A
variety of coupling methods were trialled including on- and off-resin, the addition of differing
concentrations of base (the reaction is more favourable in basic conditions), coupling times
and reaction buffers. Despite these studies, no increases in product yield were observed.
The conjugates incorporating the PEG2 and PEG24 not only had poor yield but also proved
difficult to solubilise, despite pre-dissolving the conjugates into DMSO and diluting with a
buffer containing 20% (v/v) DMSO. The PEG12 conjugate did solubilise and the inhibition
assay using this conjugate is shown in Figure 2.18. It can be seen here that the IC50 is not
significantly different to the inhibition shown by WSRVGYW on its own (48.6 µM compared
to 40.1 µM). This indicates that only one of the ligands is interacting with the protease and
hence the significant steric hinderance introduced by the long PEG linker is likely affecting
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Figure 2.18: Dose response curve for WSR-PEG12-LLE conjugate. The dose response fit to
the data yields an IC50 value of 48.6 µM.
the ability of the second ligand to interact.
The Thermodynamical Effect of the Linker
There has been much debate about the the influence of the linker in multivalent systems,
and the role it plays in the enhancement of avidity that has been regularly reported. In par-
ticular, the effect on conformational entropy that a multi-jointed, flexible linker may have on
the favourability of an interaction has been contested. The avidity of an interaction can be
described in terms of an effective concentration, whereby the concentration of an unbound
ligand near an unbound receptor can be increased if a tethered ligand is bound nearby [185].
From polymer theory, this concentration can be related to the probability that the distance
between ligands equals that between the receptors, where the linker is considered to behave
as a random coil polymer [235]. A random-coil polymer is modelled as a gaussian distri-
bution and hence, a linker that is either too long or too short will dramatically effect the
probability of binding.
Various groups have argued that a long, flexible linker (such as the PEG used here) will
prevent binding due to the large amounts of conformational entropy that is loss upon com-
plexion (∼0.7 kcal mol−1 for each freely rotating bond) [186]. However, several groups have
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shown a dependence of effective molarity on linker length, showing that a flexible linker
which is slightly longer than the distance between receptors shows an enhancement of affin-
ity. Linkers longer than this ideal length, gradually decrease the binding affinity [236–238].
Detailed studies of the thermodynamics involved in these interactions have further shown
that linker length has a weak influence on the enhancement of avidity since the free energy
of heterodivalent binding is greater than the potential losses due to the conformational en-
tropy [239]. These studies support the use of PEG-linked bivalent constructs to improve the
avidity of interactions, thus providing stronger enzyme inhibitors.
2.4 Conclusion
This Chapter has described the use of phage display to identify five peptide sequences which
bind to HIV-1 protease with various strengths of binding affinity. These peptides were ex-
tensively characterised through a range of biophysical and biochemical techniques. All five
sequences shared several characteristics including a preference for aromatic residues, are
positively charged and hydrophobic. Of these five peptides, WSRVGYW, has been the most
thoroughly studied, since it displays the best binding and unlike the others does not suffer
from solubility issues.
It was hoped that this peptide, in combination with a known peptide inhibitor of the enzyme
could be built into peptide-polymer conjugates to design stronger inhibitors of the enzyme.
This principle of enhanced avidity through multivalency has been well discussed in the litera-
ture and is an area of ongoing study for the design of biomimetic compounds. Unfortunately
the desired avidity effects were not observed when using WSRVGYW and LLEYSL and a
PEG linker. It is likely that the binding sites of these peptides are too close together for an
enhanced concentration to be created. The use of different length PEG chains would help
to elucidate this and improving the yield and solubility of these conjugates remains an area
to be studied. A better understanding of where these peptides interact with the enzyme is
also desirable and this will be further studied computationally in Chapter 4.
Given the likelihood that both these peptide ligands are interacting with the enzyme’s active
site, new ligands which bind outside of this site were sought. Since the peptides described
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previously in the literature failed to provide a suitable alternative, we turned back to phage
display. Phage display was carried out against the HIV-1 protease as described above. How-
ever, in this instance all three commercially available libraries were used; PhD.-7, PhD.-12
and PhD.-c7c. These were used since all three have unique advantages; as described above,
the seven amino acid long sequences are an ideal length to interact with the enzyme’s active
site. The 12 amino acid long library, however, has been shown to identify stronger affinity
peptides since they may have some secondary structure and there are more residues available
to form interactions. The circular library, forms a more rigid structure which can be useful in
certain protein interactions. The phages isolated in this study have been assessed for binding
to the protease (data not shown) but not yet sequenced to identify suitable peptides. In this
case, peptides which do not show inhibition of the enzyme but bind strongly will be selected.
In addition, preliminary studies have been carried out with Dr Robert Chapman investigat-
ing the use of RAFT polymerisation to create a library of polymers which can have different
sizes, architectures, valencies and backbones (to adapt the flexibility of the polymer). In
these preliminary studies, WSRVGYW was synthesised conjugated to an acrylate monomer
through the N-terminus, allowing control of grafting density through polymerisation length.
LLEYSL was synthesised with an N-terminal azide group, allowing a single copy to be con-
jugated to the end of the polymer through copper mediated click chemistry. These initial
experiments showed different inhibition for different polymer lengths but were put on hold
while more suitable ligands were chosen. Future work aims to use novel RAFT polymerisa-
tion techniques [240] to design a large library of different polymer-ligand combinations and
test these for enhanced protease inhibition.
Chapter 3
The detection of HIV-1 protease
through peptide mediated
FRET
Measure what is measurable and
make measurable what is not so
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3.1 Introduction
This chapter describes the design and implementation of a detection mechanism for HIV-1
protease based on a FRET signal generated by the interaction of multiple dye-labelled
peptides with the protease molecule. The peptides used here are those identified in Chapter
2. The principles of FRET and its use in bionanotechnology is described before the assay
itself is discussed. Sections of this chapter have been accepted for publication in Chemistry
of Materials as “Designing fluorescent peptide sensors with dual specificity for the detection
of HIV-1 protease” authored by K. Herpoldt, A. Artzy-Schnirman, A.J. Christofferson, A.J.
Makarucha, R. de la Rica, I. Yarovsky and M.M. Stevens.
3.1.1 Fo¨rster Resonance Energy Transfer
Fo¨rster Resonance Energy Transfer (FRET) was first described theoretically by Theodor
Fo¨rster in 1948 [241]. FRET is now a well-established biophysical technique whereby en-
ergy transfer will occur between two non-radiatively coupled fluorophores as long as they
are within a certain distance of each other (usually less than 100 A˚). This transfer occurs
because of dipole-dipole interactions between an excited state donor fluorophore (D) and a
ground state acceptor (A) where the emission spectrum of D must overlap with the excita-
tion spectrum of A [242].
FRET is usually characterised by a decrease of intensity in the donor fluorophore’s emission
spectrum, a reduction in the fluorescence (excited state) lifetime of the donor fluorophore
and an increase in the acceptor molecule’s emission spectrum (sensitisation). Whilst it is
usual for FRET systems to utilise two fluorophores, the acceptor molecule need not always
be emissive. Many FRET systems utilise quencher molecules – either dark quencher dye
molecules which have no native emission, instead radiating the transferred energy as heat
(e.g. Black Hole Quenchers or Dabsyl, a common dark quencher of fluorescein) or gold
nanoparticles which can also dipole-dipole couple with a large variety of fluorescent dyes
but which, themselves, are non-radiative [243,244].
Since the energy transfer between the two fluorophores occurs due to dipole coupling, the
process is highly distance dependent with an r6 dependence, where r is the separation be-
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tween D and A. This relationship arises from Fermi’s Golden Rule for describing quantum
mechanical state transistions and the electrodynamical description of a dipole in the electric
field. A full derivation of the process involved is beyond the scope of this thesis but can be
found in [245]. The rate of energy transfer, kT , can then be given by:
kT (r) =
1
τD
(
R0
r
)6
(3.1)
Here τD is the lifetime of the excited donor state in the absence of an acceptor and R0 is
the Fo¨rster distance which defines the distance at which the energy transfer is 50% efficient.
R0 has a characteristic value for each FRET D-A pair, defined by the extent of the spec-
tral overlap between the donor emission and acceptor excitation. The value of Ro can be
calculated by:
R0 =
9000Q0(ln10)κ2
128pi5n4NA
∫
fD(λ)A(λ)λ4dλ (3.2)
where Q0 is the quantum yield of the donor in the absence of the acceptor, κ2 describes the
orientation factor between the two dipoles, which for the case of dye molecules free to rotate
can be approximated as 2/3. n is the refractive index of the medium and NA is Avogadro’s
number. The integral describes the spectral overlap between the fluorophores with respect
to wavelength. fD is the normalized donor emission spectrum, and A is the acceptor molar
extinction coefficient.
The FRET efficiency (i.e the fraction of energy transfer occuring per donor excitation)
is given by:
E = kT
kT + kf +
∑
ki
= 11 + (r/R0)6
(3.3)
where kf is the radiative decay rate of the fluorophore and
∑
ki is the rate constant of other
decay pathways. Through equation 3.1 this can be written as
E = 1− τ
′
D
τD
(3.4)
where τ ′D is the lifetime of the excited donor state in the presence of an acceptor.
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3.1.2 FRET as a tool for measuring biological interactions
Due to the highly distance dependent nature of this technique, FRET has found many ap-
plications in biology where it has been used to probe protein structure and conformation,
monitor inter-cellular processes and biological imaging ranging from the single-molecule level
to ensemble imaging [246].
Whilst traditional methods such as X-ray crystallography and nuclear magnetic resonance
spectroscopy are used to generate a large proportion of high-resolution protein structures,
they are less suitable for dynamic proteins, membrane-bound proteins (which can be dif-
ficult to crystallise), multi-component protein complexes and intrinsically disordered pro-
teins [247]. These structures, derived as they are from crystallised proteins, may also not
accurately represent the native protein structure in solution.
FRET (in particular single molecule FRET, smFRET) can be used alongside these tra-
ditional protein chemistry techniques to unlock structural as well dynamic information since
the lengthscales involved match well with the sizes of proteins and nucleic acids. Through
molecular biology techniques, mutant forms of the protein of interest can be generated,
allowing the insertion of selected amino acids at various locations along the length of the
protein. If this insertion is unique (e.g. the addition of a cysteine), specific points can be
fluorescently labelled. With the addition of an N-terminus modification, FRET can then be
used as a molecular ruler to define distances between known residues within a protein [248].
smFRET also allows the monitoring of dynamic processes such as protein synthesis by the
ribosome revealing information on enzyme function that is otherwise inaccessible [249].
The use of FRET for protein studies and especially for the monitoring of inter-cellular
processes is not, however, restricted only to the use of dye molecules. The amino acid tryp-
tophan is naturally fluorescent at 340-360 nm due to its indole ring [242] and these can be
used as site-specific modifications (Phe and Tyr are also fluorescent but their quantum yield
is too low for strong energy transfer). The use of fluorescent proteins such as the green
fluorescent protein (GFP) and its variants are well established for their use in in vivo and
in vitro labelling [250]. By encoding these proteins in plasmids, expression in a wide vari-
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ety of cells and organisms is possible. These proteins allow the monitoring of inter-cellular
processes by monitoring the fluorescence signal as the cell or organism grows.
A system to visualise the inhibition of HIV-1 protease based on fluorescent proteins was
developed by Jin et al. [251]. Here mCherry (a red fluorescent protein) was joined to GFP
via a peptide sequence cleavable by HIV-1 PR. The addition of inhibitors of the enzyme to
the cell population prevents the peptide from being cleaved and thus the fluorescence of the
GFP is not recovered.
FRET can occur between different fluorescently tagged proteins, giving information about
biomolecular interactions. However, these proteins are large (>25 kDa) and some interac-
tions are thus out of range for an energy transfer to occur. The large size of these proteins
can also prevent native proteins from folding correctly. A full discussion of other fluorescent
materials that can be used in FRET applications is beyond the scope of this thesis but is
well described by Sapsford, Berti and Medintz [252].
3.1.3 FRET for the detection of enzymes
As discussed in Chapter 1 several families of enzymes play critical roles in modulating dis-
ease states. Because of this many of these enzymes have been well studied as targets for
drug development and a large volume of work exists on methods to screen for potential in-
hibitors of these proteins. FRET provides a straightforward technique which can be applied
to high-throughput assays for measuring the presence and activity of enzymes.
Protease enzymes are particularly well suited to monitoring through FRET since their ac-
tivity causes the hydrolysis of peptide bonds. This activity generates two (or more) distinct
peptide fragments. Previously the activity of these enzymes was monitored by HPLC and
mass spectrometry to analyse the formation of fragments from the precursor protein [253].
This method is however time consuming and for large proteins it can be difficult to identify
the fragments which have been produced. FRET allows the real-time monitoring of protease
activity through the generation of a FRET signal, normally a recovery in fluorescence of the
donor molecule as proteolysis removes a bound quencher molecule or FRET pair.
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For such protease assays, quantum dots (luminescent semiconductor nanoparticles) offer an
excellent experimental system as several acceptor molecules can be bound to a single donor
molecule, increasing the sensitivity of the cleavage signal. This was first described by Med-
intz et al. and Shi et al. in 2006 [254,255]. In both cases the quantum dot is conjugated to
the dye molecule through a peptide sequence that contains a specific recognition sequence
for a protease. When incubated with the enzyme, the substrate is cleaved causing separation
between donor and acceptor.
FRET is however not limited to the detection of proteases. Assays have also been devel-
oped for the monitoring of kinases, enzymes which are responsible for the phosphorylation
of substrates. Since phosphorylation alters the sensitivity of a protein to being cleaved by a
protease, substrates can be designed where the presence of a kinase reduces the ability of a
protease to cleave the peptide, thus preventing the recovery of the donor fluorescence [256].
This process is however complicated, relying on the presence of two enzymes and the design
of a substrate peptide which is short enough for efficient energy transfer but long enough
to allow specific phosphorylation and cleavage is challenging. An alternative strategy was
developed by Ghadiali et al. and then furthered by Lowe et al. [257, 258]. This system
conjugated a kinase peptide substrate to quantum dots. Phosphorylation of the sequence
was then detected through the addition of an fluorescently labelled antiphosphotyrosine an-
tibody, giving rise to a FRET signal (a decrease in donor fluorescence). This assay format
is more sensitive (< nM) and less complex than previously designed systems.
3.1.4 FRET based detection of HIV-1 protease
The methods of detecting and monitoring proteases described above are all limited by the
same factors. Firstly, the signal generation is dependent on proteolytic cleavage which can be
susceptible to non-specific enzymes. Secondly, the substrates designed must be long enough
to minimise any off-target cleavage but are limited in length (and hence complexity) by the
FRET separation distance.
The assay described here is a FRET-based method of detection of HIV-1 protease which
uses multiple recognition elements and does not rely on peptide cleavage (Figure 3.1). The
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Figure 3.1: Schematic of the detection mechanism of HIV-1 protease. a) A fluorescent sensor
binds specifically to the HIV-1 PR molecule (peptide sensor 1 – WSRVGYW-AF647). b)
A second sensor (peptide sensor 2 – LLEYSL-BHQ-3), tagged with a fluorescent quencher,
interacts with the active site of the protease. The biorecognition events trigger an energy
transfer process between peptide sensors 1 and 2 and the signal from the fluorescent dye
decreases.
FRET signal is generated when multiple peptide sensors are bound to the same HIV-1 PR
molecule. These peptide sensors are based on the peptide sequences derived through phage
display, as described in Chapter 2. These peptide sequences are then labelled with fluores-
cent dye molecules to actuate the detection signal. This approach to biomarker detection
requires two independent binding events, a strategy that improves the specificity of the
assay.
3.2 Materials and Methods
Unless otherwise stated all reagents and materials were purchased from Sigma-Aldrich
(Poole, UK) and used without further purification. HIV-1 protease was purchased from
BioVendor (Brnu, Czech Republic) and used without further purification.
3.2.1 Peptide Synthesis
Peptides were synthesized as described previously by standard Fmoc solid-phase peptide syn-
thesis using a PTI Quartet peptide synthesizer (Protein Technologies Inc., Tuscon, USA).
Synthesis took place on Fmoc-Rink Amide aminomethyl-polystyrene resin (AGTC Bioprod-
ucts, Hessel, UK). After synthesis the peptides were cleaved and deprotected with 95:2.5:2.5
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trifluoroacetic acid (TFA):triisopropylsilane (TIS):H2O for 3 hours and precipitated and
washed with cold diethyl ether (DEE). The crude peptides were purified to >95% (deter-
mined by LC-MS) on a preparative C18 HPLC column using a water/acetronitrile mobile
phase containing 1% (v/v) TFA.
3.2.2 Fluorophore Peptide Labelling
Alexa Fluor 647 (AF647) was purchased as a succinimidyl ester from Life Technologies (Pais-
ley, UK). The dyes were dissolved to 1 mg/mL in dimethyl sulfoxide (DMSO) and coupled
at a 1:1 ratio with purified peptides including 0.2 equivalent of 4-dimethylaminopyridine
(DMAP). The reaction was left overnight at room temperature. The solution was then
diluted 10x into an acidic mobile phase of water/acetonitrile containing 0.1% (v/v) TFA
and purified on a semi-preparative HPLC using a C18 column. Coloured fractions were
collected and analyzed by UV-Vis spectroscopy to identify the single fraction containing
the conjugated peptide-dye. BHQ-3 as a succinimidyl ester was purchased from Biosearch
Technologies (Petaluma, USA) and conjugated in the manner described above for the Alexa
Fluor dyes. Fractions collected after HPLC purification were identified via LC-MS.
NHS-Fluorescein and NHS-Rhodamine were purchased from Pierce Biotechnology (Rock-
ford, USA). The dyes were dissolved in DMSO to 100 mM and then added at a 1:1 ra-
tio to the Fmoc-protected peptides whilst still on resin (pre-cleavage). The dyes were al-
lowed to couple overnight at room temperature in dimethylformamide (DMF) with 25 µL
N,N -Diisopropylethylamine (DIPEA). The peptides were then cleaved from the resin and
purified as described above. Fractions collected after HPLC were identified via LC-MS.
3.2.3 UV-Vis Absorption Spectroscopy
UV-Vis absorption spectroscopy measures the attentuation of light intensity when incident
light is passed through a sample analyte compared to a reference standard (usually the
solvent or buffer the analyte of interest is dissolved in). The observed attenuation is due to
the absorption of photons by the analyte, either by scattering or by electronic transitions
to an excited state. The concentration of the analyte in solution can be calculated using
the Beer-Lambert law [259] which relates concentration, c to the absorbance, A at the peak
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absorbance wavelength λ through equation 3.5.
Aλ = −ln(I/Io) = λcl (3.5)
Here Io is the intensity of light passed through the reference solution, I is the measured
intensity of light passed through the solution containing the analyte, λ is the molar extinc-
tion coefficient (M−1cm−1) and l is the absorption path length.
UV-visible absorption spectra were measured at room temperature on a Perkin Elmer
LAMBDA 25 spectrophotometer (Waltham, MA) using 1 cm path-length quartz cuvettes or
on a Thermo Fisher Nanodrop 2000 UV-vis spectrophotometer (Willmington, USA) where
a 1.5 µL drop of sample placed on the detector gives a pathlength of 1 mm.
3.2.4 FRET Surface Assay
Amine functionalized glass slides (Sigma-Aldrich) were immersed in 0.1 M sodium bicarbon-
ate (pH 8.6) with 10% (v/v) glutaraldehyde and left for 1 hour. The slides were then washed
thoroughly with deionized water before being dried with nitrogen. HIV-1 protease was pre-
pared at 50 µg/mL in 0.1 M sodium bicarbonate with 10 mM sodium cyanoborohydride.
10 µL of the protein solution was spotted onto the pre-prepared glass slide and left for 3
hours in a humidity chamber. The slides were then washed thoroughly with deionized water.
Unreacted amines were blocked with a solution of 1 M ethanolamine in 0.1 M sodium
bicarbonate with 1% (w/v) BSA (at pH 8.6). The slides were left to block for 1 hour and
then washed thoroughly. The slide was immersed in WSR-647 for 1 hour in the dark before
washed in PBST (0.05% (v/v) Tween-20) before being imaged at 700 nm with a Li-Cor
Odyssey Infra-red scanner. Half the slide was then immersed in LLE-BHQ-3 whilst the
other half was left in PBST for an hour in the dark. The slide was then washed thoroughly
with PBST again and reimaged. The intensity of the spots was quantified using Li-Cor
Image Studio.
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Figure 3.2: Schematic of on-surface FRET. a) HIV-1 protease is immobilised on a membrane,
b) The membrane is incubated with WSR-AF647 and washed, c) the membrane is incubated
in LLE-BHQ-3 and a decrease in fluorescence is observed.
3.2.5 In Solution FRET
LLE-fluor and WSR-rhod at 20 µM were added to varying concentrations of HIV-1 PR in
the PR assay buffer described in Chapter 2 to a final volume of 60 µL in the wells of a
384 clear-bottom black microwell plate. The plate was incubated in the dark at 4oC for an
hour before the fluorescent spectra were read on a SpectraMax M5 plate reader (Molecular
Devices). The solution was excited at 480 nm and the emission was read between 510 and
600 nm with a cutoff value of 495 nm.
3.2.6 Lifetime Fluorescence Measurements
In addition to the steady-state FRET measurements described above, fluorescence lifetime
measurements were also carried out. Time-dependent fluorescence spectroscopy allows the
determination of FRET efficiency through measuring the fundamental decay of the dye
molecule under excitation of a single light pulse. This measurement is often considered to
be more accurate than steady-state calculations since it does not require consideration of
the intensity of the dye which can be heavily influenced by environmental factors such as
buffer pH.
As discussed in Section 3.1.1, the rate of decay of a fluorophore (ki) can be used to calculate
the rate of the non-radiative energy transfer (kT ). Figure 3.3 shows the energy transfer
processes schematically in relation to the measured lifetime. Figure 3.3a shows the response
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Figure 3.3: Fluorescence lifetime of dye pairs illustrated through Jablonski diagrams. a)
In the absence of a donor molecule, an excited fluorophore returns to its ground energy
state through vibrational relaxation and fluorescence emission. The rate of decay, ki, gives
the lifetime of the donor molecule. b) In the presence of an acceptor molecule, the excited
fluorophore can also transfer energy non-radiatively and return to the ground state through
alternate decay paths, Σki. Figure adapted from [260].
of the donor on its own, where there is only a single decay pathway, giving a lifetime τD. In
Figure 3.3b, the excited state can either decay through the original pathway to the ground
state or via non-radiative transfer to the acceptor molecule. Energy transfer to the coupled
acceptor molecule results in a shorter lifetime of the fluorescent donor dye, τ ′D.
Fluorescence lifetime can be measured using Time-Correlated Single Photon Counting (TC-
SPC). In TCSPC a pulsed light source is used to excite the dye and the time taken for a
single photon to arrive at the detector is measured relative to the excitation pulse. Through
repeated pulses an intensity vs. time graph is produced, from which the averaged fluores-
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cence decay can be extracted. The greater the number of counts that are collected, the
higher the statistical precision of the data.
To measure the lifetime of LLE-fluor in the presence and absence of WSR-rhod, the FRET
assay in solution was set-up as described in Section 3.2.5 using a concentration of 4 µM of
HIV-1 PR in a total volume of 100 µL. Measurements were made on a DeltaFlex TCSPC
system (Horiba) using a NanoLED with an excitation wavelength of 467 nm and 30,000
counts were recorded. Fluorescence lifetimes were extracted through an exponential fit to
the normalized data in OriginPro 8.5.
3.3 Results and Discussion
3.3.1 Peptide Synthesis, Conjugation and Purification
The peptides NH2-WSRVGYW-CONH2 and NH2-LLEYSL-CONH2 were synthesised since
they showed the best interactions with HIV-1 protease (as discussed in Chapter 2). After
HPLC purification MALDI confirmed synthesis with an observed m/z of 952.6 (expected
952.6) and 758.6 (expected 735.88, observed is M+Na+) respectively. Purified peptides were
then conjugated to AF647 and BHQ-3 (Figure 3.4).
AF647 is a near infra-red (NIR) fluorophore with a peak emission at 665 nm. The Alexa
Fluor dyes are well-suited to biological labelling since they are less hydrophobic than other
dye molecules and are less-sensitive to changes in fluorescence due to environmental changes
in pH. They are also reasonably stable to self-quenching and do not suffer from photobleach-
ing as noticably as other dyes [261], but as a result are less bright. BHQ-3 acts as a dark
quencher for AF647 and as an interacting FRET pair will reduce the fluorescence of the dye.
The FRET pair was chosen since as a NIR pair it can be measured and quantified using the
Li-Cor scanner which is designed for reading signals in this wavelength range.
After conjugation of WSRVGYW to AF647, the coloured fractions obtained after HPLC
were analysed by MALDI-TOF and LC-MS. No peaks of the correct mass were obtained.
LC-MS analysis of the pure dye before synthesis also showed no discernable peak. MALDI-
CHAPTER 3. FRET BASED DETECTION OF HIV-1 PROTEASE 102
Figure 3.4: FRET pair for on-surface detection of HIV-1 protease. a) spectra for AF-647
(fluorescent donor) and BHQ-3 (dark quencher), b) peptide-dye structure for LLE-BHQ-3,
c) peptide-dye structure for WSR-AF647.
TOF experiments were carried out on a series of matrices (Table 3.1) by Dr Lisa Haigh
(Mass Spectrometry Manager, Imperial College London, Department of Chemistry). No
peaks corresponding to the correct mass were obtained with any matrix in positive or neg-
ative ionisation mode. The inability to see peptides conjugated to AF647 via MALDI-TOF
has been reported before [262] and is likely due to the highly charged nature of the dye
molecule preventing effective ionisation. In order to identify which fractions contained the
conjugate the sample was thus analysed by UV-Vis absorption spectrometry. Samples which
contained peaks at 220 and 280 nm (indicative of the peptide backbone and the aromatic
groups) and 647 nm (corresponding to the Alexa Fluor dye) were assumed to have the con-
jugate (Figure 3.5) and were lyophilised and resuspended in water before use.
LLE-BHQ-3 was conjugated in the manner described above, however coloured fractions
obtained after HPLC were analysed with LC-MS and fractions were identified containing a
sinapinic acid alpha-cyano-4-hydroxycinnamic acid
nitroaniline dihydroxybenzoic acid
dithranol 2-[(2E)-3-(4-tert-butylphenyl)-2-methylprop-2-enylidene]malononitrile
picolinic acid 2’,4’,6’-Trihydroxyacetophenone monohydrate
All trans retinol aza thiothymine
3-indoleacrylic acid diaminobenzophenone
Table 3.1: Matrices used to identify WSR-AF647 through MALDI-TOF measurements
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Figure 3.5: Confirmation of peptide-dye conjugation. a) HPLC trace of WSRVGYW. The
fraction corresponding to pure WSRVGYW (black trace) was isolated and its mass verified
by MALDI. The peptide was then conjugated to Alexa Fluor 647 and repurified by HPLC
(red trace). Colored fractions were collected and the UV-Vis spectra analyzed b). Fractions
containing absorbance peaks corresponding to 220nm (peptide backbone), 280nm (aromatic
side chain) and 647nm (dye) were assumed to contain fluorophore-labelled peptides.
m/z peak at 1443.7 (expected 1410.59, observed mass in positive mode = M + methanol
+ H+). Samples containing the conjugate were lyophilised and resuspended in water before
use.
3.3.2 On Surface FRET
A FRET assay for the detection of proteases on surface has been described by Kim et
al. [263]. In this work, quantum dots were conjugated to gold nanoparticles (which act
as quenchers) through a peptide ligand with a recognition sequences for capsase, matrix
metalloproteinase-7 and thrombin. These conjugates were immobilised on a surface and
then incubated with the enzyme in solution. The assay aimed to generate high-throughput,
multiplexed detection of various disease related enzymes in solution.
Our FRET assay was designed to be carried out on surface as this simplifies the labora-
tory work flow and allows multiple experiments to be carried out simultaneously on a single
membrane under the same experimental conditions. In contrast to the work described above,
our assay immobilises the protease rather than the substrate. This is because the assay de-
sign does not rely on protease cleavage. Immobilising the protein also serves to concentrate
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Figure 3.6: On surface FRET showing detection of HIV-1 PR using two independent recog-
nition events. a) recognition of HIV-1 PR by peptide sensor 1 (WSR-AF647), no recognition
of control proteins is seen. b) after addition of the second sensor, LLE-BHQ-3, the fluo-
rescence from the protein is reduced due to FRET from the fluorescence dye to the dark
quencher.
dilute samples which will improve the detection capabilities of the assay.
The studies were carried out with the HIV-1 PR immobilised to amine functionalised glass
slides through gluteraldehyde coupling, using sodium cyanoborohydride as the reducing
agent [264]. However, the experiments can also be carried out on nitrocellulose membrane
which speeds up the experimental procedure, allows more simultaneous experiments on the
same sheet but is more susceptible to non-specific binding of the hydrophobic dye to the
membrane.
Figure 3.6 shows the results from this assay. As can be seen, increased washing of the
membrane reduces the intensity of the observed signal. This is because of the weak affin-
ity between WSR-AF647 and HIV-1 PR. However, the signal decrease observed when the
quencher labelled peptide is added is significant compared to the loss of signal observed
through washing. This decrease in signal supports the hypothesis that both peptides are
binding to the protease giving an energy transfer due to two independent recognition events.
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Figure 3.7: Surface FRET controls showing a) no decrease in signal compared to additional
washing in PBST when the membrane is incubated with LLEYSL in the absence of quencher
molecule, experiment is shown in duplicate. b) no decrease in fluorescence intensity is
observed when WSR-AF647 and LLE-BHQ-3 are incubated together in the absence of HIV-1
PR.
Control Experiments
In order to confirm that the effects observed in Section 3.3.2 were due to quenching of the
AF647 dye by the BHQ-3 and that this effect was because of the presence of the protease
rather than an interaction between the two peptides, control experiments were performed.
The first of these experiments (Figure 3.7a) was to determine whether the decrease in flu-
orescence observed was due to a genuine FRET signal or because of displacement of the
fluorescent probe from the protease by the secondary peptide. It was hypothesised that
this might be possible since both peptides interact with the active site (Chapter 2, Figure
2.13). Since LLEYSL is known to interact more strongly with HIV-1 PR than WSRVGYW,
competitive interactions could cause WSR-AF647 to be displaced. In order to determine
whether this was the case, after initial incubation with WSR-AF647, the membrane was
then split and half incubated with the peptide LLEYSL at the same concentration as LLE-
BHQ-3. This peptide was synthesised without the presence of the BHQ-3 quencher. The
other half was washed in PBST.
CHAPTER 3. FRET BASED DETECTION OF HIV-1 PROTEASE 106
As can be observed from (Figure 3.7a) no decrease in signal compared to additional washing
was seen when the immobilised protease was incubated with the peptide in the absence of
the quencher molecule. This confirms that the decrease in signal in Figure 3.6 was due to
an energy transfer between dye and quencher.
The second control experiment was to confirm that a FRET signal was only observed in
the presence of HIV-1 PR. In order to confirm this the fluorescence spectrum of WSR-
AF647 was measured in a fluorometer (FluoroLog spectrophotometer, Horiba, Stanmore,
UK). LLE-BHQ-3 was then added at a 1:1 molar ratio and the spectrum measured again
(Figure 3.7b). The spectrum of LLE-BHQ-3 on its own was also measured. No decrease
in fluorescence intensity was observed, indicating that the two peptides do not interact on
their own. As a result, any FRET signal that does occur must be mediated by the presence
of HIV-1 PR.
Concentration Dependence
To determine how sensitive the assay on surface was, HIV-1 PR was diluted in PBST to
create a concentration gradient. 5 µL of each solution was spotted onto a nitrocellulose
membrane and allowed to dry. The membrane was then blocked in 2% (w/v) skim milk
for 2 hours at room temperature before being washed in PBST (0.05% (v/v) Tween-20) to
remove excess milk proteins. The fluorophore-labelled peptide was then diluted 1:1000 in 1%
(w/v) skim milk and the membrane incubated in this mixture for 1 hour. The membrane was
washed well to remove non-specifically bound dye and then imaged on a Li-Cor Odyssey
Infra-red scanner. The intensity of the spots was quantified using Li-Cor Image Studio
(Figure 3.8). LLE-BHQ-3 was not added in this experiment.
The increase in fluorescence observed with increasing concentrations of protease is effectively
linear. Concentrations up to 400 nM are visible with the naked eye. Below this concentration
(200 nM) there is very little distinction with the blank solution (PBST only).
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Figure 3.8: Concentration gradient of immobilized HIV-1 PR incubated with WSR-AF647
at 210 nM.
3.3.3 In Solution FRET
Having established the detection of HIV-1 PR when immobilised, it is also of interest to
detect the enzyme in solution and to compare the limits of detection between both methods.
Due to the drying effects observed when proteins are immobilised on surface, it is likely
that the assay would be more sensitive on surface (since the PR molecules would be more
concentrated on surface).
Peptide-Dye Conjugations
For these experiments a new FRET pair was chosen that is more readily water soluble than
those used on-surface and would thus be more stable in the buffered solutions involved.
Fluoroscein-rhodamine, a very common FRET pair was chosen (Figure 3.9) due to ease of
conjugation to peptides. The NHS-dyes were added to WSRVGYW and LLEYSL whilst the
peptides were still on resin at a 1:1 molar ratio. After cleavage by TFA the peptides were
then purified by HPLC and analysed by LC-MS. Fractions showing a m/z of 1093.5 (LLE-
fluor, expected: 1094.27, observed mass in negative mode = M-H+) and 683 (WSR-rhod,
expected: 1364.6, observed mass in positive mode = M+2H+) were identified and the frac-
tions lyophilised to remove residual acetonitrile and TFA. The peptide-dye conjugates were
then resuspended in water before use and their concentration determined through UV-Vis
absorption spectrometry.
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Figure 3.9: FRET pair for in-solution detection of HIV-1 protease. a) spectra for fluorescein
(fluorescent donor) and rhodamine (fluorescent acceptor) - spectral data obtained from Life
Technologies. The solid lines represent the excitation (absorption) spectra and the dashed
lines the emission spectra. b) peptide-dye structure for LLE-fluor, c) peptide-dye structure
for WSR-rhod.
HIV-1 Protease Detection
Since LLEYSL and WSRVGYW have very different affinities for HIV-1 PR, preliminary
studies were carried out to determine the concentration of each peptide sensor required to
generate a good FRET signal. Six concentrations of donor (30 µM, 15 µM, 300 nM, 30 nM,
3 nM, 0 nM) were tested against six concentrations of acceptor (45 µM, 30 µM, 15 µM, 5
µM, 2.5 µM, blank). Each experiment was performed in the presence of 1 µL HIV-1 PR (as
received) in a total volume of 100 µL, giving a final PR concentration of 1.2 µM. Samples
were excited at 496 nm and measured between 520 and 600 nm with a cutoff at 515 nm.
Figure 3.10 shows a selection of the donor-acceptor combinations to visualise differences
observed. Firstly, from Figure 3.10a it can be seen that concentrations of donor (LLE-fluor)
below 15 µM do not give a strong signal. This puts a lower limit on the concentration of
donor that can be used in subsequent assays. From 3.10b-d we can see that a signal exists
in the acceptor channel (WSR-rhod), even with no donor present. This is due to the broad
absorption peak of rhodamine (Figure 3.9).
Concentrations of WSR-rhod above 30 µM were also not suitable since the self-excitation
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Figure 3.10: FRET signal with varying concentrations of WSR-rhod and LLE-fluor. All
experiments were done in the presence of 1 µL (1.2 µM) HIV-1 PR. Each concentration of
acceptor was tested against 6 concentrations of donor. a) Fluorescence signal in the absence
of acceptor dye, b) FRET with acceptor concentration of 15 µM, c) FRET with acceptor
concentration of 30 µM, d) FRET with acceptor concentration of 45 µM.
peak in these instances is of a similar magnitude to the donor peak, making true FRET sig-
nals difficult to distinguish. For further experiments, LLE-fluor and WSR-rhod were both
used at a concentration of 20 µM. These values were chosen to ensure that the donor signal
was strong enough to be measured and that the cross-talk excitation of the acceptor signal
was not excessive.
The assay was performed in a high salt buffer (as described in Chapter 2) adjusted to pH
7 since the fluorescein emission is highly sensitive to pH and under acidic conditions the
fluorescent intensity is reduced [265]. While the activity of the enzyme is reduced at this
higher pH, the high salt content of the buffer ensures that the enzyme is still conformation-
ally stable [151]. Before measuring the fluorescence signal the well plate was incubated for
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Figure 3.11: FRET signal with varying concentrations of HIV-1 protease at fixed concen-
trations of WSR-rhod and LLE-fluor. a) normalised fluorescence signal showing increased
acceptor fluorescence with increasing concentration of HIV-1 PR. b) Limit-of-detection of
FRET assay in solution.
1 hour in the dark at 4oC. The assay was incubated in the cold in order to slow the koff
rate of the peptides and which should improve the assay’s sensitivity. Figure 3.11a shows
the normalised fluorescence at varying concentrations of HIV-1 PR. An increase in acceptor
fluorescence can be observed as the concentration of PR increases. For these studies the
fluorescence was measured between 510 and 600 nm with an excitation wavelength of 480
nm (and a cut off of 495 nm) to reduce the cross-excitation of the acceptor dye.
Figure 3.11b shows the linear relationship between protein concentration and acceptor in-
tensity. All experiments were carried out in triplicate. From the linear fit to the graph, the
limit of detection of this assay can be calculated as three times the standard deviation of the
signal of the blank (3σ). This gives a value of 654 nM which corresponds well to the lowest
concentration that was detectable by eye through the assay on surface (Section 3.3.2).
Efficiency Calculations
Following from the work described in Chapter 2 (2.3.4), we are interested in understanding
where the phage peptide WSRVGYW might be interacting with the HIV-1 PR molecule.
Whilst the most accurate method of determining this would be to crystallise the peptide
with the protease, as described above, FRET allows us to measure distances in solution,
with the protein in its native form.
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Since LLEYSL is a good inhibitor of the enzyme it is reasonable to assume that it interacts
in the active site of the enzyme. By calculating the FRET distance between the two fluo-
rophore labelled peptides we can extract some information about where WSRVGYW may
be interacting. In order to do this we must calculate the efficiency of the energy transfer.
It can be seen from Figure 3.12 that there is very little difference in fluorescein lifetime
in the presence and absence of the acceptor dye, this is indicative of a weakly interacting
system. Using equation 3.4 we can calculate the efficiency from the fluorescence lifetime
measurements shown in Figure 3.12 giving a value of 9.95%. This low rate of energy trans-
fer could be explained by several factors. Firstly, in order for both peptides to interact and
inhibit the active site, it is possible that one of the sensors only interacts with the edge of
the hydrophobic binding pocket. This could result in one or both of the dye molecules being
some distance from the protease molecule, reducing the energy transfer.
It is also likely that the high koff of WSR-rhod contributes to this weak energy trans-
fer. We would expect to observe a double-exponential in the lifetime measurements in the
presence of the acceptor. This would indicate two off-rates – a fast, quenched population and
the slower, unquenched population observed in the measurements of the donor alone [266].
We do not see these two populations in the lifetime measurements in Figure 3.12b however
the low rate of energy transfer may mask this effect. Since the concentration of WSR-rhod
used in this assay is below the KD of the peptide (the concentration at which half the total
molecules are interacting with the protein), it is reasonable to assume that only approxi-
mately half of the protease molecules are labelled with a FRET pair.
Using a value of R0 for fluorescein-rhodamine of 54 A˚ taken from [242] the FRET efficiency
can be used to calculate a distance between the two fluorophores when interacting with
HIV-1 PR by combining Equation 3.3 and 3.4 to give:
r = R0 6
√
τ ′D
τD − τ ′D
(3.6)
This calculation gives a value of distance between dyes of 7.60 nm. This distance is slightly
larger than the lengthscale of the protease molecule which is an oblate ellipsoid, measured
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Figure 3.12: Lifetime fluorescence measurements of LLE-fluorescein interacting with HIV-1
PR in the presence and absence of WSR-rhodamine. a) Linear-linear scale showing exponen-
tial decay including the Instrument Response Function (IRF)) b) data from (a) represented
on a semi-log scale.
by crystallography to be approximately 55 by 35 by 25 A˚ [143]. Calculating a distance
between a FRET pair with such a low efficiency is also difficult since the r6 dependence
becomes insensitive to changes above the Fo¨rster distance. This may also not be an accu-
rate representation of distance since other differences may occur due to variations of the
orientation factor (κ is assumed to be 2/3 when the dyes are free to rotate). Differences
in this value would impact the Fo¨rster radius used to calculate the dye-dye distance. The
use of rhodamine as an acceptor dye can also introduce errors to this calculation due to its
broad absorption spectrum and hence significant direct excitation.
3.3.4 Assay Specificity
Pepsin is the most ubiquitous member of the family of aspartyl proteases, present in the
digestive tract of mammals. Like HIV-1 protease it displays a wide substrate specificity
(preferentially cleaving peptide bonds between hydrophobic and aromatic amino acids) with
a catalytic mechanism that is shared between members of the enzyme family. This shared
catalytic mechanism is dependent on a conserved Asp-Thr-Gly sequence, present on each
monomer. However, pepsin has a conserved tyrosine 43 residues after the first Asp. This
Tyr is absent in the family of retroviral proteases and is important in defining the active site
that binds the substrate [267]. Since these two enzymes share a common catalytic method,
the ability of pepsin to produce a false positive using the commercial HIV-1 protease assay
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Figure 3.13: A comparison of assay specificity using different enzymes, a) the commercial
HIV-1 substrate shows some vulnerability to non-specific cleavage by pepsin, an aspartyl
protease but not to enzymes from a different family. b) The assay developed here shows no
response to an excess of pepsin when compared to the blank control.
(dependent on substrate cleavage) was investigated.
The experiments were carried out under the same conditions as described above but with
pepsin at a manufacturer’s recommended working concentration of 4 mg/mL in place of
HIV-1 PR. Figure 3.13 show the results of this study. As can be seen in Figure 3.13a, the
commercial substrate is susceptible to cleavage by pepsin. Whilst the activity of the enzyme
against the substrate is clearly less than with HIV-1 PR, it demonstrates the vulnerability
to non-specific cleavage that such FRET-based enzyme detection mechanisms suffer from.
The enzyme papain, a cysteine protease, is included as a control from a different enzymatic
family to show that substrates are usually vulnerable to non-specific enzymes from struc-
turally similar enzymes.
Figure 3.13b shows the same concentration of pepsin (at large excess) incubated with the
peptide sensors. The experimental conditions are identical to those used for the in-solution
FRET assay described above. In this instance, no difference can be observed between the
blank and the pepsin indicating that multiple interactions with the nanosensors generate a
highly specific signal.
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3.4 Conclusion
The work detailed in this chapter aimed to detect the presence of HIV-1 protease through
a FRET signal mediated by the interaction with multiple peptide sensors. This approach
to biomarker detection requires two independent binding events, a strategy that improves
the specificity of the assay and reduces the chance of false positives. In contrast to stan-
dard FRET based assays for the detection of proteases discussed above, this methodology
is not dependent on proteolytic cleavage, a transduction method which can be particularly
susceptible to non-specific enzymes. The need for the multiple wash steps that are required
with conventional ELISA assays is also removed, streamlining the laboratory process. The
on surface nature of this assay also allows an extension to high-throughput screening since
several experimental conditions can be trialled on one membrane.
However, the assay suffers from certain limitations - the FRET signal generated through
this method does not give rise to a very high FRET efficiency. Since both peptides show
inhibitory behaviour we can assume that they both interact in the vincinity of the pro-
tease’s active site. From this we would expect the two peptides to be interacting close to
one another, which should cause a higher FRET efficiency. Since this is not observed, it is
likely that the poor binding affinity of WSRVGYW is to blame. The weaker affinity of the
acceptor labelled peptide would result in not every protease molecule being labelled with a
FRET pair, lowering the efficiency of energy transfer.
The limit-of-detection of this assay is higher than many other reported enzymatic assays
(Esseghaier et al., for instance, describe an SPR/magnetic bead mediated detection of HIV-1
protease with a detection limit of approximately 0.5 pM [268]). However, the limit of detec-
tion is in good agreement with other ELISA-like assays which utilise phage derived peptides
in place of antibodies (Kitamura et al. report a peptide aptamer based assay for Cathepsin
E, an aspartyl protease, with a limit of detection of 10 µg/mL [269]). While the sensitivity
of this assay is lower than would be expected from an antibody-based system, the advan-
tages in environmental stability and length scale make these sensors well suited to FRET
applications. The use of multiple recognition events also gives this assay an advantage due
to its robustness to false positive signals caused by other enzymes.
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FRET can be combined with molecular dynamics to guide high-precision structral modelling
[270]. In order to elucidate the interactions between the peptides described in Chapter 2
and HIV-1 protease and to develop a model for the simultaneous binding of both sensors
to HIV-1 protease observed in this chapter, Chapter 4 focuses on using molecular dynamics
simulations to explore these interactions.
Chapter 4
Molecular Dynamics as an
insight to peptide-protein
interactions
. . . everything that living things do
can be understood in terms of the
jigglings and wigglings of atoms.
RICHARD FEYNMAN
The Feynman Lectures in Physics, 1963
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4.1 Introduction
This chapter describes the molecular simulation of interactions between HIV-1 protease and
the peptides identified in Chapter 2 and provides further analysis on the results presented in
Chapter 3. The principles of classical molecular dynamics, molecular docking and their use
in drug design and biotechnology are described before the studies themselves are discussed.
Simulations were performed during a research exchange visit with the group of Prof. Irene
Yarovsky at the Royal Melbourne Institute of Technology under the guidance of Dr. Andrew
Christofferson. Sections of this chapter have been accepted for publication in Chemistry of
Materials as “Designing fluorescent peptide sensors with dual specificity for the detection of
HIV-1 protease” authored by K. Herpoldt, A. Artzy-Schnirman, A.J. Christofferson, A.J.
Makarucha, R. de la Rica, I. Yarovsky and M.M. Stevens.
4.1.1 Computational Chemistry and its Application to Biological
Systems
Molecular and Structural Biology aim to describe biological systems in terms of the under-
lying chemistry and physics. The first molecular models were built of wood and rubber at a
scale of 1 inch:1A˚ and while based on X-ray diffraction data, lacked any information about
the dynamics of the structure [271]. Given the complexity of macromolecular structures,
computational models are crucial to understanding the forces that control these systems.
A rigorous model of a macromolecular system relies on a quantum mechanical description
of the constituent atoms. These models require huge computational resources and are only
now feasible for systems of a few 100 atoms, far smaller than the majority of biologically
relevant molecules. The 2013 Nobel Prize in Chemistry was awarded to Martin Karplus,
Michael Levitt and Arieh Warshel ”for the development of multiscale models for complex
chemical systems”. Their breakthrough was the realisation that an accurate model does not
require all parts of the system to be described with the same level of detail. For instance,
bonds that do not take part in a chemical reaction can be described classically rather than
quantum mechanically with no major loss of accuracy. Similarly, solvent interactions that
are greater than 10 A˚ away do not require a quantum description. This work, and the
development of the molecular mechanical forcefield, led to the first computational models of
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proteins, solvated molecular systems and protein folding [272–274].
Computational studies offer access to sub-microsecond timescales which are difficult to study
experimentally (or are only just becoming feasible to study with the development of ultra-
fast laser systems). They also allow biomolecular interactions to be studied and understood
in detail that can be difficult to achieve in the laboratory. Such theoretical studies not only
elucidate existing macromolecular systems but are also now able to predict protein structure
and folding ab initio with great success – a crucial step in the development of new materials
for a vast array of applications ranging far beyond their biological origins [275].
4.1.2 Computational Studies of HIV-1 Protease
As discussed in Section 1.5, computational studies have played a key role in the development
of new inhibitors of HIV-1 protease, in particular in understanding the substrate binding
mechanism. The enzyme is a popular protein for molecular studies due to its small size,
well-characterised structure, single binding site and large quantities of experimental data
available for comparison.
Previous studies on the enzyme have revealed differences in binding affinity of common
drugs for HIV-1 and HIV-2 protease [276], clarified the role of hydrogen bonding between
the inhibitor main chain and the active site (energy contributions of up to 68% are predicted
to arise from these interactions) [277] and examined the relationship between protein rigid-
ity and binding [278]. As more becomes known about the genetic mutations seen in HIV
reproduction (Section 1.4.2), computational methods have also been utilised to screen drug
targets against a range of known HIV-1 protease mutants and to predict the effect of these
mutations on drug resistance [279,280].
Alongside these studies which focused on drug design, computational approaches have also
revealed much about the fundamental structural biology of the protease. For example, the
catalytic mechanism was developed through molecular studies [158] and then later through
quantum techniques [159, 281]. An understanding of the dynamics of the protease flaps
(and their involvement in substrate binding) was also gained through simulations [282–284].
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These studies are difficult to do experimentally; not only are the time scales of these mo-
tions fast but the usual experimental techniques to measure these dynamic processes involve
fluorescent protein labelling. Given the small size of HIV-1 protease, such large protein
structures would destroy the native enzyme conformation, making the process challenging
to follow. Folding of the protein and dimerisation of the two monomers has also been studied
computationally with the aim of developing dimerisation inhibitors of the enzyme, which
may be more resistant to mutation (experimentally similar systems are described in Section
2.1.2) [285].
4.1.3 Identifying Peptide-Protease Binding Sites
The use of computational methods provides a way of answering questions about experimen-
tal data which may prove difficult to elucidate otherwise. The previous chapters both raised
questions about the nature of the peptide interactions involved. Chapter 2 discussed the
use of the peptides, isolated through phage display, in polymer conjugates and their use as
multivalent inhibitors of HIV-1 protease. Despite a vast body of literature that suggests
that the approach should work, an enhancement of binding affinity was not observed. Sev-
eral explanations for this were hypothesised, including the weak affinity of the peptides in
combination with a strongly inhibiting peptide such as LLEYSL and the possibility that
competitive interactions prevented multiple peptides interacting with the same protease
molecule.
Chapter 3 further described the use of one of these phage display derived peptides alongside
the inhibitory sequence, as FRET-based sensors of the enzyme. This detection mechanism
required that both peptides be interacting with same molecule in order for an energy trans-
fer to occur. The efficiency of the transfer was however weak, suggesting that either the
dye molecules were some distance from each other, or that very few protease molecules were
dual-labelled with both peptide sensors.
This chapter thus aims to attempt to answer these questions by elucidating possible binding
sites and mechanisms of the peptides with the protease. This understanding can help to
design better inhibitors and sensors of the enzyme.
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4.2 Methods
Computational studies were prepared on a desktop PC before being evaluated on high per-
formance computing systems. We acknowledge the generous allocation of computational
resources from the Australian National Computational Infrastructure (NCI), the Western
Australian computational facility (iVEC), the Victorian Partnership for Advanced Com-
puting (VPAC) and the Victorian Life Sciences Computational Initiative (VLSCI). Protein
structures are visualised using Visual Molecular Dynamics (VMD) 1.9.1 and UCSF Chimera
1.9 [142,286].
4.2.1 Molecular Docking
Molecular docking is a computational chemistry tool which is used to predict the interac-
tions between biomolecular complexes (usually protein-ligand interactions). It is a technique
that has been widely utilised by the pharmaceutical industry, where it allows large libraries
of compounds to be screened in silicio, allowing a faster, less expensive refinement of drug
candidates [287]. Molecular docking is often employed preferentially over molecular dynam-
ics studies as it can cover large high-dimensional spaces efficiently through iterative Monte
Carlo calculations and genetic algorithms which are less computationally expensive than
other methods.
Several pieces of software are available for performing molecular docking (reviewed in [288])
but in this work we use AutoDock 4.2.20 [289]. An automated docking procedure consists
of a conformational space search combined with a ranking algorithm to identify which of
the proposed interactions are best. AutoDock 4 uses a Lamarckian Genetic Algorithm to
perform the space search. This technique combines a localised search (which seeks a local
minimum energy state) with a global search which looks for the best energy state within a
defined space. For the local search, the ligand performs a random walk around the protein
and at each timestep (δt), a change is made to the ligand conformation, either as a displace-
ment or as a torsional rotation. The energy of this conformation is evaluated to find the
local minima [290].
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In contrast, a genetic algorithm defines the conformation state of a protein-ligand pair as
a ‘genotype’. Structures are ‘mated’ with the resulting (child) conformation inheriting fea-
tures from both parent structures. Random mutations are also added to the structure of
the ‘child’ in a small fraction of calculations. ‘Selection’ of a successful structure is decided
through evaluation of the minimum energy. In this way, a larger conformational space can
be searched to find a global minimum than with a traditional local search [291]. AutoDock
4 combines these two techniques into a hybrid protocol such that the ’child’ structure un-
dergoes refinement via a local search to find a lower energy state. This combination is found
to be more accurate than either method on its own and allows more complex structures to
be evaluated [291].
In order to evaluate the energy for each conformation, AutoDock 4 uses a semi-empirical
free energy force field based on the AMBER force field (discussed in more detail in Section
4.2.2). This field includes contributions from the energy of desolvation of binding and the
loss of rotational entropy upon binding. By comparing the energy of the ligand and protein
separately and together in the free and bound state a change in energy can be calculated.
This is discussed in more detail in Section 4.2.3. In order to rapidly evaluate this function,
AutoDock first generates a 3-dimensional grid around the protein and places a probe atom
at each gridpoint. The energy between this atom and the protein at each point is calculated
and the affinity to common atom types (carbon, nitrogen, oxygen, hydrogen) and electro-
static potential is mapped across the area. These maps function as look-up tables where
each atom of the ligand is evaluated by comparison to the energy of the surrounding grid
points [290].
Before docking was performed, structures for the protease and peptides were prepared.
For HIV-1 protease, three separate crystal structures were used, based on observations of
different native protein conformation states [292]. These structures (Figure 4.1) were re-
trieved from the RCSB Protein Data Bank (PDB) and consisted of the protease with flaps
open (PDB ID 2PC0), semi-open (PDB ID 1HHP) and closed (PDB ID 1HVC). In the
work below, residues will be referred to as 1-99 for monomer A of the enzyme, 1’-99’ for
monomer B, while amino acids in ligands will be labelled from 199 onwards. Two side chains
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Figure 4.2: Grid regions defined for docking simulations in AutoDock. a) active site re-
gion, b) hinge region, c) unrestrained region covering the whole protease, d) protease dimer
interface region.
in the semi-open structure were mutated (I3V and C95A) to match the wild-type protease
sequence. As discussed in Section 1.5, the closed conformation of the enzyme retains a wa-
ter molecule within the active site. This molecule was included within docking calculations
for 1HVC and all other crystallographic water molecules were removed. Missing hydrogens
were added to the structures using AutoDockTools (ADT) from Autodock 4.2.20. Peptide
structures for all five peptides identified through phage display (Chapter 2) and the inhibitor
sequence LLEYSL were prepared using Biovia Materials Studio and exported as a PDB file.
For docking studies, four overlapping grids were defined based on areas of interest (Fig-
ure 4.2). These areas included the active site, the interface region, the hinge region and
a grid which included the whole enzyme to allow an unforced result for comparison. The
hinge region was chosen as it was hypothesised that binding in this region could prevent
the protease flaps from closing, thereby causing protein inhibition. The phage and inhibitor
peptides were used as ligands and ADT was used to assign Gasteiger charges. Gasteiger
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charges are partial charges which are attributed to each atom within a molecule to account
for charge rearrangement in chemical bonding [293].
The peptide sequences were docked into the four grids for the three protease structures.
Docking was performed using the standard protocol outlined in [294], with a maximum of
10,000,000 energy evaluations and 27,000 genetic algorithm generations using the Lamarck-
ian Genetic Algorithm. For each docking calculation, the top 100 structures based on the
Autodock estimation of free energy of binding were examined, and the 3D structures of the
top ten were evaluated for geometric fit variation to select the distinctive starting structures
for subsequent molecular dynamics (MD) simulations.
4.2.2 Classical Molecular Dynamics
Classical Molecular Dynamics (MD) uses Newton’s laws of motion to predict the behaviour
of an ensemble of atoms over time. In essence, Newton’s second law which states that the
acceleration of an object is directly proportional to the magnitude of the net force (in the
same direction) and is inversely proportional to the mass of the object, is applied to all
atoms in a system. This allows us to write:
~Fi = mi · ~ai = −∇Vi
→ ~Fi = mi · d~vi
dt
= mi · d
2~ri
dt2
→ ~ri(t) =
∫ ∫ −∇Vi
mi
dt
(4.1)
Here the force (F) is equivalent to the gradient of the potential energy of the system (∇V )
and ~vi is the velocity of the atom. Thus in order to follow the movement of atoms with
time, we must solve the equations in 4.1 through numerical integration with a timestep of
τ . The Verlet Algorithm [295] lets us write this as:
~r(t+ τ) = 2~r(t)− ~r(t− τ)− ∇Vi
m
τ2 (4.2)
Hence, by knowing the current and previous positions of the atoms and through calculating
the force acting on the atom we can calculate the next position and so on. Several different
software packages exist to perform these calculations and while they have many similarities,
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Figure 4.3: Schematic showing the variables defined in molecular dynamics force fields to
describe a group of atoms.
differences exist in their representation of the forcefield, Vi. The work described here uses
Amber 12 and its forcefield ff99SB [296,297]. The forcefield is defined by:
V (r)n =
∑
bonds
Kr(r − req)2 +
∑
angles
Kθ(θ − θeq)2 +
∑
dihedrals
Kd
2 [1 + cos(nφ− γ)]
+
∑
i<j
[
Aij
R12ij
− Bij
R6ij
+ qiqj
rRij
] (4.3)
The first and second terms of this equation gives a Hooke’s law representation of the energy
of bond stretching and bending. The third gives the energy of bond torsions (which takes the
stereochemistry of a molecule into account) and the final term represents the non-bonded
energy contributions including the van der Waals forces and the electrostatic interactions
between atoms. The parameters r, θ and φ are defined for a molecular structure in Figure
4.3. The force field also includes parameters for the constants defined in the above equation.
The docked structures from the AutoDock experiments were saved as PDB files. LEaP,
the molecular editing package within AMBER, was used to solvate the systems with a
TIP3P water box extending at least 12 A˚ from the complex resulting in a box containing
approximately 34000-36000 atoms. Chloride ions were also added at this stage to neutralize
CHAPTER 4. MOLECULAR DYNAMICS STUDIES OF HIV-1 PROTEASE 126
the overall charge. Asp25 in the catalytic site was protonated to mimic the native confor-
mation of the protease (discussed in Section 1.5). The correct protonation state has also
been shown to have a large influence on the calculated free energy of binding of inhibitors
of HIV-1 protease [298].
Simulations were then made using AMBER’s sander (Simulated Annealing with NMR-
Derived Energy Restraints) package. Sander is responsible for performing the initial en-
ergy equilibration of the system by relaxing the structure down an energy gradient. It then
performs the molecular dynamics by integrating the Newtonian equations described above.
Bond lengths involving hydrogen were constrained using the SHAKE algorithm (to allow
a 2 fs timestep). The particle-mesh Ewald (PME) scheme was used for the electrostatic
interactions, with a nonbond interaction cutoff (electrostatics and van der Waals) of 8 A˚.
The use of a PME scheme allows the protein to be simulated in a pseudo-infinite water
box (matching real systems) by accounting for electrostatic interactions across a periodic
boundary.
Minimisation of the systems involved a steepest descent algorithm followed by a conjugate
gradient method, with a convergence criterion of 10-4 kcal/mol·A˚ and position restraints
of 2 kcal/mol·A˚2. Equilibration of the systems to standard temperature and pressure con-
sisted of 50 ps of constant-volume MD as the system was heated from 0 to 300 K, followed
by 50 ps of constant-pressure MD. Full simulations were then carried out of up to 20 ns
for each system (atomic coordinates were saved every 10 ps). Standard temperature and
pressure (300 K, 1 atm) were maintained through a Langevin thermostat and a Berendsen
barostat [299,300].
4.2.3 MM-PBSA
An estimate of the free energy of binding can be calculated by the Molecular Mechanics
Poisson-Boltzmann Surface Area (MM-PBSA) method [301]. To calculate this free energy
we would ideally consider the case illustrated in Figure 4.4a where the change in energy
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Figure 4.4: Thermodynamic cycle for calculating the free energy of binding. a) the ideal
case where protein and ligand are both solvated b)to avoid solvent-solvent interactions dom-
inating the calculation, binding can be separated into solvated and vacuum states and the
final result calculated through equivalence. Adapted from [301].
from unbound to bound state is calculated in the solvated state. That is,
∆G0bind = ∆Gcomplex −∆Gligand −∆Gprotein (4.4)
However, in this case the energy calculations would be dominated by contributions from
solvent-solvent interactions and these energy fluctuations can be an order of magnitude
larger than the energy of binding. In order to circumvent this, we can use an equivalent
calculation outlined in Figure 4.4b. This can then be calculated as:
∆G0bind,solv = ∆G0bind,vacuum +∆G0solv,complex − (∆G0solv,ligand +∆G0solv,protein) (4.5)
Solvated energies are calculated through the Poisson-Boltzmann equation which calculates
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the electrostatic potential and adds an empirical hydrophobic term [302]. The in vacuo term
is calculated through an estimation of the molecular mechanics terms such that:
∆G0bind,vacuum = Ebond + Eangle + Etors + EV dW + Eelec − T∆S (4.6)
The entropy contribution is found through normal mode analysis (discussed below). The
free energy terms can be calculated by running separate molecular dynamics simulations for
the complex and each component (multiple trajectory protocol) or by extracting each state
from a single trajectory of the bound ensemble. Using a single trajectory over the multiple
trajectory protocol is usually preferential since it is less computationally expensive and the
likelihood of obtaining free energies between separate trajectories is minimal.
Normal mode analysis is used to calculate the entropic cost of a binding interaction. The
translational and rotational contributions can be calculated through standard statistical me-
chanics (reviewed in [303]). The vibrational entropy can be estimated by approximating the
vibrational potential energy surface of the protein at the local minima through analysis of
the normal modes of the harmonic approximation. These calculations are complex (detailed
in [304]) and extremely computationally expensive since the diagonalisation of the matrix to
extract the eigenvalues scales with (3N)3 where N is the number of atoms. Higher frequency
vibrations have lower entropy costs since the amplitude is smaller.
To perform this analysis, MMPBSA was run using the MMPBSA.py script within the Am-
ber package. Calculations were performed on the final 10 ns of the simulation runs, with
all frames (1000 total) used in the enthalpy (∆G) calculation. Normal mode analysis was
carried out on every fifth frame (200 total) due to the greater computational cost involved.
Default values of 0.00542 kcal/(mol/A˚2) were used for the surface tension and 0.1 M for the
ionic strength, with an offset of 0.92 kcal/mol, and a dielectric constant of 80. For nmode
calculations a default convergence root mean square gradient of 10−4 kcal·mol−1·A˚−1 was
used.
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4.2.4 Replica Exchange with Solute Tempering
Replica Exchange Solute Tempering (REST) calculations were performed by Dr Andrew
Christofferson and Mr Adam Makarucha (RMIT). A discussion of these calculations is in-
cluded here for completeness.
A major limitation of traditional molecular dynamics methods is that over the usual timescale
of a simulation only a small section of the free energy surface may be sampled. This can
leave the results constrained within local minima which are not necessarily representative
of the global minimum. Replica Exchange (or Parallel Tempering) aims to overcome this
by running multiple versions of the same system equilibrated to a range of different tem-
peratures. At a determined time step, the configurations of neighbouring simulations are
exchanged based on a probability that the energy states will be present in both simula-
tions. High-temperature simulations have greater energy to cross energy barriers and sample
conformational space. Over the full course of the simulation, high-temperature conforma-
tions will be exchanged with those at low-temperature, allowing simulations to effectively
hop across energy barriers. This was first outlined for molecular dynamics by Sugita and
Okamoto [305]. For systems including explicit water, this method can be slow and compu-
tationally expensive. Since our protein-peptide system is hydrated we use Replica Exchange
with Solute Tempering (REST) where the energy of the system is scaled such that the areas
of interest are raised in temperature while the water molecules remain at 300K [306].
These experiments also included the dye molecules (BHQ-3 and AF-647) used in the surface
FRET assays in Chapter 3. The top two binding orientations (based on MM-PBSA rank-
ing) for the LLEYSL and WSRVGYW peptides were used as the starting configurations
for these conjugates. Partial charges for the dyes were determined using the Gaussian 09
software package. Structures were parameterised using the general amber force field within
the antechamber package of Amber [307].
REST simulations were performed using the Gromacs 4.6.5 MD code, with 16 replicas and
an effective temperature range of 300-600 K [308]. The average probability of exchange was
0.4, with an exchange attempt every 4 ps. Only the residues in the protease flaps (residues
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Closed Open Semi-open
Active LLE, WSR, WTL LLE, WSR, WTL LLE, WSR, WTL
Hinge LLE, WSR, WTL LLE, WSR, WTL LLE, WSR, WTL
Bottom KIN, MSI, TPY – –
Large KIN, MSI, TPY – –
Table 4.1: Summary of protein structure-peptide and grid region used in AutoDock docking
calculations.
46 to 56 and 46’ to 56’) and the peptides were perturbed. These simulations were run for
200 ns using the v-rescale thermostat and Parrinello-Rahman barostat, with the LINCS
constraint on all bonds (the equivalent of the SHAKE algorithm) [309]. A 10 A˚ cutoff for
electrostatics (PME) and non-bond interactions was applied and all other parameters were
identical to the Amber simulations.
4.3 Results and Discussion
4.3.1 Molecular Docking
Protein structures, grid areas and peptides were combined as outlined in Table 4.1. These
combinations were chosen based on experimental studies described in Chapter 2. The pep-
tides MSITRVH, KINEVWN and TPYMTPK show no inhibition so were evaluated outside
of the active site and hinge area. They were only studied on the closed protein, since the
flap position only affects the active site and so little difference is expected between the pro-
tein conformations. Peptides WSRVGYW and LLEYSL both inhibit the peptide and were
hence evaluated in both the active site and on the shoulder (which we hypothesise could
cause inhibition by preventing the flaps from closing). WTLHYSY shows a minor degree of
inhibition (which cannot be thoroughly investigated experimentally due to solubility issues)
and so was evaluated with WSR and LLE. For these peptides, all three protease conforma-
tions were considered since the position of the flaps will affect substrate binding.
For each combination listed in Table 4.1, 100 different conformations were generated and
their binding energies evaluated. Those conformations with the best binding energy (the
strongest interaction) were selected for use in the subsequent molecular dynamics. The
distribution of the calculated energies (Figure 4.5) can give an idea about the likelihood of
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a protein-peptide combination being a favourable one. For example, it can be seen that the
combinations involving the active site of the protease predominantly show binding (negative
free energies) whereas the same peptides evaluated on the hinge area showed a distribution
highly skewed to the positive free energy (non-physical condition). The structures evaluated
with the protease in its closed conformation also show stronger binding than the other two
structures (which is to be expected since the closed site will form a hydrophobic pocket).
This difference between protease conformation is lost for the hinge grid region.
The docking conformations for KIN, TPY and MSI evaluated without restraint on the
protease surface show several strong binding conformations. However, when these were vi-
sualised, the majority of the configurements consisted of the peptide within the active site.
From experimental considerations these were neglected and the highest binding states where
the peptide was not within the active site were chosen. When these peptides were docked in
a grid region with the active site excluded (‘bottom’) the distribution of free energies shows
conformations with mostly positive energies, suggesting that this is not the correct area for
peptide-protein interactions. Nonetheless, the few structures that did have a weak binding
affinity were selected and used for subsequent studies.
The scoring function used to calculate these free energies is designed to be fast and thus
is limited in its accuracy. These calculations do not take into account an explicit solvent
model, thus failing to account for the fact that polar residues will have favourable solvent
interactions which are lost upon binding [310]. In the docking studies described here, the
protein and ligands are also considered as rigid objects. In reality, proteins and peptides are
flexible biopolymers and the active site of proteins can rearrange to accommodate ligands of
different shapes [311]. To overcome this, several different methods have been implemented
(reviewed in [312]) such as softening bond constraints on the receptor or docking the ligand
into multiple receptor structures. AutoDock does allow flexible docking but accurate results
are only found for systems involving up to 10 flexible bonds [313]. Even allowing only the
active site residues to be flexible within HIV-1 protease would have involved more than 10
bonds and hence calculations performed here did not utilise the flexible options. In addi-
tion, even if the docking calculation would identify the ideal conformation, the binding free
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energy result will not be accurate since the algorithms used in scoring functions neglect the
loss of conformational entropy that occurs on protein-ligand binding. This causes a large
overestimation of the binding affinities.
Despite these limitations, molecular docking remains a powerful technique that has proved
invaluable to pharmaceutical development. The results presented here provide better start-
ing conformations for molecular dynamics simulations than random interactions of the pep-
tide with the protease molecule. Since the issues outlined here provide systematic errors to
the calculated free energy of binding, using these values as relative rather than definitive
still provides a tool to evaluate the binding between different conformations.
4.3.2 Molecular Dynamics
In total, 30 separate simulations were run involving different starting structures taken from
the AutoDock configurations. Simulations were run for 20 ns and where interesting dynam-
ics were observed, these were extended by an additional 5 ns. The trajectories of all 30
simulations were visualised to assess the validity of the calculated structures. Several of
the simulations led to the peptide dissociating from the protease, while others showed con-
formations that were structurally similar to other simulations. Trajectories were examined
using VMD to extract information about hydrogen bonds, flap tip distances and to follow
residues of interest. These are discussed in further detail below.
Binding of KINEVWN
Three simulations of KINEVWN were run with the peptide starting in different starting
configurations. Two of these were selected from the large docking region and one from
the bottom. All three simulations gave positive free energies, showing that no favourable
binding conformation was found. The simulation from the bottom grid region showed the
worst binding (∆G = 13.29 kcal/mol). This poor binding can be attributed to the lack of
hydrogen bonds present (>65% of the frames have no hydrogen bonds at all, while a single
bond is present in only 24% of frames). The peptide does not stay consistently in a single
location but is loosely held by an by an interaction between the N-terminal Lys and Glu65’.
Figure 4.6 shows representative images of the two simulations which were not restricted to
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Figure 4.6: Representative images showing the binding of KINEVWN to HIV-1 PR for two
different starting conformations. a) shows the protease from the side, with the active site
running roughly horizontally across the image. b) shows the PR molecule almost face on,
with the two ’flaps’ at the top of the image.
the bottom of the protease. Figure 4.6i is fairly well bound on both ends for first 10 ns
through the N-terminal Lys (persistent hydrogen bonds to Glu34 from the backbone) and
the C-terminal Asn. Figure 4.6ii shows the best binding out of the three configurations
(although still positive), despite also having no hydrogen bonds present for the majority of
frames (> 72%). However, for this conformation compared to the first the enthalpy of the
interaction is far more favourable, resulting in a better binding than the other two structures.
Binding of TPYMTPK
Three structures were also simulated for TPYMTPK. Of these one was from the bot-
tom ROI and the other two from the larger, unrestricted grid. Of these, only one had
a negative binding energy (∆G = -8.68 kcal/mol). This conformation is illustrated in
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Figure 4.7: Representative image showing the binding of TPYMTPK to HIV-1 PR. ai)
shows the protease molecule face on, with the binding site roughly perpendicular to the
page, aii) shows the same conformation but with one monomer coloured by residue type to
highlight binding mechanisms, acidic residues are red, basic are blue, polar side chains are
green while hydrophobic amino acids are white. b) docking conformation where the protease
is seen from the side with the active site running horizontally.
Figure 4.7a. In this configuration the peptide appears to be bound in a hydrophobic pocket,
close to the enzyme’s active site. Figure 4.7aii shows one of the protease monomers colour
coded by residue type, hydrophobic residues are white while acidic residues are red and
basic residues are blue. The C-terminus Lys shows an electrostatic affinity for the oppo-
sitely charged Glutamic acid (Glu21) while a persistent hydrogen bond (occupied for 46%
of frames) between Glu21 and Thr203 is also responsible for the observed binding. Over the
course of the simulation hydrogen bonds are present in >84% of frames.
In contrast the poor binding (∆G = 1.05 kcal/mol (Figure 4.7b) and ∆G = 9.95 kcal/mol,
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Figure 4.8: Representative image showing the binding of MSITRVH to HIV-1 PR.
not shown) of the other two simulations of this peptide can be attributed to the lack of
bonding between the peptide and protease. In both cases, the peptide is only held through
a hydrophobic interaction of Tyr202 with the protease surface.
Binding of MSITRVH
Only one structure was simulated for MSITRVH (Figure 4.8) based on visualisation of the
docking conformations. This peptide is bound through persistent hydrogen bonding between
Ser200 and Glu21’ but the C-terminus shows no interaction with the protein surface. While
originally bound to the bottom of the protease over the course of simulation it moves toward
the hinge area.
Restricting Flap Motion as an Inhibitory Mechanism
We hypothesized that binding to the hinge region of the protease could influence the activity
of the enzyme, since an interaction here would prevent the flaps of the enzyme from closing,
thereby preventing the formation of the catalytic triad required for proteolysis. To this end
we studied WSRVGYW, WTLHYSY and LLEYSL in this region. Representative images
from these simulations are given in Figure 4.9. This hypothesis is supported by crystal
structures of the clinical inhibitors Darunavir and Amprenavir being able to bind with both
the active site and on the top of the flap region [314, 315]. Others have also hypothesised
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that interactions with the flap or hinge region could form the basis of the next generation
of protease inhibitors [316].
All three peptides showed a positive free energy when interacting with the protease in
the closed form (Figure 4.9i). In all cases this is because one terminus of the peptide frees
itself from the surface of the peptide, increasing the entropy of the system. In the case of
LLEYSL, the C-terminus Leu is interacting with the edge of active site (Ile45’) and Ser203
has a reasonably persistent hydrogen bond with Asp28’. The high entropic cost associated
with the binding of WSRVGYW in this instance is due to solvent interactions from the
charged Arg201. WTLHYSY is mainly anchored to the protease through hydrophobic in-
teractions between Trp199 and Ile47’.
In contrast, the open configurations all show a negative free energy. This is most likely
due to the more open protease structure allowing the initial docking procedure to place the
peptides within the active site and interacting with the flaps. The N-terminus of LLEYSL
in this instance is well bound with Leu199 hydrogen bonded to the backbone of Glu21 and
Glu34 and Leu200 interacting with Asn83. WTLHYSY moves from the hinge area to in-
teract directly on top of the protease flaps and shows persistent hydrogen bonds between
Trp199 and Glu35.
The structure for WSRVGYW is calculated to have an unphysical binding affinity where
the ∆G of -36.1 kcal/mol corresponds to a calculated KD of 10−27 M (for comparison the
binding of biotin-streptavidin, which approaches the binding strength of a covalent bond,
has a KD on the order of 10−15 M). This overestimate of the binding strength is a result
of a favourable interaction between Arg201 and the active site Asp as well as hydrophobic
interactions with the “eye” of the protease [317].
The configurations involving the semi-open protein conformation show binding energies be-
tween those found for the open and closed systems. LLEYSL and WSRVGYW both have
small negative energies which result from the interactions between their charged residues
(Glu201 and Arg201). Again the favourable interaction is most likely due to interactions
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Figure 4.9: Representative images of WTLHYSY, WSRVGYW and LLEYSL binding to the
hinge region of HIV-1 protease. a-c show peptides LLEYSL, WSRVGYW and WTLHYSY
respectively while i-iii show the protease in closed, open and semi-open conformations.
with the “eye” of the enzyme on the underside of the flap. WTLHYSY in this scenario
does not show a negative free energy due to the lack of hydrogen bonds (>72% of frames
have no bonds present). However, the presence of this peptide in this simulation causes a
large instability in the backbone of the enzyme and the flaps of the enzyme to open (Figure
4.10). Given this part of the protease structure is highly conserved, this simulation demon-
strates that, if reproducible, it could prove an interesting target for rationally designed small
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Figure 4.10: Graphs showing the effect of the presence of WTLHYSY on the stability of
HIV-1 protease in the semi-open conformation. a) Backbone RMSD of the protein showing
large fluctuations in motion, b) Flap tip distance (Gly43-Gly43’).
molecule inhibitors which could be resistant to protein mutation.
In general, the simulations showed that the binding of WSRVGYW,WTLHYSY and LLEYSL
in this region was predicted to be orders of magnitude less than in the active site. Binding
conformations that originate in the hinge region progressively interacted with the flaps over
the course of the simulations. This is to be expected given this is the hydrophilic, solvent-
exposed surface of the protease. From these studies it is therefore reasonable to suggest that
the likely binding site of these peptides is within the active site of HIV-1 PR.
Active Site Interactions
Since the likely binding site for all peptides displaying inhibitory behaviour is within the
enzyme’s active site, WSRVGYW, WTLHYSY and LLEYSL were all simulated within this
region. Representative images of these simulations are shown in Figure 4.11. In all, 11
different simulations were run, but due to similarities in final binding configurations only
the 9 distinct conformations are illustrated here. All structures gave negative free energies,
demonstrating that the binding is much more likely here. As would be expected, the cal-
culations involving the closed protease conformation gave the strongest binding affinities,
since the closed hydrophobic cavity will prevent solvent interactions.
Binding of LLEYSL in the active site was characterised by hydrogen bonding of Asp30’and
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Figure 4.11: Representative images of WTLHYSY, WSRVGYW and LLEYSL binding to
the active site of HIV-1 protease. a-c show peptides LLEYSL, WSRVGYW and WTLHYSY
respectively while i-iii show the protease in closed, open and semi-open conformations.
Asp25’ to the sidechain of Ser203 sidechain and the backbone of Leu200. The strongest pre-
dicted binding structures also show hydrophobic interactions between Tyr202 and Phe53’.
The interaction of WSRVGYW with the active site also shows significant dependence on
hydrogen bonding between the N-terminus Trp backbone and the Ser200 sidechain with
Asp30’ and Asp29. In these simulations, we also observe several hydrophobic interactions
between Tyr205 and the C-terminus Trp with the Phe53 and Phe53’ flap residues, similar to
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that seen for LLEYSL. In several simulations of WSRVGYW from different starting config-
urations the central Val differs between calculations by an average RMSD of 1.76 A˚ showing
that the structures are similar.
The binding of WSRVGYW and LLEYSL is weaker in the semi-open and open config-
urations but the bonding observed is similar. LLEYSL is still stabilised by a persistent
hydrogen bond between Leu199 and Asp25’ and Asp25’ and Ser203. WSRVGYW is again
bound by Arg201 and Ser200 to Asp25’. For WTLHYSY in all structures, the C-terminus
Tyr is interacting with the flaps. In the semi-open and open configurations (where there is
more space within the active site), this Tyr interaction between the flaps causes the peptide
to curl within the cavity. Hydrogen bonds stabilising the interactions observed exist between
Trp200 and Asp29 and Asp25’.
On the Calculation of Binding Affinities
The free energies of binding calculated through MM-PBSA and normal mode analysis are
given in the figures showing binding conformations. The best calculated free energy for each
peptide sequence can be seen in Figure 4.12 for comparison. It can clearly be seen that
KINEWVN does not bind well to the protease in comparison to the other peptides. On
comparison with the original phage ELISA data (Figure 2.7) we can see that KINEWVN
also showed much weaker binding than the other phage peptides. This suggests that the
trend in the data matches the experimental results despite the fact that the absolute values
of the free energy of binding do not correlate well with experiment. The free energies given
can be turned into binding affinities through the equation:
∆G = RT lnKD
Co
(4.7)
Here R is the gas constant at standard temperature and pressure (STP) and Co is the stan-
dard reference concentration (1 mol/L at STP). In some cases the calculated dissociation
constant was up to 10 orders of magnitude stronger than the experimental value. The dis-
crepancy between theoretical and experimentally measured binding affinities is a subject that
has been well discussed in the literature. Since a change of only 1 kcal (4.19 kJ) results in a
5-fold change in affinity, even very small errors can very quickly result in wildly inaccurate
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Figure 4.12: Best estimated free energy of binding for the peptide/protease complexes from
MM-PBSA calculations.
binding constants. Leach et al. summarised the problem as “Accurate prediction of binding
affinitis for a diverse set of molecules turns out to be genuinely difficult” [318]. Explanations
for why this problem remains so challenging include sampling problems, interactions with
structural water molecules and the conformational strain in protein-ligand binding [319].
A thorough error analysis of the binding free energy of Indinavir bound to HIV-1 protease
yields an uncertainty of ±6.7 kcal/mol [319]. Given the free energy is predicted to be -12.3
kcal/mol, this error would suggest that the binding affinity could range between the sub-
picomolar to sub-micromolar (the measured free energy of Indinavir is -11.8 kcal/mol [320]).
Indinavir, like the peptides described here, is a large molecule and thus many protein-ligand
contacts must be considered. Each of these contacts adds its own errors and hence these
methods of calculating free energy are likely to be more accurate for small molecules.
Another important factor to consider when discussing the validity of calculated free en-
ergies is the entropic contribution. Since normal mode analyses of the vibrational entropy
are computationally demanding, only 1/10 th of the molecular dynamics frames were used
to calculate the entropy terms. This can lead to errors associated with under-sampling of
the conformational changes in the ligand binding. In general, calculating entropy accurately
remains a challenging task, one which the computational field is still actively engaged in
solving. For large molecules such as peptides, the entropic costs associated with binding are
usually high (more so for peptides which have a high charge density [321]). This often results
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in the loss in configurational energy cancelling most of the binding energy, leaving only a
small net value. This was clearly seen in the data presented here, where unfavourable bind-
ing was always a result of large entropic penalties. In calculating this entropy, it is usually
assumed that the translational and rotational contributions are negligible. This assumption
is likely not well founded, since these motions themselves depend on the strength of binding
and can vary greatly between different conformations of the same ligand [310, 322]. Given
the poor sampling implicit with nmode analysis, this is another likely source of error within
these calculations.
4.3.3 Replica Exchange Calculations
Based on experimental work described in Chapter 3, the interactions of WSRVGYW and
LLEYSL conjugated to dye molecules was also simulated to observe the impact of the pres-
ence of the dye molecule on the binding. In order to sample a greater configurational space,
REST calculations were used to overcome energetic barriers. Structures from the trajecto-
ries at different temperatures were sampled by clustering the peptide backbones separately
with an RMSD cutoff of 1.2 A˚ over the final 50 ns of the trajectory. The most populated
clusters were taken as the most likely binding conformation of the peptide-dye conjugates.
These are shown in Figure 4.13. These clustered structures are also similar to the con-
formations found from 800 ns of classical MD. Both peptides are relatively stable in their
binding positions and both are characterised by similar binding interactions. Both form a
hydrogen bond with the Gly48 backbone of the protease flap, and both have persistent hy-
drophobic contacts with the hydrophobic pocket formed by Ile50, Val82, Ile84, and Leu23, as
well as hydrophobic contacts with Phe53 on the protease flap. The experimentally observed
inhibitory action of both peptides may be due to interference with the opening of the flaps
rather than occupation of the active site as seen with other inhibitors [161].
For the WSRVGYW peptide, the structure is characterised by hydrogen bonding between
the Arg201 side-chain of the peptide and the catalytic residue Asp25’ of the HIV-1 PR.
There are also hydrogen bonds between the N-terminal Trp backbone and Gly48’ backbone,
the backbone of the dye and Lys45’, and from the side-chain of Tyr205 to the Glu21
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Figure 4.13: Representative images showing the binding of LLE-BHQ3 and WSR-AF647 to
HIV-1 protease. a) protease visualised from the top, showing both peptides interacting with
the active site, with the dye labelled peptides on each side. bi) close-up of interaction of
WSR-AF647 with the protease (peptide is shown in stick representation), bii) close-up of
interaction of LLE-BHQ3 with the protease.
side-chain. There are also persistent hydrophobic contacts between Val202 and Ile50, Val82,
Ile84, and Leu23, as well as the N-terminal Trp and Phe53’. Many of these bonds are also
present in the free MD calculations of the peptide in the active site discussed above. For
LLEYSL, hydrogen bonding exists between the C-terminal Leu and the Arg8’ side-chain and
between the side-chain of Ser203 and Gly48 backbone. There are also persistent hydropho-
bic contacts between the C-terminal Leu, Leu200 and Ile50’ and Val82’ of the protease. The
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Figure 4.14: Distance between the centre-of-mass of AF647 and BHQ3 extracted from MD
simulations.
FRET experiments in Section 3.3.3 gave an estimate of dye separation of 7.60 nm based on
the measured efficiency of energy transfer. From the REST calculations we can also extract
a theoretical distance between the dye molecules. The separation between the centre-of-mass
of the dyes over the course of the simulation can be seen in Figure 4.14. These calculations
give an average distance of 2.68 (±0.27) nm. This is significantly closer than the experi-
mental results would suggest. There are several reasons why this discrepancy may arise;
firstly the computational studies represent the ideal scenario where both peptides are bound
to the enzyme. In practice, since the concentration of WSRVGYW used in the assay is
below the KD of the peptide we can assume that at this concentration only 30.9% of PR
molecules would be labelled with an acceptor. This fractional labelling should increase the
calculated efficiency of energy transfer, thereby reducing the calculated distance. Differences
may also arise due to the different structure of the dye molecules which act as a reporter
probe (AF647/BHQ-3 vs fluorescein/rhodamine). While all four organic dyes are bulky
molecules, the differences in structures may well affect the calculated binding orientation,
leading to differences in center-of-mass distances.
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4.4 Conclusion
The work detailed in this chapter aimed to provide a theoretical background to experimen-
tal results discussed in previous chapters. To achieve this understanding, computational
chemistry techniques were employed which included molecular docking, molecular dynam-
ics, free-energy calculations and replica exchange simulations.
Chapter 2 described the identification of peptides which bound to HIV-1 protease through
phage display. Through molecular modelling potential binding sites of these peptides were
identified. Chapter 2 also attempted to use concepts of avidity to design multivalent in-
hibitors but no enhancement was seen. The results of this chapter show that this is likely
due to the close proximity of the binding sites of the two peptides used, LLEYSL and WS-
RVGYW. As has been shown, both peptides interact with the enzyme close to the active site.
The addition of the PEG12 linker was thus likely too long to allow the secondary peptide to
approach the enzyme, preventing the multivalent binding that was required. It is probable,
from these simulations, that the conjugate with the PEG2 linker may have shown enhanced
affinity since this distance would be more appropriate and further work to solve solubility
issues would help to elucidate this. If an increase of avidity was seen experimentally, the
PEG linker could be added to the simulation to further investigate these effects.
Chapter 3 described the use of WSRVGYW and LLEYSL as peptide sensors of HIV-1
protease using FRET. The simulations performed in this chapter were used to understand
the low efficiency of energy transfer found experimentally. The simulated data shows that
both peptides can simultaneously interact with the active site despite the presence of the
large organic dye molecules. The dye-to-dye distance calculated through these methods is
far smaller than seen experimentally, supporting the hypothesis that the low efficiency is due
to the high koff of WSRVGYW rather than the dyes being at some distance from each other.
In order to improve the FRET detection discussed in Chapter 3, computational alanine
scanning could be used to identify which of the residues in WSRVGYW are crucial to
binding, and computational mutations could then be made to find higher affinity peptide
sequences.
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The limitations of the methods used here have been discussed in depth. While issues re-
garding precise calculation of binding affinities exist, the methods used here are well-suited
to identifying relative binding and ranking those conformations. In order to fully validate
the results shown here, X-ray crystallography of the protease complexed with the peptides
could be performed which would further guide the design of peptides for use as inhibitiors
or sensors.
Chapter 5
The expression and purification
of recombinant HIV-1 protease
in Escherichia Coli
Enzymes are things invented by
biologists that explain things which
otherwise require harder thinking.
JEROME LETTVIN
CHAPTER 5. THE EXPRESSION OF HIV-1 PROTEASE 149
5.1 Introduction
This chapter discusses the expression and purification of recombinant HIV-1 protease in
Escherichia Coli. As discussed in Chapter 1, HIV-1 protease is the smallest of the aspartyl
protease family and has a homodimeric structure of monomers consisting of 99 amino acids
(corresponding to a folded size of 22 kDa). The enzyme was the first of the retroviral pro-
teases to be cloned and expressed recombinantly [323] and was first expressed in E.coli in
1987 by Debouck et al. [324]. When this protein was obtained, the structure of the protease
had yet to be defined and it was isolated through comparison of the HIV genetic sequence
with other known retroviral proteases [156]. It was expected that the enzyme would consist
of fewer than 130 amino acids, encoded between the gag and pol regions. Since the natural
protease is produced through autoproteolysis of the precursor polypeptide, production of
active HIV-1 protease by mimicking the production within the virus itself proved highly
effective as a means of producing active enzyme in quantities far greater than could be
achieved through extraction from live virions [323].
Further studies by Graves et al., Nutt et al. and Darke et al. [325–327] established that
the 11 kDa fragment was sufficient for enzymatic activity before the structure of the enzyme
was revealed through x-ray crystallography [143, 328]. Having established the amino and
carboxylic termini of the mature protease monomer, the enzyme could then be expressed
through the insertion of an ATG methionine initiator codon immediately before the N-
terminus and the addition of a stop codon after the carboxyl terminus. The various papers
reporting production of HIV-1 protease through this method are summarised in Table 5.1.
These methods report a range of purification techniques as well as refolding conditions.
The (relatively) short nature of the amino acid sequence that comprises the enzyme monomer
also makes it accessible to synthetic chemical techniques. Several groups have described the
preparation of HIV-1 protease through chemical peptide synthesis [329,330]. Chemical syn-
thesis allows the production of a high-yield peptide sequence which can be purified by one
step size-exclusion chromatography, rather than the multiple purification steps that are often
required when proteins are expressed in E.coli.
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However, beyond around 45 amino acids, the yield of adding an additional amino acid sig-
nificantly decreases due to the steric hindrance of the growing peptide chain. With the
purification of extremely long peptide sequences it can also be difficult to distinguish be-
tween sequences where a single amino acid has been lost, since elution times would be
roughly similar.
The work by the Kent group [330,341] circumvented this problem by synthesising two pep-
tide chains corresponding to the two halves of the monomer and then ligating the two halves
with a thioester acting as an analogue to the native peptide bond. This thioester bond is
however labile at neutral pH, resulting in a half-life of only 2 hours; however, in the acidic
conditions required for optimum enzyme activity the protease remains stable. Chemical syn-
thesis also offers the ability to do site-specific mutagenesis to include non-native chemical
groups which cannot be easily be achieved in expression systems such as E.coli.
HIV-1 protease has also been expressed as a tethered dimer where two copies of the monomer
are produced as a single polypeptide by including a short, in-frame sequence between the
carboxyl terminus of one monomer and the amino-terminus of the second [342, 343]. The
construction of such tethered dimers allows the introduction of asymmetric amino acid sub-
stitutions which can help to understand the structure-activity relationship of the enzyme.
While the majority of papers describing the expression of HIV-1 protease have utilised
E.coli, the enzyme can also be expressed in yeast, Saccharomyces cerevisiae [344]. The use
of yeast can help to overcome problems with expression in E.coli such as the toxicity of
the enzyme to the bacteria and the formation of insoluble inclusion bodies. Despite this,
expression in E.coli remains the most common technique due to its low production costs
and ease of scalability.
This chapter describes the expression and purification of HIV-1 protease in E.coli and pre-
dominantly follows protocols described by Margolin et al. [333] and Hui et al. [345].
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5.2 Materials and Methods
Unless otherwise stated all reagents and materials were purchased from Sigma-Aldrich
(Poole, UK) and used without further purification.
5.2.1 Cloning of the HIV-1 Protease Gene
The recombinant HIV-1 protease DNA was purchased from the Centre for AIDS Reagents,
NIBSC (Potters Bar, UK). The sequence coding for the protease has been cloned into a
vector pUC18 and has been modified to use codons favoured by E.coli and includes an
N-terminus methionine (Figure 5.1).
L  V  T  I  K  I  G G  Q  L  K  E  A L 
CTGGTTACCATCAAAATCGGTGGTCAACTAAAGGAAGCTCTG 
L  D  T  G  A  D  D  T V  L  E E M S 
CTGGACACTGGTGCTGATGACACCGTTCTCGAGGAAATGTCT 
L  P  G R W K P K  M  I  G  G  I  G 
TTGCCAGGTCGTTGGAAACCGAAGATGATTGGTGGCATTGGT 
G  F  I  K  V  R  Q Y D  Q  I  L  I E 
GGTTTCATCAAAGTTCGTCAGTATGATCAAATCTTGATTGAA 
      I C G H K A I  G  T  V  L  V  G  P 
ATCTGTGGTCACAAGGCTATTGGTACCGTACTAGTTGGTCCA 
QT P V N I I G R N L L T I
ACTCCTGTAAACATCATTGGTCGTAACCTGTTAACTCAGATC 
A  
QQ
AGCTTACCTGCCATGCCGCAAATCACTCTGTGGCAGCGTCCA
M  P   I T L W  R P HindIII
GGGTGCACTTTAAACTTCTAGTAAGGATCCGAATTC  
G C T L N F
 
EcoRI
Figure 5.1: Nucleotide sequence encoding for HIV-1 protease and translated amino acid
sequence of HIV-1 protease, adapted from http://www.nibsc.ac.uk, 2012.
The recombinant DNA was cloned into two expression vectors which allow expression of the
protein by host E.coli. These vectors, pET-11b and pET-24b, were bought from Novagen
(Feltham, UK). The pET vector system is based on the lac operon and is especially suited to
cloning and expressing recombinant proteins in E.coli. pET-24b carries a C-terminal His-tag
sequence, whilst pET-11b does not.
Plasmid Purification
The recombinant DNA was supplied as a DNA plasmid (pProtease) within transformed
DH5α E.coli in Lysogeny Broth (LB) containing 20% (v/v) glycerol. LB growth medium
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was prepared by dissolving 10 g of NaCl, 10 g of tryptone and 5 g of yeast extract in 1
L deionised water. The pH was adjusted to 7.0 and the medium sterilised by autoclaving.
A touch of the frozen E.coli was inoculated into 50 ml LB medium (containing 100 µg/ml
ampicillin) and incubated overnight at 37oC with vigorous shaking (180 rpm). Plasmid
isolations were performed using the QIAGEN Mini-Prep plasmid purification kit (Qiagen,
Germany).
Similarly the expression vectors to be used were transformed into DH5α E.coli cells (Life
Technologies, Paisley, UK) by adding 1 µL of the DNA to 100 µL DH5α and leaving on ice
for 40 minutes. The cells then underwent heat shock by heating to 37oC for 35 seconds,
followed by one minute in ice. To recover the cells, 900 µL of SOC media (Super Optimal
Broth which is nutrient rich to help recover cells after transformation) was added and the
cells allowed to grow for one hour at 37oC with gentle shaking. The media containing E.coli
was then plated on to LB-Agar plates containing kanamycin at 50 µg/mL for the pET-24b
vector and plates containing 100 µg/mL ampicillin for the pET-11b vector. LB-Agar plates
were prepared as the LB medium above but containing 20 g/L of agar. The plates were
grown overnight and single colonies were then inoculated in 50 mL LB medium containing
ampicillin and kanamycin as appropriate. Plasmids were purified from the overnight cultures
using the QIAGEN Mini-Prep plasmid purification kit.
Amplification and Purification
The protease gene was amplified from the purified pProtease vector using polymerase chain
reaction (PCR) . Primers were designed based on the HIV-1 protease sequence (see Appendix
C) and purchased from Life Technologies (Paisley, UK). A typical PCR reaction contained
1 µL of each primer (10 pmol/L), 2 µL of pProtease and 45 µL of PCR supermix (Life
Technologies, Paisley, UK) to give a final volume of 50 µL. PCR supermix contains Mg2+,
deoxynucleotides (dNTPs), and recombinant Taq DNA polymerase. The PCR reactions
were carried out on a thermocycler and consisted of 1 cycle of denaturation at 95oC for
2 minutes followed by 30 cycles of 95oC for 30 seconds, annealing at 55oC for 45 seconds
and extension at 72oC for 90 seconds. This was followed by 1 cycle at 72oC for 10 minutes
to polish amplicons and then stabilisation at 4oC. The resultant PCR fragments obtained
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Figure 5.2: Vector maps for expression vectors pET-28b and pET-11b. Image adapted from
Novagen pET E. coli T7 expression vector table, www.merckmillipore.co.uk, 2012.
were checked with agarose gel electrophoresis (see Section 5.2.1) and the PCR product was
purified using the Wizard SV Gel and PCR Clean-Up System (Promega UK, Southampton,
UK).
Restriction Digestion
The PCR products and purified expression vectors were then prepared for ligation using
restriction enzymes. The restriction enzymes linearise the expression vectors by cleaving
the DNA sequence at specific recognition sites (Figure 5.2) and leaving ’sticky’ ends in
the sequence which can then be joined to the complementary ’sticky’ ends in the digested
PCR product. pET-24b and pET-11b were digested with BamHI and HindIII since these
restriction sites are also found in the HIV-1 protease sequence.
To prevent recircularisation (and self-ligation) of the digested plasmids, the 5’ phosphate
group of the DNA fragments can be removed using calf alkaline phosphatase (CIP). CIP
was purchased from New England Biolabs (Hitchin, UK) and added to the restriction di-
gest. BSA was included in the reaction to prevent non-specific digestion of the DNA by the
enzymes.
A double restriction digest was carried out on the expression vectors and PCR products.
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A typical digest reaction contained 20 µL of the purified DNA, 2 µL of BamHI, 2 µL of
HindIII, 4 µL of 10x Digest Buffer SB, 2 µL of BSA, 2 µL CIP and 8 µL deionised water to
a final volume of 40 µL. This reaction mixture was incubated at 37oC for 1 hour, followed
by an incubation at 50oC for 10 minutes to allow the CIP to dephosphorylate the DNA.
Finally the reaction was heated to 65oC to inactivate the enzymes.
The restriction digests were then analysed by agarose gel electrophoresis (see section 5.2.1).
The bands obtained were then purified from the gel using the Wizard SV Gel and PCR
Clean-Up System (Promega UK, Southampton, UK).
Ligation
Ligation involves the linking of two ends of a DNA molecule using the DNA Ligase enzyme.
The ligation mixture used here consisted of 2.5 µL of PCR product, 1 µL vector DNA (giving
a 7:1 ratio of insert:vector based on the relative size of the insert to the plasmid), 1 µL T4
DNA Ligase, 1 µL 10x Ligase buffer (both purchased from New England Biolabs, Hitchin,
UK) and 4.5 µL deionised water giving a final reaction volume of 10 µL. The reaction was
incubated at room temperature for 3 hours, after which it was incubated at 16oC for 18
hours. The plasmids obtained in this way were transformed into E.coli expression strains
as described in section 5.2.1. Colonies from the overnight streak plates were analysed by
amplification with the PCR primers from Section 5.2.1 to check for the presence of the
HIV-1 protease sequence and then sent for DNA sequencing by GATC Biotech (Germany)
to confirm the insertion of the protease gene into the vector.
Agarose Gel Electrophoresis
Agarose gel electrophoresis is a technique that is used to separate molecules of DNA accord-
ing to their size. It relies on the fact that the phosphate backbone of DNA is negatively
charged at neutral pH. Because of this, when subjected to a constant electric field, the DNA
molecules will migrate towards the positive pole. The rate of this migration is size depen-
dent since the DNA molecules must pass through an agarose gel. The agarose within the
gel forms a porous matrix and the DNA must pass through these pores in order to reach the
positive pole. The smaller molecules will pass through the pores more easily than the larger
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molecules, meaning that they will move through the gel faster, resulting in a separation of
molecules by size. After the electric field is removed, the final position of the molecules with
reference to a standardised ladder (a sample of DNA molecules of pre-determined sizes) can
be determined by staining with a dye and illumination using UV radiation.
To perform the electrophoresis, a 0.8% (w/v) agarose gel was prepared by diluting a 10x
stock of Tris base-acetic acid-ethylenediaminetetraacetic acid (EDTA) (TAE) buffer in 1 L
deionised water to a 1x concentration. 0.4 g of agarose was dissolved in 50 ml (1x) TAE
buffer by heating in a microwave. Once dissolved, 5 µL of SYBR Safe (Life Technologies,
Paisley, UK) was added to the solution to visualise the nucleic acid fragments. The solution
was then poured into a gel cast and a comb added to form sample wells. The gel was allowed
to polymerise until set after which it was transferred to a gel box and covered with 1x TAE
buffer.
20 µL of the sample to be analysed by electrophoresis was mixed with 4 µL of a 6x DNA
loading dye (Life Technologies, Paisley, UK) which allows the visual tracking of the DNA
during migration. The sample was then loaded into the wells in the gel alongside 5 µL of a
DNA ladder (Life Technologies, Paisley, UK). An electric field of 1200 V/m was then applied
across the gel for 90 minutes. The gel was then removed from the electrophoresis tray and
viewed and imaged on a transilluminator (Biospectrum500, UVP, USA) under UV light.
5.2.2 Expression and Purification of HIV-1 Protease
Having cloned the HIV-1 protease into an expression vector, the plasmid is then transformed
into an E.coli strain which is optimised for the expression of recombinant proteins.
Transformation
The cloned plasmid was transformed into Rosetta (DE3)pLysS competent cells (Novagen,
Feltham, UK). These E.coli host cells are BL21 derivatives which are designed to enhance
the expression of proteins that contain codons which are rarely used in E.coli natively. DE3
indicates that the host cell is a lysogen of λDE3, and therefore carries a chromosomal copy
of the T7 RNA polymerase gene under control of the lacUV5 promoter [346]. pLysS strains
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express a T7 lysozyme which inhibits the T7 RNA polymerase prior to induction which
stabilises pET-based plasmids which encode for proteins affecting the growth and viability
of the host.
For the transformation, 1 µL of the plasmid from Section 5.2.1 was added to 20 µL of
the Rosetta cells and left on ice for 5 minutes. The cells were then placed in to a water
bath at 42oC for 30 seconds before being returned to ice for 2 minutes. 80 µL of room
temperature SOC medium was then added to recover the cells. The mixture was incubated
at 37oC for 1 hour with vigorous shaking (180 rpm) before being plated onto LB-agar plates
(as Section 5.2.1) containing 34 µg/mL chloramphenicol and 100 µg/mL ampicillin. These
plates were allowed to grow overnight at 37oC.
Protease Expression
To express the protein, a single colony from the streak plates (Section 5.2.2) was innoculated
into 10 mL of LB medium. The E.coli were allowed to grow overnight at 37oC with gentle
shaking. The overnight culture was then diluted 100x to 1 L in LB media. The culture was
then allowed to grow to mid-log phase at 37oC until the optical density at 600 nm reached
0.5-0.6.
To induce expression, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a con-
centration of 0.4 mM and glucose added to 0.5% (v/v). Since the overexpression of HIV-1
protease is toxic to the E.coli the presence of glucose helps to modulate the rate at which
the enzyme is produced by acting as a competitive inhibitor of the lac operon. This helps to
support a high density growth without killing the host cells. The culture was then allowed to
grow for a further 3 hours before centrifugation at 5000 g for 20 minutes at 4oC to sediment
the E.coli from the growth medium. The harvested cell body was then stored at -20oC.
Protease Purification
The HIV-1 protease is expressed by E.coli as inclusion bodies. Purification must thus first
isolate these insoluble inclusion bodies from the cell lysate before solubilising the bodies and
refolding the protein before further purification.
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Inclusion Body Isolation
The E.coli cell paste from Section 5.2.2 was resuspended in 100 ml ice-cold Buffer A contain-
ing 10 mM Tris-HCl at pH 8.0, 2 mM EDTA, 1 mM phenylmethyllsulfonyl fluoride (PMSF)
at 5mL/g of wet cell pellet. Lysozyme was then added at 1 mg/mL and incubated at 37oC
for 30 minutes. The solution was then frozen at -70oC overnight. IGEPAL CA-630 was
added to 0.1% (v/v) to the thawed solution before MgCl2 and DNase I were added to a
final concentration of 10 mM and 4 Kunitz units/ml, respectively. The solution was left
stiring at 4oC overnight until the viscosity decreased. The mixture was then centrifuged at
17000g for 15 minutes at 4oC. The pellet was resuspended in 20 mL 50% (v/v) acetic acid
and centrifuged again at 10000g for 30 minutes.
Gel Chromatography
Gel permeation chromatography is a method of separation based on the size of the analytes
in a solution. The column’s stationary phase is porous and hence analytes with a smaller
hydrodynamic volume may enter into the gel bed whilst large analytes cannot and thus elute
through the column much faster.
The clear supernatant from the second centrifugation was applied to a Superdex 75 100/300
column (GE Healthcare), preequilibrated with 50% (v/v) acetic acid. The column was eluted
in the same buffer at 12 mL/min and the first 25 mL (the column volume) was discarded.
0.5 mL fractions were then collected for a total of 70 mL.
Protein Refolding
Fractions collected from the column were analysed to identify those containing HIV-1 pro-
tease. These were pooled and diluted 1:1 with deionised water before being lyophilised. The
lyophilised protein was then dissolved at 2 mg/mL in cold 50% (v/v) acetic acid and added
drop wise to cold refolding buffer containing 20 mM Tris, 20 mM MES (2-ethanesulfonic
acid), 200 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 0,05% (w/v) DTT at pH 6.5 to a
final concentration of 0.1 mg/mL. The refolded protease was tested for proteolytic ability
using the fluorogenic substrate described previously.
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SDS-PAGE Electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a method of
separating proteins dependent on their size. Proteins to be analysed are treated with the
detergent sodium dodecyl sufate (SDS) which gives all the proteins a uniform charge to mass
ratio and hence the electrophoretic mobility of each protein depends only on its size. The
polyacrylamide gel acts like the agarose gel of Section 5.2.1, slowing the larger proteins as
they move along the electric field gradient. The proteins can then be visualised by staining
after the gel is removed from the electrophoresis tank.
To perform the electrophoresis, pre-cast gels with a 4-10% (w/v) SDS gradient were pur-
chased from Bio-Rad (Hemel Hempstead, UK). The gel was inserted into the gel box which
was filled with a running buffer containing 25 mM Tris-HCl, 200 mM glycine and 0.1%
(w/v) SDS. The samples containing the proteins to be analysed were prepared by combin-
ing 6 µL of the sample with 6 µL of 2x sample buffer (for 10 mL this contains 2.5 mL 0.5
M Tris-HCl (pH 6.8), 4 mL 10% SDS (w/v), 2 mL 30% glycerol (v/v), 771 mg DTT and
0.5 mL 0.1% bromophenol blue - a visualisation dye). The sample was heated to 95oC in
order to denature the protein structure and then loaded into the gel wells alongside 5 µL
of a standardised PageRuler protein ladder (Fermentas, Germany). An electric field of 1250
V/m was applied across the gel for 2 hours. The gel was then removed and washed with
deionised water for an hour to remove the SDS from the gel before being left overnight in
Coomassie blue stain (EZ-Run protein gel stain, Fisher Scientific, Loughborough, UK) to
visualise the proteins. The gel was then washed in deionised water for a further 2 hours to
remove any excess stain from the gel before being imaged using an Odyssey Infrared Imager
(Li-Cor Biosciences, USA).
Western Blots
Western blots (or protein immunoblots) are a widely used biochemical analytical technique
used to identify proteins through recognition by an antibody. SDS-PAGE gels were run as
described previously (Section 5.2.2). The gel was then removed from its case and the wells
removed. To transfer the protein bands the gel was sandwiched between filter paper next
to nitrocellulose membrane (Bio-Rad). The filter paper was first soaked in a transfer buffer
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containing 25 mM Tris, 192 mM glycine, 10% (v/v) methanol and 0.5% (w/v) SDS. The
gel was rolled to remove air bubbles before being placed in electrophoresis tank held on
ice. The tank was filled with transfer buffer and then placed under a 400 mA current for
1.5 hours. The electric current causes the protein bands within the gel to migrate onto the
nitrocellulose membrane.
After 1.5 hours the membrane was removed from the tank and blocked with 2% (w/v) skim
milk in Tris-Buffered Saline with 0.05% (v/v) Tween-20 (TBST). This blocking prevents
non-specific interactions of the dye antibodies with the membrane surface. The membrane
was then incubated with a primary antibody overnight at 4oC. The membrane was then
washed well in TBST before being incubated with an infra-red (IR) dye labelled secondary
antibody. The secondary antibody was left to react for 45 minutes in the dark before being
washed well in TBST. The gel was then imaged using an Odyssey infrared scanner.
5.3 Results and Discussion
5.3.1 Cloning of the HIV-1 Protease Gene
The gene coding for the HIV-1 protease was cloned into 2 separate expression vectors. The
results from this cloning are presented here.
Gene Amplification
The HIV-1 protease gene was amplified using PCR. The amplified section was then purified
and digested using the appropriate restriction enzymes. Figure 5.3 shows the result of this
amplification and digestion through agarose gel electrophoresis. Since the digestion of the
amplified protease gene only removes 6 base pairs, leaving sticky ends, the resolution of the
separation is insufficient to identify that the digestion has indeed taken place. However all
bands (whether digested or not) show the expected size of 330 (or 324) base pairs.
pET-11b
The pET-11b expression vector was purified and digested using BamHI and HindIII. Once
linearised and purified it was ligated with the HIV protease gene from Section 5.3.1. The
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Figure 5.3: Amplification and digestion of HIV-1 protease gene from plasmid pProtease.
Lane 10 shows a 100bp ladder from Life Technologies. Lane 1 shows the amplified product
after PCR. Lanes 2-4 show the gene after amplification and digestion. The gel has been cut
to hide colony repeats.
ligated plasmid was transformed into DH5α E.coli. The number of colonies seen on the
LB-plate after overnight growth was compared to the number of colonies seen on plates
which were inoculated with a negative control (E.coli which has been transformed with only
unligated DNA). More than 200 colonies were observed on the plate containing the ligated
plasmid whilst 40 colonies were observed on the control plates. Hence 10 separate colonies
were inoculated with 6 mL of LB medium containing 100 µg/mL ampicillin and the E.coli
allowed to grow overnight at 37oC. One µL of this E.coli was also added to a PCR reaction
using the primers from Section 5.2.1 to confirm the presence of the HIV-1 protease sequence
within the plasmid. Figure 5.4 shows the results of this analysis.
From the PCR and subsequent analysis, the E.coli which showed evidence for the inclusion
of the HIV-1 protease gene were grown and the ligated plasmids were then extracted and
purified from the E.coli and sent for sequencing. Sequencing confirmed the presence of the
desired DNA sequence within the plasmid. 750 µL of DH5α containing the ligated plasmid
was mixed with 250 µL of 80% (v/v) glycerol and stored at -80oC.
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Figure 5.4: Electrophoresis to confirm presence of HIV-1 protease gene within E.coli colonies
isolated after ligation. Lanes 1 represents a colony isolated from the growth plate. Lane 2
shows the negative ligation control (no insert). Lane 3 represents a 100bp ladder from Life
Technologies. Gel has been cropped to the left to remove colony repeats for clarity.
pET-24b
The pET-24b expression vector was purified and digested using BamHI and HindIII. After
digestion UV spectrophotometry showed a low concentration of DNA after extraction from
the electrophoresis gel (∼7 ng/mL). The purification of the DNA from the gel was optimised
by eluting the column more than once with the solution containing the dissolved agarose gel
in order to increase the binding of the DNA to the column. After optimisation the DNA
concentration reached >30ng/mL which is sufficient for ligation.
However despite suitable DNA concentrations and appropriate ratios of insert DNA to vec-
tor DNA (1:1, 6:1, 7:1 and 12:1 ratios were trialled), ligation of the pET-24b expression
vector with the HIV-1 protease sequence was unsuccessful after several attempts. It was
thus decided to not continue with this expression vector.
5.3.2 Expression and Purification of HIV-1 Protease
Having successfully cloned the HIV-1 protease sequence into the pET-11b expression vec-
tor (section 5.3.1), the ligated plasmid was transformed into Rosetta (DE3)pLysS competent
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Figure 5.5: Electrophoresis of cell paste of E.coli. a) Electrophoresis showing the insoluble
and soluble fractions of the digested cell paste after centrifugation (CF). The majority of the
protease can be found in the insoluble fraction. Commercially available protease is included
for size comparison. Gel has been cropped to remove replicates for clarity. b) Western blot
of an equivalent gel from part a), no cross-reactivity of the antibody can be observed. Gel
has been cropped to remove the insoluble fraction for clarity.
cells (Section 5.2.2). These E.coli were then grown until their mid-log phase (OD600=0.5-0.6).
IPTG was then added to induce expression of the protease. Samples of the E.coli were taken
pre- and post-induction for protein analysis using SDS-PAGE (Section 5.2.2). The overex-
pression of HIV-1 protease leads to the formation of inclusion bodies which are difficult to
solubilise. When the digested E.coli cell paste is centrifuged, the majority of the protease
thus ends up in the insoluble phase (Figure 5.5a). Figure 5.5b shows a western blot of an
equivalent gel, showing that the primary band in the insoluble phase is the HIV-1 protease
and that the antibody for the enzyme shows no cross-reactivity with other E.coli proteins.
50% (v/v) acetic acid was then used to solubilise these inclusion bodies so that purification
could occur.
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Figure 5.6: UV-vis trace showing protein concentration as collected from eluted volume after
size exclusion purification. Fractions between the dashed lines were checked for PR content
and pooled for further use.
Protein Purification
Having solubilised the protein, the clear supernatant from the second centrifugation step
was uploaded to the size exclusion column and 0.5 mL fractions collected until the protein
concentration was negligible as measured by a Bradford Assay. The Bradford assay is a
rapid way to measure a sample’s protein concentration and is based on the principle that
the absorbance of the Coomassie Brilliant Blue dye shifts when it complexes with a protein.
In this instance, the protein concentrations were not quantified, but the assay was used as
a qualitative measure of when to halt fraction collection.
The collected fractions were then measured by UV-Vis absorption spectroscopy to determine
protein concentration. Samples were measured on a Nanodrop 3000 (as discussed in Section
3.2.3) and the absorbance at 280 nm was recorded. The results of this study are shown
in Figure 5.6. The observed double peak in the protein elution is also reported by Hui et
al. who found that the second peak contained the majority of the protease molecules [345].
The measured samples all had a ratio of ∼1.15 when comparing the absorbance at 260/280
nm. This is indicative of a >95% pure protein sample, since the presence of DNA/RNA will
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Figure 5.7: Confirmation of the presence of HIV-1 PR in the samples collected from the size
exclusion column. a) Dot blot showing fractions 32-77 and a positive control (commercial
HIV-1 PR) incubated in the presence of α-HIV-1 PR antibody. b) Electrophoresis of selected
fractions, showing that the dominant protein in all fractions is the desired HIV-1 PR.
affect the 260 nm reading, while the absorbance at 280 nm is due to the aromatic groups
within the protein.
To confirm the presence of the protease a dot blot was carried out. This is similar to
a Western Blot, but proteins are not first separated by size via SDS electrophoresis. In
this instance, 5 µL of sample is dotted onto nitrocellulose membrane and left to dry. The
membrane is then blocked in a solution containing 2% (w/v) skim milk for an hour at
room temperature. The membrane is then incubated with a primary antibody (mouse anti-
HIVprotease, Abcam, UK) at a 1:1000 dilution in the presence of the blocking solution.
This is left for an hour at room temperature before being washed thoroughly in TBST.
An infra-red dye-labelled secondary antibody is then added to the membrane (at a 1:1000
dilution in the presence of skim milk) and left to incubate for 30 minutes. The membrane
is then washed again thoroughly before being imaged.
Figure 5.7a shows the result of this study, where fractions 32-77 (corresponding to the sec-
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Figure 5.8: The activity of purified HIV-1 protease. a) activity assay based on the cleavage
of a fluorescently labelled substrate shows protease has refolded. b) Electrophoresis showing
stages of the expression and purification process. The final lane (post-column) still shows
some native E.coli proteins but the dominant band is HIV-1 protease.
ond peak in protein concentration and constituting a total collected volume of 22 mL) are
checked for the presence of the protease. The high background seen here is due to the warp-
ing of the membrane due to the presence of acetic acid in the samples. However, despite
this background signal, it can clearly be seen that the protease is present in these samples.
The bottom right dot (marked ’+’) represents commercial protein as a positive control.
A selection of fractions were then analysed by SDS-electrophoresis (Figure 5.7b) to assess
the purity of the eluted samples. While a weak band can be observed at ∼37 kDa (this is
dominant native E.coli protein, as can be seen in Figure 5.5), its intensity is weak in com-
parison to the band at 11 kDa. The smearing of the bands is a result of the residual acetic
acid within the sample (samples were diluted 1:10 with deionised water and neutralised be-
fore analysis in the gel) and similar bands have been reported in Hui et al. [345]. Fractions
corresponding to the second peak (43-65) were pooled, diluted 1:1 in deionised water and
lyophilised.
Protein Refolding and Activity
In all 8 mg lyophilised HIV-1 PR was extracted from 3 g E.coli. This protein was then
redissolved in 50% (v/v) acetic acid before being added dropwise to cold refolding buffer
(to a final concentration of 0.1 mg/mL). The protein was then allowed to refold at 4oC
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for an hour before being assayed for activity. As can be seen in Figure 5.8a, the refolded
protease does show some activity but much less than would be expected from this concen-
tration of enzyme. The reason for this is due to the poor solubility of the enzyme. Despite
pre-dissolving the enzyme in acetic acid, on addition to the refolding buffer, the enzyme sed-
iments. By centrifuging the protein solution to remove insoluble protein, the concentration
of protease in solution was measured to be ∼0.023 mg/mL by UV-vis. This is likely still
an over-estimate of the actual protease concentration since as can be seen in Figure 5.8b,
despite the purification process removing the majority of contaminant E.coli protein, some
remains within the sample, and this may well contribute to the soluble protein measured.
On the Solubility of HIV-1 Protease
The insolubility of proteins expressed as inclusion bodies has been well-documented and
many methods have been suggested to overcome these problems [347]. During the course of
these experiments, many such protocols were explored with little effect. Traditional meth-
ods to solubilise proteins include the addition of 6 M guanidine-HCl or 8 M urea [348]. The
high concentration of these molecules causes the protein structure to denature and the ag-
gregates to disperse. However, in the case of this enzyme, while the protein was solubilised,
a step-wise dialysis into refolding buffer (to remove the denaturing agent) again caused a
loss of solubility.
Alternative methods trialled involved the use of detergents such as sarkosyl (sodium lauroyl
sarcosinate), Triton X-100 and CHAPS ( 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate). These surfactants are reported to solubilise more than 95% of proteins
by disrupting the aggregates [349–351]. However, these detergents proved difficult to remove
in subsequent stages of purification, and their use at a high concentration (above the critical
lamellar concentration) prevented the efficient dialysis of these solutions.
5.4 Conclusion
The decision to produce recombinantly expressed HIV-1 protease in-house initially arose
from difficulties in guaranteeing a commercial supply. However, as has been described pre-
viously, “the purification of the HIV protease proved difficult” [352]. The protease monomer
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is highly hydrophobic and thus solubilisation of the enzyme remains the main problem. Re-
ports repeatedly mention the inability to solubilise this protein using detergents, sonication
or mechanical processes and aggregates are often only solubilised in the presence of high
concentrations of glycerol [337, 352]. In addition, the autoproteolysis of the enzyme means
that any correctly folded protein is subsequently rapidly degraded.
As a result of these problems, and despite many different experimental protocols trialled,
HIV-1 protease was not successfully produced at a high enough concentration for the rest
of the experiments outlined in this thesis. In all, it remains remarkable that an enzyme
that is unstable, requires an extremely high salt concentration to fold correctly and auto-
degrades rapidly should be responsible for the crucial step in the lifecycle of a virus such as
HIV. During the course of these experiments, problems with the supplier were resolved, and
commercially available protease was used for the experiments described within this thesis.
Chapter 6
Conclusions and Future Work
. . . and Nature always seeks an end.
ARISTOTLE
On the Generation of Animals
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Motivation of the Thesis
Many disease states are mediated by the activity of proteases. These enzymes play key
roles in many biological processes making them natural targets for both the design of new
detection mechanisms but also for the development of new pharmaceuticals. One of the best
studied enzymes in this regard is the viral protease of the Human Immunodeficiency Virus.
In the 25 years since its discovery, it has been the focus of a large body of research aiming
to understand its function and inhibit its activity.
HIV-1 protease is a key enzyme in the lifecycle of HIV/AIDS and, as discussed in Chapter 5,
is a structurally unique enzyme compared to other members of the aspartyl protease family.
Understanding its structure-function relationship and stability has been an important part
in developing inhibitors of the enzyme, which remains a key goal in HIV/AIDS research.
Despite 20 years of pharmaceutical investment and the development of 10 excellent clinical
protease inhibitors, new strategies are still required. This need is driven in part by the
lack of new drugs to reach late stage clinical trial or approval in the last 10 years and also
by the growing population who require access to antiretroviral therapy. Currently under
40% of those infected with HIV/AIDS have access to appropriate treatment and of those
that do, the associated increased life expectancy leads to a greater chance of acquiring a
drug-resistant species.
The detection of HIV has also been well studied, however as outlined in Chapter 1, these de-
tection methods all rely on costly reagents and instrumentation. While state-of-the-art, 4th
generation diagnostics are well-established in the developed world, many clinics in resource-
limited settings are restricted to using earlier versions of tests. Diagnosis at the point-of-care
in these locations is limited by the need for cold-chain transport, the instability of the test
reagents, the costs involved and appropriately trained personnel.
This thesis aimed to examine the role peptide-protein interactions could have in developing
new concepts in detecting the presence of HIV and in inhibiting the HIV-1 protease. Pep-
tides are ideally suited to both challenges described above, being as they are, both natural
substrates of enzymes and incredibly stable to environmental conditions such as temperature
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and pH. These molecules also allow for a wide range of versatility in design and are easy to
synthesise. These factors mean they are easier to modify for a multitude of uses than larger
proteins.
Multivalency in Drug Design
Many biological systems make use of multivalency to modulate the binding and molec-
ular recognition between macromolecules. These interactions are commonly observed in
antibody-antigen binding, cell attachment and carbohydrate-glycoprotein signalling. Chap-
ter 2 sought to exploit these concepts to design new molecules which could inhibit HIV-1
protease. By constructing a macromolecular inhibitor which recognised multiple binding
sites on the same protein, it is hypothesised that poorly binding ligands can have an en-
hanced effective affinity. The use of multivalency is also expected to improve the resistance
to protease mutation by allowing the construct to interact with areas of the enzyme away
from the active site which are more highly conserved.
The first step in developing such a macromolecule involving identifying peptide ligands
which would act as recognition elements. Phage display was used to find these ligands and
five sequences were isolated which bind to the enzyme with varying binding affinities. The
use of a phage library encoding seven amino acid long peptides was chosen due to the stabil-
ity and ease of synthesis of these peptides. The choice of a longer sequence may have found
peptides which bound more strongly (since these peptides can have a secondary structure)
however, phage are limited to displaying 1010 different sequences. This covers all potential
seven amino acid long sequences but only a small fraction of possible amino acid sequences
of longer peptides.
Of these peptides, WSRVGYW was found to show the best binding affinity. In combi-
nation with another peptide inhibitor of the enzyme, it was hoped that the conjugation of
multiple peptide ligands into a macromolecular structure would lead to an increased avidity
and thus an enhanced IC50. Unfortunately, the desired enhancement effects were not ob-
served when using WSRVGYW and LLEYSL and a PEG12 linker. As discussed in Chapter
2 and later verified in Chapter 4, it is likely that the binding sites of these peptides are too
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close together for an enhanced concentration to be created.
This use of polymer-peptide conjugates to form multivalent ligands has been well described
by a number of groups. Indeed the principles of multivalency are now being actively explored
in drug design, where hybrid drugs could target multiple molecules associated with a disease.
As seen with the development of Lopinavir, the co-formulation of drugs can dramatically
improve circuation times and pharmokinetics.
Given the body of literature that describes the improved affinity shown by multivalent
conjugates, it is not unreasonable to assume that the approach described within this thesis
should work with further study. Current limitations are due to solubility and yield of the
PEG conjugates and a need for a ligand that binds the protease outside of the active site.
Future work will focus on the characterisation of new binding sites identified through phage
display and the incorporation of these ligands into the wide range of polymer architecture
that is accessible with RAFT polymer chemistry, allowing the system to move beyond a
simple, heterobifunctional ligand. Polymer-peptide conjugates offer a great versatility for
the design of macromolecules which interact with biological targets, especially given the
complexities polymer chemistry can unlock. In combination with lessons from the fields
of biologics and molecularly imprinted polymers, the concept of multivalency is likely to
become ever more important in pharmaceutical design.
Biophysical Tools for Understanding Protein Interactions
Understanding biological interactions has been hugely aided by advancements in scientific
fields far removed from biology. This thesis has made use of these biophysical tools to explore
and exploit the peptide-protein interactions developed in Chapter 2. Both FRET (Chap-
ter 3) and computational modelling (Chapter 4) have been well described in the literature
and provide access to structural and kinetic information on protein-ligand interactions that
is not readily available otherwise. These methods provide complementary information to
standard chemical analysis techniques.
The work described in Chapter 3 aimed to detect the presence of HIV-1 protease through
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a FRET signal mediated by the interaction with multiple dye-labelled peptides. Again, the
use of multivalency was a key feature of this study, requiring two binding events to the same
protease molecule to generate a FRET signal. FRET has been well utilised for detecting
enzymes but, in contrast to the method described here, most commonly requires the pro-
teolytic cleavage of a substrate labelled with a FRET pair on either terminus. While this
method is easy to implement once a suitable enzyme substrate has been identified, many
peptides are suspectible to cleavage by non-specific enzymes. The advantage of the use of
multivalency removes this vulnerability to false-positives by requiring several substrates to
be interacting uniquely with the target enzyme.
In comparison to many biomarker detection assays, this system is limited by its high limit-
of-detection. This could be improved in future studies by using two peptide sequences which
both show high affinity to the target; LLEYSL shows strong affinity to the target, while WS-
RVGYW only shows moderate binding. With stronger affinity peptides the methodology
developed here shows excellent potential for the detection of a range of biomarkers, not only
HIV-1 protease. Not only would assays developed using this multivalent approach show
high specificity but the requirement for both peptides to interact with the protein removes
the need for multiple wash steps, blocking and immobilisation that many techniques (for
example ELISA) require.
Chapter 4 meanwhile, aimed to provide a theoretical understanding of the experimental
work outlined in Chapters 2 and 3. Computational chemistry techniques allow a huge range
of experimental conditions to be trialled and the most promising results studied in further
detail. The limitations of the methods used have been thoroughly discussed, both in this
thesis and within the wider literature. Depite these challenges, the use of these simulations
to explore biological concepts remains highly beneficial to our understanding of processes
on this time and length-scale.
In order to improve the binding affinity of the phage display isolated peptides, computational
sequence mutations could easily be carried out to identify potentially stronger binders. In
addition, it would be of interest to perform a similar set of molecular modelling experiments
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using HIV-2 protease, clinically observed mutated proteases and other aspartyl proteases
(such as pepsin) to more fully understand the origins of the high specificity found through
the FRET assay as well as to model whether the peptide-polymer conjugates would still
bind to proteases with one or multiple mutated amino acids.
Outlook
The themes explored within this thesis have all been underpinned by the concepts of molec-
ular recognition. Despite being an ubiquitous process in Nature, and crucial to almost every
concept in molecular biology, we are still far from a total understanding of protein-ligand
interactions. Controlling and exploiting interactions on this molecular scale remains a daunt-
ing challenge and the ability to develop molecules with high-affinity and high-specificity for
a target will revolutionise many fields including biotechnology, pharmacology and regenera-
tive medicine but also in more widely reaching fields such as energy and industrial catalyis.
Most of the success stories in identifying ligands to biomacromolecules have occurred either
serendipitously (such as the marine pharmacognosy which identified the inhibitory peptide
isolated from oyster proteins, used throughout this thesis), or through the use of display
technologies such as the phage display used in Chapter 2. While these techniques have iden-
tified ligands of a wide range of molecules, they are limited in only being able to sample a
tiny proportion of potential sequences, significantly reducing the likelihood of identifying the
most high-affinity, selective binders. To date, while several groups have reported the design
of ligands which bind their target to levels approaching antibody recognition, no one has
yet been able to generate ligands which bind with the affinity seen in biotin-(strept)avidin
recognition.
In addition to experimental techniques, computational approaches will doubtless play a
key role in the future of this field. The development of in silicio methods has allowed for the
rational design of ligands and the ability to perform computational mutagenesis to identify
a series of potential binding sequences. Many of these computationally designed ligands and
proteins show remarkable agreement with their experimentally produced crystal structures.
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As further insights into molecular recognition evolve and as computational techniques be-
come more powerful, it will soon become possible to design functional proteins that interact
with biological macromolecules and in doing so, fundamentally change the way we treat dis-
ease. These rationally designed proteins will also enable new synthetic pathways in organic
chemistry for a diverse range of applications. Much like the computer has left the realm
of the electrical engineer and become the tool of so many, molecular biology now offers the
opportunity to become an interdisciplinary scientist’s design tool.
“But physicists can learn molecular detail, and biologists can learn differential
equations. . . If it is not our revolution, it will be someone else’s.” ∼ George Whitesides
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Appendix A
Sequenced phage DNA
The DNA isolated from phage colonies was sequenced by GATC Biotech (Germany). The
sequences were then viewed in GeneRunner 3.05 and translated into 6 reading frames (+1-3
and -1-3). The protein sequence that contained the sequence SHS. . . GGG was located to
obtain the phage displayed pepetide sequence.
In the sequences below @, & and # reperesent the stop codons TAA, TAG and TGA.
Underscores are used in places where the DNA sequence was not of high enough quality to
accurately determine the codon being read. The sequence of the phage displayed peptide is
given in bold and underlined.
Out 2
2-1
GAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITY
FTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRG
RWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFY
SHSHTVHGLMGGGSAETVESC@QNPIQKI LL
2-2
YAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLF
RAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLL
PSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQ
ADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSVPGGLPWGGGSAETVESC
@QNPIQKISFT V
2-3
LFW LSSSGKRGL&@C SYYAS#FLLALCICIS&MWYS#ISTDESFYL##CCSVSSFY#
RR FFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLC
YVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#H
GAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITY
FTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRG
RWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFY
SHSSVLATILGGGSAETVESC@QNPIQKIITN D
2-4
SKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSK
MSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRV
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TIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPF
GAFFLEIFNVKKLLFAIPLVVPFYSHSWSRVGYWG XWGRNC&KLFSKIPYRKFIY
#RR
2-5
I IS&MWYS#ISTDESFYL##CCSVSSFY#RRFFFPTS&LV#&ASS#NRIR#FTMIKV
EIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGL
YTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWY
NRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRC
CLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPI
QLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSSGSSSQHGGGSAETVESC@QNPIQ
KI L
2-6
LVECGIPK TDESFYL##CCSVSS Y#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIK
PSQAQFTTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTV
HLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRW
GSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSL
LRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLK
APFGAFFLEIFNVKKLLFAIPLVVPFYSHSIVASAHYGGGSAETVESC Q PIQKII V
E
2-7
No sequenceable DNA
2-8
SA VECGIPKS TDESFYL##CCSVSSFY#RRFFFPTS&LV#&ASS#NRIR#FTMIKV
EIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGL
YTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWY
NRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRC
CLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPI
QLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSTSGFYSGGGGSAETVESCLAKSHT
ENHLLT
2-9
FGF RRLVN GL&@CCSYYAS#FLLAL CIS&MWYS#ISTDESFYL##CCSVSSFY#R
R FFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCY
VD GNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HG
AGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYF
TRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGR
WLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYS
HSHGARGAFGGGSAETVESC@QNPIQKI
2-10
IWV SSSGKRGL&@CCSYYAS#FLLALCICIS&MWYS#ISTDESFYL##CCSVSSFY#
RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLC
YVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#H
GAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITY
FTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRG
RWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFY
SHSSISNELLGGGSAETVESC@QNPIQKIIY#R
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2-11
Q P AILVXSSSGKRGL&@CCSYYAS#FLLALCICIS&MWYS#ISTDESFYL##CCSVS
S Y#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLN
EQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVP
AK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLR
SGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNIS
VMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLV
VPFYSHSHRPSQMPGGGSAETVESCLAKSHTENHLLT
2-12
CSY AS#FLLAL XCIS&MWYS#ISTDESFYL##CCSVSSFY#RR FFPTS&LV#&ASS
#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKITL
DEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDT
NLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SS
KPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCL
RNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSEWKDDYGGGG
WAETVESCLAKSHTENSFTN E
Out 3
3-1
LAI VLSSSGKRGL&@CCSYYAS#FLLALCICIS&MWYS#ISTDESFYL##CCSVSSFY
#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQL
CYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#
HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGIT
YFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMR
GRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPF
YSHSFSAKWAIGGGSAETVESC@QNPIQKIITN E
3-2
WFLSSSGKRGL&@CC YYAS#FLL L CIS&MWYS#ISTDESFYL##CCSVSSFY#R
RFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCY
VDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HG
AGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYF
TRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGR
WLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYS
HSGDPFRYDGGGAETVESCLAKSHTENHY R
3-3
AI V SSSGKRGYDSVX LVIPFGVMYLH@LNVVFLNLN&&IFLPVIMLFR@FVLLT@
IFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCYV
DLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGA
GRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFT
RLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGR
WLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYS
HSFTDLHMRGGGSAETVESC@QNPIQKIIY#R
3-4
SSSGKRGL&@C S YAS#FLLA ICIS&MWYS#ISTDESFYL##CCSVSSFY#RRFFF
PTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQ TTRSGVSRQGKPYSLNEQLCYVDLG
NEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGR
GFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRL
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METSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWL
LSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHS
MTPMTLRGGGSAETVESC@Q PIQKIIT
3-5
P AI VLSSSGKRGL&@C SY S#FLLALCI IS&MWYS#ISTDESFYL##CCSVSSFY#
RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLC
YVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#H
GAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITY
FTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRG
RWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFY
SHSHHFFSVIGGGSAETVESCLA SHTENHLLT K
3-6
AILVLSSSGKRGL&@CCSYYAS#FLLALCICIS&MWYS#ISTDESFYL##CCSVSSFY
#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQL
CYVD GNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#
HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGIT
YFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMR
GRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPF
YSHSSNFSTYNGGGSAETVESC QNPIQKIITN E
3-7
L MPRNSFW L CIS&MWYS#ISTDESFYL##CCSVSSFY#RRFFFPTS&LV#&ASS#
NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKITLD
EGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTN
LRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSK
PL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLR
NSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSTTMTELYGGXWA
ETVESCLAKSHTENHY# R
3-8
LQ PLAI VLSSSGKRGL&@XCSYYAS#FLLALCICIS&MWYS#ISTDESFYL##CCSV
SSFY#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQ TTRSGVSRQGKPYSLN
EQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVP
AK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLR
SGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNIS
VMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLV
VPFYSHSYIDLRSVGGGSAETVESCLAKSHTENHLLT
3-9
MSV Y FASFVLGWCLRSG T FTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTI
PQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGA
FFLEIFNVKKLLFAIPLVVPFYSHSSAAQGMAGGGSAETVESC@Q PIQKIIT
3-10
CKSL LFWF SSSGKRGL&@CCSYYAS#FLLAL CIS&MWYS#ISTDESFYL##CCSV
SSFY#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSL
NEQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLV
PAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCL
RSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNI
SVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPL
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VVPFYSHSSTVKYIDGGGSAETVESCLAKSHTENHY#R N
3-11
PLAKL LQKPLXI VLSSSGKRGL& CSYYAS#FLLALCICIS&MWYS#ISTDESFYL#
#CCSVSS Y#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQG
KPYSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMID
RLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVL
GWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKP
QRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLL
FAIPLVVPFYSHSMSSSLVRGGGSAETVESC@Q PIQKIIY#RRN
3-12
V VKFVLLNVD SF S TGIM PVL#N H GNSTMIKG&N#TISRPN LLVSGVSRQGK
PYSLNEQLCYVD GNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRL
RLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLG
WCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQ
RPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLF
AIPLVVPFYSHSSEPRVAYGGGWAE C&KLFSK PYRKFHY T
Out 4
4-1
WQN FCK WF SSSGKRGL&@ YYAS#FLLALCICIS&MWYS#ISTDESFYL##C
CSVSSFY#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKP
YSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRL
RLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLG
WCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQ
RPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLF
AIPLVVPFYSHSTPYMTPKGGGSAETVESCLAKSHTENHLLT
4-2
DESFYL##CCSVSSFY#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQ TTRS
GVSRQGKPYSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQF
GSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVY
SFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKR
PLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEI
FNVKKLLFAIPLVVPFYSHSLTSPQSLGGGSAETVESCLAKSHTENFIY# R
4-3
YYAS FLLA ICIS&MWYS#ISTDESFYL##CCSVSSFY#RRF FPTS&LV#&ASS#N
RIR#FTMIKVEIKPSQAQ TTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKITLDE
GQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNL
RCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKP
L@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRN
SPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSMSITRVHGG AETV
ESCLAKSHTENHY# R
4-4
FAKA L SSSGKRG &@CC YYAS#FL ALCICIS&MWYS#ISTDESFYL##CCSVSS
FY#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNE
QLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPA
K#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRS
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GITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISV
MRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVV
PFYSHSTSAHHRMGGGSAETVESC@QNPIQKI L T
4-5
K #L F F WFSSVQGAKALY LK&SQ VYV ILG#MKYPGF VKELL DE SAQPYAP
WS TPVHLSSFKSWSVSVP MIDPSA SFRAK#HGAGRGFRHNLSGDDTNLRCTLFR
AWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLP
SFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQA
DKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSSAHWLYGGGGSAETVESCL
AKSHTE
4-6
CQDYS&&RSASLCAWSVTPFICPSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNL
SGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&
KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQL
SVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSDRTTSWV
GGGSAETVESCLAKSHTENSLLTS
4-7
PLWQN FCKS LFW SSSGKRGL&@CCSYYAS#FLLALCICIS&MWYS#ISTDESFY
L##CCSVSSFY#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSR
QGKPYSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLM
IDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASF
VLGWCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPC
KPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVK
KLLFAIPLVVPFYSHSWTLHYSYGGGSAETVESC@QNPIQKIIY#RR
4-8
CSYYA #FL ALCICIS&M YS#ISTDESFYL##CCSVSSFY#RRFFFPTS&LV#&ASS
#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKIT
LDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDD
TNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@S
SKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSC
LRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSAETVESC@Q PI
QKNSLLT
4-9
TMPRNSF ALSI IS&MWYS#ISTDES L##CCSVSSFY#RR FFPTS&LV#&ASS#NR
IR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVD GNEYPVLVKITLDEG
QPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLR
CTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL
@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNS
PRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSMSITRVHGGG AETV
ESCLAKSHTENHY#RR
4-10
#FLLALC IS&MWYS#ISTDESFYL##CCSVSSFY#RRF FPTS&LV#&ASS#NRIR#
FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVDLGNEYPVLVKITLDEGQP
AYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRGFRHNLSGDDTNLRCT
LFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLMETSS&KSL@SSKPL@P
LLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLSLSAQLSVSSCLRNSPR
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KQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSMTDSAYTGGGSAETVE
SC@QNPIQKIIY#R
4-11
QN FCKS LFW LSSSGKRGL&@C SYYAS#FLLALCICIS&MWYS#ISTDESFYL##C
CSVSS Y#RRFFFPTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKP
YSLNEQLCYVDLGNEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRL
RLVPAK#HGAGRGFRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLG
WCLRSGITYFTRLMETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQ
RPNISVMRGRWLLSLSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLF
AIPLVVPFYSHSSSHTPP@GGGSAETVESCLA SHTENHLLT
4-12
LSSSGKR @CCSYYAS#FL ALCICIS&MWYS#ISTDESFYL##CCSVSS Y#RRFFF
PTS&LV#&ASS#NRIR#FTMIKVEIKPSQAQFTTRSGVSRQGKPYSLNEQLCYVDLG
NEYPVLVKITLDEGQPAYAPGLYTVHLSSFKVGQFGSLMIDRLRLVPAK#HGAGRG
FRHNLSGDDTNLRCTLFRAWYNRWGSKMSVLVYSFASFVLGWCLRSGITYFTRLM
ETSS&KSL@SSKPL@PLLPSFRCCLSLLRVTIPQKRPLTPCKPQRPNISVMRGRWLLS
LSAQLSVSSCLRNSPRKQADKPIQLKAPFGAFFLEIFNVKKLLFAIPLVVPFYSHSKIN
EVWNGGGSAETVESC@QNPIQKIIY#RR
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Mass Spectroscopy
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Appendix C
PCR primer design
To amplify the HIV-1 protease gene two primers were designed for use in PCR.
Forward:
5’-AAGCTTACCTCATATGCCGCAAATC-3’
Reverse (complementary):
5’-GAATTCGGATCCTTACTAGAAGTT-3’
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